Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8877019,central compartment apparent volume of distribution,The higher concentrations were the result of the 30 to 40% smaller central compartment apparent volume of distribution that was observed in the elderly subjects as compared with the young volunteers (2.8 +/- 1.1 vs 3.9 +/- 1.11 kg-1 for 1 mg dose).,The effect of age on the pharmacokinetics of the opioid antagonist nalmefene. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877019/),1/[kg],2.8,346,DB01183,Naloxone
,8877019,central compartment apparent volume of distribution,The higher concentrations were the result of the 30 to 40% smaller central compartment apparent volume of distribution that was observed in the elderly subjects as compared with the young volunteers (2.8 +/- 1.1 vs 3.9 +/- 1.11 kg-1 for 1 mg dose).,The effect of age on the pharmacokinetics of the opioid antagonist nalmefene. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877019/),1/[kg],3.9,347,DB01183,Naloxone
,8877019,distributional half-life (t1/2 lambda 1),The elderly volunteers also had a significantly shorter distributional half-life (t1/2 lambda 1) than young volunteers (0.7 +/- 0.7 vs 1.3 +/- 0.8 h for 1 mg dose).,The effect of age on the pharmacokinetics of the opioid antagonist nalmefene. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877019/),h,0.7,348,DB01183,Naloxone
,8877019,distributional half-life (t1/2 lambda 1),The elderly volunteers also had a significantly shorter distributional half-life (t1/2 lambda 1) than young volunteers (0.7 +/- 0.7 vs 1.3 +/- 0.8 h for 1 mg dose).,The effect of age on the pharmacokinetics of the opioid antagonist nalmefene. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877019/),h,1.3,349,DB01183,Naloxone
,23507688,run time,Reversed-phase chromatography using a gradient elution with methanol and 0.04% formic acid solution (pH 3.5) was used for separation in a run time of 5 min.,Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),min,5,1583,DB01183,Naloxone
,23507688,m/,"The analytes were detected in the positive ion mode using multiple reaction monitoring (MRM) of the transitions at m/z 300.4→215.2 for codeine, 286.2→152.0 for morphine, and 462.2→286.2 for M3G and M6G.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),,300.4,1584,DB01183,Naloxone
,23507688,m/,"The analytes were detected in the positive ion mode using multiple reaction monitoring (MRM) of the transitions at m/z 300.4→215.2 for codeine, 286.2→152.0 for morphine, and 462.2→286.2 for M3G and M6G.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),,215.2,1585,DB01183,Naloxone
,23507688,m/,"The analytes were detected in the positive ion mode using multiple reaction monitoring (MRM) of the transitions at m/z 300.4→215.2 for codeine, 286.2→152.0 for morphine, and 462.2→286.2 for M3G and M6G.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),,286.2,1586,DB01183,Naloxone
,23507688,m/,"The analytes were detected in the positive ion mode using multiple reaction monitoring (MRM) of the transitions at m/z 300.4→215.2 for codeine, 286.2→152.0 for morphine, and 462.2→286.2 for M3G and M6G.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),,152.0,1587,DB01183,Naloxone
,23507688,m/,"The analytes were detected in the positive ion mode using multiple reaction monitoring (MRM) of the transitions at m/z 300.4→215.2 for codeine, 286.2→152.0 for morphine, and 462.2→286.2 for M3G and M6G.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),,462.2,1588,DB01183,Naloxone
,23507688,m/,"The analytes were detected in the positive ion mode using multiple reaction monitoring (MRM) of the transitions at m/z 300.4→215.2 for codeine, 286.2→152.0 for morphine, and 462.2→286.2 for M3G and M6G.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),,286.2,1589,DB01183,Naloxone
,23507688,response,"The method has the following performance characteristics: a reliable response range of 0.05-80 ng/ml for codeine, M3G and M6G and a response range of 0.05-5.0 ng/ml for morphine with correlation coefficients (r) of >0.997 for all analytes.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),[ng] / [ml],0.05-80,1590,DB01183,Naloxone
,23507688,response range,"The method has the following performance characteristics: a reliable response range of 0.05-80 ng/ml for codeine, M3G and M6G and a response range of 0.05-5.0 ng/ml for morphine with correlation coefficients (r) of >0.997 for all analytes.",Simultaneous analysis of codeine and its active metabolites in human plasma using liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration of codeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507688/),[ng] / [ml],0.05-5.0,1591,DB01183,Naloxone
,12738349,half-life,The addition of naloxone does not affect the efficacy of buprenorphine for two reasons: (1) naloxone is poorly absorbed sublingually relative to buprenorphine and (2) the half-life for buprenorphine is much longer than for naloxone (32 vs. 1 h for naloxone).,Pharmacokinetics of the combination tablet of buprenorphine and naloxone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12738349/),h,32,2170,DB01183,Naloxone
,12738349,half-life,The addition of naloxone does not affect the efficacy of buprenorphine for two reasons: (1) naloxone is poorly absorbed sublingually relative to buprenorphine and (2) the half-life for buprenorphine is much longer than for naloxone (32 vs. 1 h for naloxone).,Pharmacokinetics of the combination tablet of buprenorphine and naloxone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12738349/),h,1,2171,DB01183,Naloxone
,15966752,time to maximum plasma concentration,"The mean time to maximum plasma concentration following sublingual administration is variable, ranging from 40 minutes to 3.5 hours.",Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966752/),min,40,3559,DB01183,Naloxone
,15966752,time to maximum plasma concentration,"The mean time to maximum plasma concentration following sublingual administration is variable, ranging from 40 minutes to 3.5 hours.",Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966752/),h,3.5,3560,DB01183,Naloxone
,15966752,terminal elimination half-life,The terminal elimination half-life of buprenorphine is long and there is considerable variation in reported values (mean values ranging from 3 to 44 hours).,Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966752/),h,3 to 44,3561,DB01183,Naloxone
,827709,binding to,"Studies on naltrexone disposition indicate that (a) binding to plasma proteins in several species varies from 20-26 per cent, (b) distribution of drug from blood is extremely rapid and extensive, (c) beta-naltrexol is a major metabolite of naltrexone in man, monkey and guinea pig among six species studied, whereas alpha-naltrexol is a minor metabolite in the monkey and guinea pig only, and (d) metabolic reduction of naltrexone occurs in the 100,000 x g supernatant of guinea pig liver.",Testing of drug delivery systems for use in the treatment of narcotic addiction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/827709/),%,20-26,4399,DB01183,Naloxone
,2745633,detection limit,The detection limit is 3 ng (signal-to-noise ratio = 3) free naloxone per ml plasma.,Quantitative and pharmacokinetic analysis of naloxone in plasma using high-performance liquid chromatography with electrochemical detection and solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2745633/),ng,3,6118,DB01183,Naloxone
,2745633,signal-to-noise ratio,The detection limit is 3 ng (signal-to-noise ratio = 3) free naloxone per ml plasma.,Quantitative and pharmacokinetic analysis of naloxone in plasma using high-performance liquid chromatography with electrochemical detection and solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2745633/),,3,6119,DB01183,Naloxone
,22169470,maximum hydromorphone plasma concentration (C(max)),"The obtained main pharmacokinetic parameters of hydromorphone in postoperative patients were as follows: the maximum hydromorphone plasma concentration (C(max)) was (24.15 ± 12.51)ng/mL, the time to the C(max) was (10.0 ± 0.0)min, and the elimination half-life was (2.7 ± 0.8)h.",Determination of hydromorphone in human plasma by a sensitive RP-HPLC-ESI-MS method and its application to a clinical pharmacokinetic study in postoperative patients after low dose intravenous administration with infusion pump. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169470/),[ng] / [ml],24.15,6633,DB01183,Naloxone
,22169470,time to the C(max),"The obtained main pharmacokinetic parameters of hydromorphone in postoperative patients were as follows: the maximum hydromorphone plasma concentration (C(max)) was (24.15 ± 12.51)ng/mL, the time to the C(max) was (10.0 ± 0.0)min, and the elimination half-life was (2.7 ± 0.8)h.",Determination of hydromorphone in human plasma by a sensitive RP-HPLC-ESI-MS method and its application to a clinical pharmacokinetic study in postoperative patients after low dose intravenous administration with infusion pump. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169470/),min,10.0,6634,DB01183,Naloxone
,22169470,elimination half-life,"The obtained main pharmacokinetic parameters of hydromorphone in postoperative patients were as follows: the maximum hydromorphone plasma concentration (C(max)) was (24.15 ± 12.51)ng/mL, the time to the C(max) was (10.0 ± 0.0)min, and the elimination half-life was (2.7 ± 0.8)h.",Determination of hydromorphone in human plasma by a sensitive RP-HPLC-ESI-MS method and its application to a clinical pharmacokinetic study in postoperative patients after low dose intravenous administration with infusion pump. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169470/),h,2.7,6635,DB01183,Naloxone
,23001479,latency,"In the second study, similar hyperalgesic responses were observed in mice lacking the multidrug resistance protein 3 (MRP3) transporter protein (Mrp3(-/-) mice) in the liver and their wild-type controls (FVB mice; latency reductions: 3.1 ± 0.2 s at t = 30 min, P < 0.001 versus within-strain baseline).",Morphine induces hyperalgesia without involvement of μ-opioid receptor or morphine-3-glucuronide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23001479/),s,3.1,8469,DB01183,Naloxone
,29568976,relative bioavailability,The relative bioavailability of intranasal to intramuscular naloxone was 0.75.,Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29568976/),,0.75,10208,DB01183,Naloxone
,8491826,signal-to-noise ratio,A signal-to-noise ratio of 4.5 is obtained when a 1 ng/ml spiked plasma sample is analyzed.,Determination of nalmefene in plasma by high-performance liquid chromatography with electrochemical detection and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491826/),,4.5,11810,DB01183,Naloxone
,6114837,terminal plasma half-life,"The route of administration significantly affected terminal plasma half-life values obtained for unconjugated naltrexone (2.7 hr, iv; 8.9 hr, oral), but had little effect on comparable values obtained for total drug, conjugated naltrexone, and unconjugated and conjugated 6 beta-naltrexol.",Metabolism and disposition of naltrexone in man after oral and intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114837/),h,2.7,14464,DB01183,Naloxone
,6114837,terminal plasma half-life,"The route of administration significantly affected terminal plasma half-life values obtained for unconjugated naltrexone (2.7 hr, iv; 8.9 hr, oral), but had little effect on comparable values obtained for total drug, conjugated naltrexone, and unconjugated and conjugated 6 beta-naltrexol.",Metabolism and disposition of naltrexone in man after oral and intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114837/),h,8.9,14465,DB01183,Naloxone
,20672450,AUC0-24h,"Compared to baseline values, BUP AUC0-24h (46.8 vs. 46.2 ng*hr/mL) and Cmax (6.54 vs. 5.88 ng/mL) did not differ significantly after achieving steady-state LPV/r.",Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[h·ng] / [ml],46.8,15377,DB01183,Naloxone
,20672450,AUC0-24h,"Compared to baseline values, BUP AUC0-24h (46.8 vs. 46.2 ng*hr/mL) and Cmax (6.54 vs. 5.88 ng/mL) did not differ significantly after achieving steady-state LPV/r.",Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[h·ng] / [ml],46.2,15378,DB01183,Naloxone
,20672450,Cmax,"Compared to baseline values, BUP AUC0-24h (46.8 vs. 46.2 ng*hr/mL) and Cmax (6.54 vs. 5.88 ng/mL) did not differ significantly after achieving steady-state LPV/r.",Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[ng] / [ml],6.54,15379,DB01183,Naloxone
,20672450,Cmax,"Compared to baseline values, BUP AUC0-24h (46.8 vs. 46.2 ng*hr/mL) and Cmax (6.54 vs. 5.88 ng/mL) did not differ significantly after achieving steady-state LPV/r.",Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[ng] / [ml],5.88,15380,DB01183,Naloxone
,20672450,AUC0-24 hours,"Similar analyses of norBUP, the primary metabolite of BUP, demonstrated no significant difference in norBUP AUC0-24 hours (73.7 vs. 52.7 ng x h/mL); however, Cmax (5.29 vs. 3.11 ng/mL) levels were statistically different (P < 0.05) after LPV/r administration.",Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[h·ng] / [ml],73.7,15381,DB01183,Naloxone
,20672450,AUC0-24 hours,"Similar analyses of norBUP, the primary metabolite of BUP, demonstrated no significant difference in norBUP AUC0-24 hours (73.7 vs. 52.7 ng x h/mL); however, Cmax (5.29 vs. 3.11 ng/mL) levels were statistically different (P < 0.05) after LPV/r administration.",Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[h·ng] / [ml],52.7,15382,DB01183,Naloxone
,20672450,Cmax,"Similar analyses of norBUP, the primary metabolite of BUP, demonstrated no significant difference in norBUP AUC0-24 hours (73.7 vs. 52.7 ng x h/mL); however, Cmax (5.29 vs. 3.11 ng/mL) levels were statistically different (P < 0.05) after LPV/r administration.",Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[ng] / [ml],5.29,15383,DB01183,Naloxone
,20672450,Cmax,"Similar analyses of norBUP, the primary metabolite of BUP, demonstrated no significant difference in norBUP AUC0-24 hours (73.7 vs. 52.7 ng x h/mL); however, Cmax (5.29 vs. 3.11 ng/mL) levels were statistically different (P < 0.05) after LPV/r administration.",Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[ng] / [ml],3.11,15384,DB01183,Naloxone
,20672450,AUC0-24 hours,Naloxone concentrations were similarly unchanged for AUC0-24 hours (0.421 vs. 0.374 ng x hr/mL) and Cmax (0.186 vs. 0.186 ng/mL).,Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[h·ng] / [ml],0.421,15385,DB01183,Naloxone
,20672450,AUC0-24 hours,Naloxone concentrations were similarly unchanged for AUC0-24 hours (0.421 vs. 0.374 ng x hr/mL) and Cmax (0.186 vs. 0.186 ng/mL).,Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[h·ng] / [ml],0.374,15386,DB01183,Naloxone
,20672450,Cmax,Naloxone concentrations were similarly unchanged for AUC0-24 hours (0.421 vs. 0.374 ng x hr/mL) and Cmax (0.186 vs. 0.186 ng/mL).,Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[ng] / [ml],0.186,15387,DB01183,Naloxone
,20672450,AUC0-24 hours,The AUC0-24 hours and Cmin of LPV in this study did not significantly differ from historical controls (159.6 vs. 171.3 microg x hr/mL) and (2.3 vs. 1.3 microg/mL).,Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[h·μg] / [ml],159.6,15388,DB01183,Naloxone
,20672450,AUC0-24 hours,The AUC0-24 hours and Cmin of LPV in this study did not significantly differ from historical controls (159.6 vs. 171.3 microg x hr/mL) and (2.3 vs. 1.3 microg/mL).,Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[h·μg] / [ml],171.3,15389,DB01183,Naloxone
,20672450,Cmin,The AUC0-24 hours and Cmin of LPV in this study did not significantly differ from historical controls (159.6 vs. 171.3 microg x hr/mL) and (2.3 vs. 1.3 microg/mL).,Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[μg] / [ml],2.3,15390,DB01183,Naloxone
,20672450,Cmin,The AUC0-24 hours and Cmin of LPV in this study did not significantly differ from historical controls (159.6 vs. 171.3 microg x hr/mL) and (2.3 vs. 1.3 microg/mL).,Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20672450/),[μg] / [ml],1.3,15391,DB01183,Naloxone
,17192502,time to maximum concentration (tmax),"Following single- and multiple-dose administration of fentanyl buccal tablet, the median time to maximum concentration (tmax) was 52.2 and 49.8 minutes, respectively.",Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192502/),min,52.2,15845,DB01183,Naloxone
,17192502,time to maximum concentration (tmax),"Following single- and multiple-dose administration of fentanyl buccal tablet, the median time to maximum concentration (tmax) was 52.2 and 49.8 minutes, respectively.",Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192502/),min,49.8,15846,DB01183,Naloxone
,17192502,Peak plasma concentration of fentanyl (Cmax),Peak plasma concentration of fentanyl (Cmax) was 0.88 ng/mL for the single-dose regimen and 1.77 ng/mL for the multiple-dose regimen.,Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192502/),[ng] / [ml],0.88,15847,DB01183,Naloxone
,17192502,Peak plasma concentration of fentanyl (Cmax),Peak plasma concentration of fentanyl (Cmax) was 0.88 ng/mL for the single-dose regimen and 1.77 ng/mL for the multiple-dose regimen.,Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192502/),[ng] / [ml],1.77,15848,DB01183,Naloxone
,17192502,half-life,"Steady state was reached within 5 days, consistent with the observed median half-life of approximately 22 hours following multiple doses.",Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192502/),h,22,15849,DB01183,Naloxone
,108382,total body clearance,A two-compartment open pharmacokinetic model was fitted to plasma level-time data for naltrexone in two dogs and yielded a total body clearance of 51-55 ml/min/kg.,Plasma naltrexone kinetics after intravenous bolus administration in dogs and monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/108382/),[ml] / [kg·min],51-55,16516,DB01183,Naloxone
,108382,terminal half-life,Plasma level-time data for intravenous naltrexone in six monkeys yielded an average terminal half-life of 7.8 hr and a total body clearance of 64 ml/min/kg.,Plasma naltrexone kinetics after intravenous bolus administration in dogs and monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/108382/),h,7.8,16517,DB01183,Naloxone
,108382,total body clearance,Plasma level-time data for intravenous naltrexone in six monkeys yielded an average terminal half-life of 7.8 hr and a total body clearance of 64 ml/min/kg.,Plasma naltrexone kinetics after intravenous bolus administration in dogs and monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/108382/),[ml] / [kg·min],64,16518,DB01183,Naloxone
,3247293,h,The plasma (dog and human) hydrolysis half-life of 3 was found to be approximately 30 min.,Naltrexone-3-salicylate (a prodrug of naltrexone): synthesis and pharmacokinetics in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3247293/),min,30,19089,DB01183,Naloxone
,3247293,t1/2,"Compound 2 was previously shown to hydrolyze in dog and human plasma with a fast deacetylation step to 3, followed by slower hydrolysis of 3 to 1 (t1/2, approximately 30 min).",Naltrexone-3-salicylate (a prodrug of naltrexone): synthesis and pharmacokinetics in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3247293/),min,30,19090,DB01183,Naloxone
,3247293,half-life,The half-life of naltrexone in dogs after oral administration of 3 was similar to that observed after oral administration of 2 (approximately 1 hr).,Naltrexone-3-salicylate (a prodrug of naltrexone): synthesis and pharmacokinetics in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3247293/),h,1,19091,DB01183,Naloxone
,15380723,flow rate,The chromatographic separation was performed on a C(18) column using a mobile phase consisting of 35:65 (v/v) acetonitrile:2 mM ammonium acetate with 0.01 mM ammonium citrate at a flow rate of 0.25 mL/min.,Development and validation of a liquid chromatography-mass spectrometry method for the quantitation of naltrexone and 6beta-naltrexol in guinea pig plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380723/),[ml] / [min],0.25,24555,DB01183,Naloxone
,15380723,recoveries,"The mean recoveries for naltrexone, naltrexol, and naloxone were 91.7, 89.3, and 99.0%, respectively.",Development and validation of a liquid chromatography-mass spectrometry method for the quantitation of naltrexone and 6beta-naltrexol in guinea pig plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380723/),%,91.7,24556,DB01183,Naloxone
,15380723,recoveries,"The mean recoveries for naltrexone, naltrexol, and naloxone were 91.7, 89.3, and 99.0%, respectively.",Development and validation of a liquid chromatography-mass spectrometry method for the quantitation of naltrexone and 6beta-naltrexol in guinea pig plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380723/),%,89.3,24557,DB01183,Naloxone
,15380723,recoveries,"The mean recoveries for naltrexone, naltrexol, and naloxone were 91.7, 89.3, and 99.0%, respectively.",Development and validation of a liquid chromatography-mass spectrometry method for the quantitation of naltrexone and 6beta-naltrexol in guinea pig plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380723/),%,99.0,24558,DB01183,Naloxone
,15380723,limit of detection (LOD),"The lower limit of quantification (LLOQ) for naltrexone and 6beta-naltrexol was 1.25 ng/mL, and the limit of detection (LOD) was 0.75 ng/mL.",Development and validation of a liquid chromatography-mass spectrometry method for the quantitation of naltrexone and 6beta-naltrexol in guinea pig plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380723/),[ng] / [ml],0.75,24559,DB01183,Naloxone
,21395892,bioavailability,Buprenorphine bioavailability was 38-44% and T(max) was 35-40 minutes after all intranasal doses.,The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395892/),%,38-44,25521,DB01183,Naloxone
,21395892,T(max),Buprenorphine bioavailability was 38-44% and T(max) was 35-40 minutes after all intranasal doses.,The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395892/),min,35-40,25522,DB01183,Naloxone
,21395892,bioavailability,"Naloxone bioavailability was 24% and 30% following 2/0.5 and 8/2 mg, respectively.",The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395892/),%,24,25523,DB01183,Naloxone
,21395892,bioavailability,"Naloxone bioavailability was 24% and 30% following 2/0.5 and 8/2 mg, respectively.",The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395892/),%,30,25524,DB01183,Naloxone
,31246123,lag time,"Naloxone administered IN was well absorbed after a short lag time (mean ± SD, 2.3 ± 1.4 minutes).",Pharmacokinetics and pharmacodynamics of intranasal and intravenous naloxone hydrochloride administration in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31246123/),min,2.3,27599,DB01183,Naloxone
,31246123,maximum plasma concentration,"Mean maximum plasma concentration following IN and IV administration was 9.3 ± 2.5 ng/mL and 18.8 ± 3.9 ng/mL, respectively.",Pharmacokinetics and pharmacodynamics of intranasal and intravenous naloxone hydrochloride administration in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31246123/),[ng] / [ml],9.3,27600,DB01183,Naloxone
,31246123,maximum plasma concentration,"Mean maximum plasma concentration following IN and IV administration was 9.3 ± 2.5 ng/mL and 18.8 ± 3.9 ng/mL, respectively.",Pharmacokinetics and pharmacodynamics of intranasal and intravenous naloxone hydrochloride administration in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31246123/),[ng] / [ml],18.8,27601,DB01183,Naloxone
,31246123,time to maximum concentration,Mean time to maximum concentration following IN administration was 22.5 ± 8.2 minutes.,Pharmacokinetics and pharmacodynamics of intranasal and intravenous naloxone hydrochloride administration in healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31246123/),min,22.5,27602,DB01183,Naloxone
,31246123,terminal half-life,"Mean terminal half-life after IN and IV administration was 47.4 ± 6.7 minutes and 37.0 ± 6.7 minutes, respectively.",Pharmacokinetics and pharmacodynamics of intranasal and intravenous naloxone hydrochloride administration in healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31246123/),min,47.4,27603,DB01183,Naloxone
,31246123,terminal half-life,"Mean terminal half-life after IN and IV administration was 47.4 ± 6.7 minutes and 37.0 ± 6.7 minutes, respectively.",Pharmacokinetics and pharmacodynamics of intranasal and intravenous naloxone hydrochloride administration in healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31246123/),min,37.0,27604,DB01183,Naloxone
,31246123,bioavailability,Mean bioavailability of naloxone administered IN was 32 ± 13%.,Pharmacokinetics and pharmacodynamics of intranasal and intravenous naloxone hydrochloride administration in healthy dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31246123/),%,32,27605,DB01183,Naloxone
,19071491,limit of detection,And the limit of detection was 0.1ng/ml for naltrexone and 0.36ng/ml for 6-beta-naltrexol.,"Simultaneous analysis of naltrexone and its major metabolite, 6-beta-naltrexol, in human plasma using liquid chromatography-tandem mass spectrometry: Application to a parent-metabolite kinetic model in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19071491/),[ng] / [ml],0.1,27886,DB01183,Naloxone
,19071491,limit of detection,And the limit of detection was 0.1ng/ml for naltrexone and 0.36ng/ml for 6-beta-naltrexol.,"Simultaneous analysis of naltrexone and its major metabolite, 6-beta-naltrexol, in human plasma using liquid chromatography-tandem mass spectrometry: Application to a parent-metabolite kinetic model in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19071491/),[ng] / [ml],0.36,27887,DB01183,Naloxone
,22541841,absolute bioavailability,"The mean absolute bioavailability of naloxone from the orally administered PR tablets was very low, ranging from 0.9% for the 5 mg dose to 2% for the 40, 80 and 120 mg doses, based on AUC(t) values.",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,0.9,30364,DB01183,Naloxone
,22541841,absolute bioavailability,"The mean absolute bioavailability of naloxone from the orally administered PR tablets was very low, ranging from 0.9% for the 5 mg dose to 2% for the 40, 80 and 120 mg doses, based on AUC(t) values.",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,2,30365,DB01183,Naloxone
,22541841,absolute bioavailability,"Where AUC(inf) values were calculated, these confirmed the results based on AUC(t) values (mean absolute bioavailability ranging from 1.9% to 2.2% for the 20 mg to 120 mg oral doses).",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,1.9,30366,DB01183,Naloxone
,22541841,absolute bioavailability,"Where AUC(inf) values were calculated, these confirmed the results based on AUC(t) values (mean absolute bioavailability ranging from 1.9% to 2.2% for the 20 mg to 120 mg oral doses).",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,2.2,30367,DB01183,Naloxone
,22541841,absolute bioavailability,"The absolute bioavailability of naloxone was higher following rectal administration compared with oral administration, but was still low at 15%.",Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,15,30368,DB01183,Naloxone
≤,22541841,oral absolute bioavailability,The mean oral absolute bioavailability of naloxone in this study was ≤ 2% at doses ranging from 5 mg to 120 mg.,Low absolute bioavailability of oral naloxone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541841/),%,2,30369,DB01183,Naloxone
,18321686,equivalent steady state plasma concentrations,6-Beta-naltrexol equivalent steady state plasma concentrations of 6.4 ng/ml were obtained after application of the codrug as compared to 1.2 ng/ml from 6-beta-naltrexol base.,In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321686/),[ng] / [ml],6.4,32584,DB01183,Naloxone
,18321686,equivalent steady state plasma concentrations,6-Beta-naltrexol equivalent steady state plasma concentrations of 6.4 ng/ml were obtained after application of the codrug as compared to 1.2 ng/ml from 6-beta-naltrexol base.,In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321686/),[ng] / [ml],1.2,32585,DB01183,Naloxone
,18321686,steady state plasma concentration,The steady state plasma concentration of hydroxybupropion after codrug application was 6.9 ng/ml.,In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321686/),[ng] / [ml],6.9,32586,DB01183,Naloxone
,22108639,steady-state transdermal absorption rates,"In vivo steady-state transdermal absorption rates at 90 and 180 μA/cm(2) were 136 and 305 μg/h/cm(2), respectively.","In vitro and in vivo transdermal iontophoretic delivery of naloxone, an opioid antagonist. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22108639/),[μa] / [cm(2],90,34764,DB01183,Naloxone
,22108639,steady-state transdermal absorption rates,"In vivo steady-state transdermal absorption rates at 90 and 180 μA/cm(2) were 136 and 305 μg/h/cm(2), respectively.","In vitro and in vivo transdermal iontophoretic delivery of naloxone, an opioid antagonist. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22108639/),[μa] / [cm(2],180,34765,DB01183,Naloxone
,22108639,steady-state transdermal absorption rates,"In vivo steady-state transdermal absorption rates at 90 and 180 μA/cm(2) were 136 and 305 μg/h/cm(2), respectively.","In vitro and in vivo transdermal iontophoretic delivery of naloxone, an opioid antagonist. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22108639/),[h·μg] / [cm(2],136,34766,DB01183,Naloxone
,22108639,steady-state transdermal absorption rates,"In vivo steady-state transdermal absorption rates at 90 and 180 μA/cm(2) were 136 and 305 μg/h/cm(2), respectively.","In vitro and in vivo transdermal iontophoretic delivery of naloxone, an opioid antagonist. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22108639/),[h·μg] / [cm(2],305,34767,DB01183,Naloxone
,23936895,peak effect (Emax),"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,69.6,37015,DB01183,Naloxone
,23936895,peak effect (Emax),"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,55.2,37016,DB01183,Naloxone
,23936895,area under the effect curve,"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,86.3,37017,DB01183,Naloxone
,23936895,area under the effect curve,"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,66.7,37018,DB01183,Naloxone
,23936895,Emax,"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,87.6,37019,DB01183,Naloxone
,23936895,Emax,"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,86.6,37020,DB01183,Naloxone
,23936895,area under the curve over 2 h,"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,120.6,37021,DB01183,Naloxone
,23936895,area under the curve over 2 h,"MSN showed significantly lower scores for drug liking and high VAS scores on both mean peak effect (Emax) (69.6 and 55.2, respectively) and in area under the effect curve over 2 h (86.3 and 66.7, respectively) following dosing compared with MS (Emax 87.6 and 86.6, respectively; area under the curve over 2 h 120.6 and 132.9, respectively; P<0.001).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),,132.9,37022,DB01183,Naloxone
,23936895,peak plasma concentration (Cmax),"Mean peak plasma concentration (Cmax) and median time to Cmax for morphine following administration of MSN and MS were similar (27.3 ng⁄mL and 0.57 h versus 27.7 ng⁄mL and 0.6 h, respectively).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),ng⁄ml,27.3,37023,DB01183,Naloxone
,23936895,peak plasma concentration (Cmax),"Mean peak plasma concentration (Cmax) and median time to Cmax for morphine following administration of MSN and MS were similar (27.3 ng⁄mL and 0.57 h versus 27.7 ng⁄mL and 0.6 h, respectively).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),ng⁄ml,27.7,37024,DB01183,Naloxone
,23936895,time to Cmax,"Mean peak plasma concentration (Cmax) and median time to Cmax for morphine following administration of MSN and MS were similar (27.3 ng⁄mL and 0.57 h versus 27.7 ng⁄mL and 0.6 h, respectively).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),h,0.57,37025,DB01183,Naloxone
,23936895,time to Cmax,"Mean peak plasma concentration (Cmax) and median time to Cmax for morphine following administration of MSN and MS were similar (27.3 ng⁄mL and 0.57 h versus 27.7 ng⁄mL and 0.6 h, respectively).",Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),h,0.6,37026,DB01183,Naloxone
,23936895,Cmax,Naltrexone mean Cmax was 1497 pg⁄mL after MSN and median time to Cmax was 0.55 h.,Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),pg⁄ml,1497,37027,DB01183,Naloxone
,23936895,time to Cmax,Naltrexone mean Cmax was 1497 pg⁄mL after MSN and median time to Cmax was 0.55 h.,Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23936895/),h,0.55,37028,DB01183,Naloxone
,30351180,Tmax,"3. Naldemedine was the major circulating component in plasma with a median Tmax of approximately 0.8-0.9 h and a geometric mean t1/2,z of approximately 11 h.","Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30351180/),h,0.8-0.9,37268,DB01183,Naloxone
,30351180,"t1/2,z","3. Naldemedine was the major circulating component in plasma with a median Tmax of approximately 0.8-0.9 h and a geometric mean t1/2,z of approximately 11 h.","Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30351180/),h,11,37269,DB01183,Naloxone
,30351180,recovery of,"Overall, the recovery of total radioactivity was 92% (57.3% in urine; 34.8% in feces) after administration of [oxadiazole-14C]-naldemedine and 85% (20.4% in urine; 64.3% in feces) after administration of [carbonyl-14C]-naldemedine.","Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30351180/),%,92,37270,DB01183,Naloxone
,30351180,recovery of,"Overall, the recovery of total radioactivity was 92% (57.3% in urine; 34.8% in feces) after administration of [oxadiazole-14C]-naldemedine and 85% (20.4% in urine; 64.3% in feces) after administration of [carbonyl-14C]-naldemedine.","Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30351180/),%,57.3,37271,DB01183,Naloxone
,30351180,recovery of,"Overall, the recovery of total radioactivity was 92% (57.3% in urine; 34.8% in feces) after administration of [oxadiazole-14C]-naldemedine and 85% (20.4% in urine; 64.3% in feces) after administration of [carbonyl-14C]-naldemedine.","Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30351180/),%,34.8,37272,DB01183,Naloxone
,30351180,recovery of,"Overall, the recovery of total radioactivity was 92% (57.3% in urine; 34.8% in feces) after administration of [oxadiazole-14C]-naldemedine and 85% (20.4% in urine; 64.3% in feces) after administration of [carbonyl-14C]-naldemedine.","Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30351180/),%,85,37273,DB01183,Naloxone
,30351180,recovery of,"Overall, the recovery of total radioactivity was 92% (57.3% in urine; 34.8% in feces) after administration of [oxadiazole-14C]-naldemedine and 85% (20.4% in urine; 64.3% in feces) after administration of [carbonyl-14C]-naldemedine.","Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30351180/),%,20.4,37274,DB01183,Naloxone
,30351180,recovery of,"Overall, the recovery of total radioactivity was 92% (57.3% in urine; 34.8% in feces) after administration of [oxadiazole-14C]-naldemedine and 85% (20.4% in urine; 64.3% in feces) after administration of [carbonyl-14C]-naldemedine.","Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30351180/),%,64.3,37275,DB01183,Naloxone
,28960888,maximum plasma concentration,"On day 1 of the single ascending dose studies and day 10 of the multiple ascending dose studies, respectively, the maximum plasma concentration levels of naldemedine were 1.98 to 2510 ng/mL and 73.8 to 700 ng/mL, peaked at 0.5 hours and 0.5 to 0.75 hours, and the fraction excreted in urine was 15.9% to 20.5% and 19.7% to 19.1%.","Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28960888/),[ng] / [ml],1.98 to 2510,37450,DB01183,Naloxone
,28960888,maximum plasma concentration,"On day 1 of the single ascending dose studies and day 10 of the multiple ascending dose studies, respectively, the maximum plasma concentration levels of naldemedine were 1.98 to 2510 ng/mL and 73.8 to 700 ng/mL, peaked at 0.5 hours and 0.5 to 0.75 hours, and the fraction excreted in urine was 15.9% to 20.5% and 19.7% to 19.1%.","Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28960888/),[ng] / [ml],73.8 to 700,37451,DB01183,Naloxone
,28960888,fraction excreted in urine,"On day 1 of the single ascending dose studies and day 10 of the multiple ascending dose studies, respectively, the maximum plasma concentration levels of naldemedine were 1.98 to 2510 ng/mL and 73.8 to 700 ng/mL, peaked at 0.5 hours and 0.5 to 0.75 hours, and the fraction excreted in urine was 15.9% to 20.5% and 19.7% to 19.1%.","Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28960888/),%,15.9,37452,DB01183,Naloxone
,28960888,fraction excreted in urine,"On day 1 of the single ascending dose studies and day 10 of the multiple ascending dose studies, respectively, the maximum plasma concentration levels of naldemedine were 1.98 to 2510 ng/mL and 73.8 to 700 ng/mL, peaked at 0.5 hours and 0.5 to 0.75 hours, and the fraction excreted in urine was 15.9% to 20.5% and 19.7% to 19.1%.","Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28960888/),%,20.5,37453,DB01183,Naloxone
,28960888,fraction excreted in urine,"On day 1 of the single ascending dose studies and day 10 of the multiple ascending dose studies, respectively, the maximum plasma concentration levels of naldemedine were 1.98 to 2510 ng/mL and 73.8 to 700 ng/mL, peaked at 0.5 hours and 0.5 to 0.75 hours, and the fraction excreted in urine was 15.9% to 20.5% and 19.7% to 19.1%.","Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28960888/),%,19.7,37454,DB01183,Naloxone
,28960888,fraction excreted in urine,"On day 1 of the single ascending dose studies and day 10 of the multiple ascending dose studies, respectively, the maximum plasma concentration levels of naldemedine were 1.98 to 2510 ng/mL and 73.8 to 700 ng/mL, peaked at 0.5 hours and 0.5 to 0.75 hours, and the fraction excreted in urine was 15.9% to 20.5% and 19.7% to 19.1%.","Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28960888/),%,19.1,37455,DB01183,Naloxone
,26329350,maximum plasma concentration,"Naloxegol was rapidly absorbed, with a maximum plasma concentration (geometric mean) of 51 ng/mL reached before 2 hours after dosing.","Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26329350/),[ng] / [ml],51,38337,DB01183,Naloxone
,26329350,cumulative recovery of radioactivity,"Mean cumulative recovery of radioactivity was 84.2% of the total dose, with ~68.9% recovered within 96 hours of dosing.","Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26329350/),%,84.2,38338,DB01183,Naloxone
,26329350,cumulative recovery of radioactivity,"Mean cumulative recovery of radioactivity was 84.2% of the total dose, with ~68.9% recovered within 96 hours of dosing.","Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26329350/),%,68,38339,DB01183,Naloxone
,26329350,recoveries,"Fecal excretion was the predominant route of elimination, with mean recoveries of total radioactivity in feces and urine of 67.7% and 16.0%, respectively.","Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26329350/),%,67.7,38340,DB01183,Naloxone
,26329350,recoveries,"Fecal excretion was the predominant route of elimination, with mean recoveries of total radioactivity in feces and urine of 67.7% and 16.0%, respectively.","Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26329350/),%,16.0,38341,DB01183,Naloxone
,9208648,elimination half-lives,"The elimination half-lives of NTX were 78 +/- 6 min and 74 +/- 6 min, respectively.",[Pharmacokinetics of naltrexone hydrochloride and naltrexone glucuronide in the dog]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9208648/),min,78,38826,DB01183,Naloxone
,9208648,elimination half-lives,"The elimination half-lives of NTX were 78 +/- 6 min and 74 +/- 6 min, respectively.",[Pharmacokinetics of naltrexone hydrochloride and naltrexone glucuronide in the dog]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9208648/),min,74,38827,DB01183,Naloxone
,9208648,absolute bioavailability,"Although NTX could be absorbed rapidly in the dog after po administration, the plasma concentration of the parent drug was very low and its absolute bioavailability was 15.8%.",[Pharmacokinetics of naltrexone hydrochloride and naltrexone glucuronide in the dog]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9208648/),%,15.8,38828,DB01183,Naloxone
,9208648,elimination half-lives,"Dosing NTX intravenously and orally, the plasma levels of the conjugate were 1.3 and 23 times as high as that of the parent drug, the elimination half-lives of the glucuronide from plasma were 3.4 h and 12.6 h, respectively.",[Pharmacokinetics of naltrexone hydrochloride and naltrexone glucuronide in the dog]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9208648/),h,3.4,38829,DB01183,Naloxone
,9208648,elimination half-lives,"Dosing NTX intravenously and orally, the plasma levels of the conjugate were 1.3 and 23 times as high as that of the parent drug, the elimination half-lives of the glucuronide from plasma were 3.4 h and 12.6 h, respectively.",[Pharmacokinetics of naltrexone hydrochloride and naltrexone glucuronide in the dog]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9208648/),h,12.6,38830,DB01183,Naloxone
,24216276,flow rate,"The mobile phase was composed of acetonitrile-10mmol/L ammonium formate (86:14, v/v), with a flow rate of 0.4mL/min.",Determination of naloxone-3-glucuronide in human plasma and urine by HILIC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216276/),[ml] / [min],0.4,41435,DB01183,Naloxone
,24216276,AUC0-24,"In human subjects receiving 100mg tilidine and 8mg naloxone, mean AUC0-24 of N3G was 160.93±52.77ng/mLh and mean Cmax was 75.33±25.27ng/mL.",Determination of naloxone-3-glucuronide in human plasma and urine by HILIC-MS/MS. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216276/),[ng] / [mlh],160.93,41436,DB01183,Naloxone
,24216276,Cmax,"In human subjects receiving 100mg tilidine and 8mg naloxone, mean AUC0-24 of N3G was 160.93±52.77ng/mLh and mean Cmax was 75.33±25.27ng/mL.",Determination of naloxone-3-glucuronide in human plasma and urine by HILIC-MS/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216276/),[ng] / [ml],75.33,41437,DB01183,Naloxone
,25456560,Tmax,"In both studies, samidorphan was rapidly absorbed, with a Tmax of 1 hour, and AUC increased with increasing dose.","Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25456560/),h,1,41670,DB01183,Naloxone
,25456560,half-life,"Samidorphan plasma levels declined in a monoexponential manner, with a half-life of ~7 to 9 hours.","Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25456560/),h,7 to 9,41671,DB01183,Naloxone
<,25456560,accumulation ratios,"Accumulation was low, with accumulation ratios <1.65.","Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25456560/),,1.65,41672,DB01183,Naloxone
,9048269,elimination half-life,"Pharmacokinetic analysis revealed an elimination half-life of 117.5 minutes (+/-53.2), and a clearance of 38.8 L/hr (+/-17.4) with a methylnaltrexone dose of 0.64 mg/kg.","Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9048269/),min,117.5,47186,DB01183,Naloxone
,9048269,clearance,"Pharmacokinetic analysis revealed an elimination half-life of 117.5 minutes (+/-53.2), and a clearance of 38.8 L/hr (+/-17.4) with a methylnaltrexone dose of 0.64 mg/kg.","Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9048269/),[l] / [h],38.8,47187,DB01183,Naloxone
,34048932,passive permeation,In vitro passive permeation of NAL after 6 h was observed to be 8.25±1.06 µg/cm2.,Microneedle-mediated transdermal delivery of naloxone hydrochloride for treatment of opioid overdose. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34048932/),[μg] / [cm2],8.25,47565,DB01183,Naloxone
,34048932,lag time,Application of 500 µm MNs for 2 min significantly reduced the lag time to ~ 8 min and increasing the donor concentration for the same treatment group doubled the permeation (p < 0.05).,Microneedle-mediated transdermal delivery of naloxone hydrochloride for treatment of opioid overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34048932/),min,8,47566,DB01183,Naloxone
,11524321,t(1/2),Full resensitization of the blood pressure response occurred by 4 h for DAMGO (t(1/2) = 15 min) and by 48 h for [Dmt(1)]DALDA (t(1/2) = 1.8 h).,Resensitization of blood pressure response to mu-opioid peptide agonists after acute desensitization. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11524321/),min,15,48065,DB01183,Naloxone
,11524321,t(1/2),Full resensitization of the blood pressure response occurred by 4 h for DAMGO (t(1/2) = 15 min) and by 48 h for [Dmt(1)]DALDA (t(1/2) = 1.8 h).,Resensitization of blood pressure response to mu-opioid peptide agonists after acute desensitization. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11524321/),h,1.8,48066,DB01183,Naloxone
,17329173,total chromatographic run time,The method had a total chromatographic run time of 4.5 min and linear calibration curves over the concentration range of 10-5000 pg/mL.,Application of a sensitive liquid chromatographic/tandem mass spectrometric method to pharmacokinetic study of nalmefene in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329173/),min,4.5,48170,DB01183,Naloxone
,2147593,initial volume of distribution,The initial volume of distribution was significantly smaller in the elderly patients (310 +/- 109 ml.kg-1 vs 491 +/- 112 ml.kg-1 mean +/- SD).,Pharmacokinetics of sufentanil in the elderly surgical patient. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2147593/),[ml] / [kg],310,49463,DB01183,Naloxone
,2147593,initial volume of distribution,The initial volume of distribution was significantly smaller in the elderly patients (310 +/- 109 ml.kg-1 vs 491 +/- 112 ml.kg-1 mean +/- SD).,Pharmacokinetics of sufentanil in the elderly surgical patient. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2147593/),[ml] / [kg],491,49464,DB01183,Naloxone
greater,2147593,rate of ventilation,Six of seven elderly patients required administration of naloxone at the termination of surgery to achieve an adequate rate of ventilation (greater than eight breaths.min-1) while only one younger patient required antagonism of ventilatory depression.,Pharmacokinetics of sufentanil in the elderly surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2147593/),[breaths] / [min],eight,49465,DB01183,Naloxone
,31463821,plasma clearance,"In study 1, intravenous SAM had a plasma clearance of 33.7 L/h, volume of distribution of 341 L, and elimination half-life of 7-8 h.",Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463821/),[l] / [h],33.7,51336,DB01183,Naloxone
,31463821,volume of distribution,"In study 1, intravenous SAM had a plasma clearance of 33.7 L/h, volume of distribution of 341 L, and elimination half-life of 7-8 h.",Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463821/),l,341,51337,DB01183,Naloxone
,31463821,elimination half-life,"In study 1, intravenous SAM had a plasma clearance of 33.7 L/h, volume of distribution of 341 L, and elimination half-life of 7-8 h.",Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463821/),h,7-8,51338,DB01183,Naloxone
,31463821,absolute bioavailability,"SAM was well-absorbed following sublingual or oral administration and reached peak concentrations (Cmax) within 2 h, with absolute bioavailability of 71% (sublingual) and 69% (oral).",Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463821/),%,71,51339,DB01183,Naloxone
,31463821,absolute bioavailability,"SAM was well-absorbed following sublingual or oral administration and reached peak concentrations (Cmax) within 2 h, with absolute bioavailability of 71% (sublingual) and 69% (oral).",Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463821/),%,69,51340,DB01183,Naloxone
,27440072,MRT0-t,"The results of pharmacokinetic study indicated that a sustained release behavior could be obtained with MRT0-t (30.34 ± 12.47) h for LXT-101 and MRT0-t (2.37 ± 0.876) h for NTX, about 10 and 4 times longer than those of aqueous solution respectively.",Release Characteristics In Vitro and In Vivo of In Situ Gels for a Novel Peptide Compared with Low-Molecular-Weight Hydrophilic Drug. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27440072/),h,30.34,51626,DB01183,Naloxone
,27440072,MRT0-t,"The results of pharmacokinetic study indicated that a sustained release behavior could be obtained with MRT0-t (30.34 ± 12.47) h for LXT-101 and MRT0-t (2.37 ± 0.876) h for NTX, about 10 and 4 times longer than those of aqueous solution respectively.",Release Characteristics In Vitro and In Vivo of In Situ Gels for a Novel Peptide Compared with Low-Molecular-Weight Hydrophilic Drug. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27440072/),h,2.37,51627,DB01183,Naloxone
,32192089,Plasma levels,"Plasma levels were 4.6 ng/mL, 16.8 ng/mL, and 43.4 ng/mL for the three IM doses, and a significant correlation between percent RO and plasma NLX level was observed (r = 0.80).",The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32192089/),[ng] / [ml],4.6,52599,DB01183,Naloxone
,32192089,Plasma levels,"Plasma levels were 4.6 ng/mL, 16.8 ng/mL, and 43.4 ng/mL for the three IM doses, and a significant correlation between percent RO and plasma NLX level was observed (r = 0.80).",The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32192089/),[ng] / [ml],16.8,52600,DB01183,Naloxone
,32192089,Plasma levels,"Plasma levels were 4.6 ng/mL, 16.8 ng/mL, and 43.4 ng/mL for the three IM doses, and a significant correlation between percent RO and plasma NLX level was observed (r = 0.80).",The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32192089/),[ng] / [ml],43.4,52601,DB01183,Naloxone
,12006217,K(i),"In the electrically-stimulated guinea pig ileum, 6beta-naltrexol was more potent (K(i) = 94 +/- 25 pM), than naloxone (420 +/- 150 pM), and naltrexone (265 +/- 101 pM).","In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006217/),pM,94,54576,DB01183,Naloxone
,12006217,K(i),"In the electrically-stimulated guinea pig ileum, 6beta-naltrexol was more potent (K(i) = 94 +/- 25 pM), than naloxone (420 +/- 150 pM), and naltrexone (265 +/- 101 pM).","In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006217/),pM,420,54577,DB01183,Naloxone
,12006217,K(i),"In the electrically-stimulated guinea pig ileum, 6beta-naltrexol was more potent (K(i) = 94 +/- 25 pM), than naloxone (420 +/- 150 pM), and naltrexone (265 +/- 101 pM).","In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006217/),pM,265,54578,DB01183,Naloxone
,12006217,duration,"The duration of antagonist activity to decrease by 50% was 80, 125 and 340 minutes for naltrexone, naloxone and 6beta-naltrexol, respectively.","In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006217/),min,80,54579,DB01183,Naloxone
,12006217,duration,"The duration of antagonist activity to decrease by 50% was 80, 125 and 340 minutes for naltrexone, naloxone and 6beta-naltrexol, respectively.","In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006217/),min,125,54580,DB01183,Naloxone
,12006217,duration,"The duration of antagonist activity to decrease by 50% was 80, 125 and 340 minutes for naltrexone, naloxone and 6beta-naltrexol, respectively.","In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006217/),min,340,54581,DB01183,Naloxone
,10907964,initial disposition half-life (t(1/2alpha)),"The initial disposition half-life (t(1/2alpha)) was 0.36+/-0.11 hour, the terminal elimination half-life (t(1/2beta)) 8.7+/-2.3 hours, clearance 0.729+/-0.172 L/kg/hr, and steady-state volume of distribution 7.21+/-2.49 L/kg.",Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10907964/),h,0.36,57026,DB01183,Naloxone
,10907964,terminal elimination half-life (t(1/2beta)),"The initial disposition half-life (t(1/2alpha)) was 0.36+/-0.11 hour, the terminal elimination half-life (t(1/2beta)) 8.7+/-2.3 hours, clearance 0.729+/-0.172 L/kg/hr, and steady-state volume of distribution 7.21+/-2.49 L/kg.",Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10907964/),h,8.7,57027,DB01183,Naloxone
,10907964,clearance,"The initial disposition half-life (t(1/2alpha)) was 0.36+/-0.11 hour, the terminal elimination half-life (t(1/2beta)) 8.7+/-2.3 hours, clearance 0.729+/-0.172 L/kg/hr, and steady-state volume of distribution 7.21+/-2.49 L/kg.",Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10907964/),[l] / [h·kg],0.729,57028,DB01183,Naloxone
,10907964,steady-state volume of distribution,"The initial disposition half-life (t(1/2alpha)) was 0.36+/-0.11 hour, the terminal elimination half-life (t(1/2beta)) 8.7+/-2.3 hours, clearance 0.729+/-0.172 L/kg/hr, and steady-state volume of distribution 7.21+/-2.49 L/kg.",Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10907964/),[l] / [kg],7.21,57029,DB01183,Naloxone
,1844212,plasma clearance,The plasma clearance of sufentanil and fentanyl (902 vs 914 ml.min-1) are similar.,[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[ml] / [min],902,58068,DB01183,Naloxone
,1844212,plasma clearance,The plasma clearance of sufentanil and fentanyl (902 vs 914 ml.min-1) are similar.,[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[ml] / [min],914,58069,DB01183,Naloxone
,1844212,volumes of distribution,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[l] / [kg],4.9,58070,DB01183,Naloxone
,1844212,volumes of distribution,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[l] / [kg],11.3,58071,DB01183,Naloxone
,1844212,half-life,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),min,250,58072,DB01183,Naloxone
,1844212,half-life,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),min,562,58073,DB01183,Naloxone
,2340348,sensitivities,Specific and sensitive reverse-phase HPLC assays of buprenorphine and its metabolite in biological fluids were developed with sensitivities of 2-6 ng ml-1 using fluorimetric detection.,Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),[ng] / [ml],2-6,58734,DB01183,Naloxone
,2340348,terminal rate constants,The terminal rate constants of the IV infusion studies from the triexponential fits of plasma concentration-time data averaged 41.6 +/- 7.5 h with an averaged total body clearance of 191 +/- 19 ml min-1.,Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),h,41.6,58735,DB01183,Naloxone
,2340348,total body clearance,The terminal rate constants of the IV infusion studies from the triexponential fits of plasma concentration-time data averaged 41.6 +/- 7.5 h with an averaged total body clearance of 191 +/- 19 ml min-1.,Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),[ml] / [min],191,58736,DB01183,Naloxone
less,2340348,half-life,"This terminal rate constant was in contrast to the less than 100 min half-life of the second exponential fitting of the less lipophilic morphine, naloxone, and naltrexone.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),min,100,58737,DB01183,Naloxone
,2340348,apparent volumes of distribution,"The apparent volumes of distribution of buprenorphine, referenced to the total plasma concentration, were 33 +/- 61 (Vc, central compartment volume) and 663 +/- 891 (Vd, total body volume), indicative of a highly bound, sequestered or lipophilic drug.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),,33,58738,DB01183,Naloxone
,2340348,Vc,"The apparent volumes of distribution of buprenorphine, referenced to the total plasma concentration, were 33 +/- 61 (Vc, central compartment volume) and 663 +/- 891 (Vd, total body volume), indicative of a highly bound, sequestered or lipophilic drug.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),,33,58739,DB01183,Naloxone
,2340348,Vd,"The apparent volumes of distribution of buprenorphine, referenced to the total plasma concentration, were 33 +/- 61 (Vc, central compartment volume) and 663 +/- 891 (Vd, total body volume), indicative of a highly bound, sequestered or lipophilic drug.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),,663,58740,DB01183,Naloxone
,2340348,terminal half-life,"Direct IV administration of the metabolite, buprenorphine glucuronide, gave a terminal half-life of 6 h and more than 90 per cent of the systemically circulating metabolite was excreted in bile; only 10 per cent in urine.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),h,6,58741,DB01183,Naloxone
,2340348,oral bioavailability,"The oral bioavailability, estimated from the areas under the buprenorphine plasma concentration-time curve following IV and oral administration of buprenorphine in the dogs, was 3-6 per cent.",Pharmacokinetics of morphine and its surrogates. X: Analyses and pharmacokinetics of buprenorphine in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340348/),%,3-6,58742,DB01183,Naloxone
,27781278,Cmax,"The adjuvants increased Cmax (21 ± 16 ng/ml vs 75 ± 33 ng/ml; 3.6-fold) and AUC(0-22 h) (10.6 ± 8.11 μg min/ml vs 22.9 ± 11.7 μg min/ml; 2.2-fold) values of buprenorphine (control vs adjuvant-treated, respectively).",Improving the oral bioavailability of buprenorphine: an in-vivo proof of concept. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781278/),[ng] / [ml],21,60072,DB01183,Naloxone
,27781278,Cmax,"The adjuvants increased Cmax (21 ± 16 ng/ml vs 75 ± 33 ng/ml; 3.6-fold) and AUC(0-22 h) (10.6 ± 8.11 μg min/ml vs 22.9 ± 11.7 μg min/ml; 2.2-fold) values of buprenorphine (control vs adjuvant-treated, respectively).",Improving the oral bioavailability of buprenorphine: an in-vivo proof of concept. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781278/),[ng] / [ml],75,60073,DB01183,Naloxone
,27781278,AUC(0-22 h),"The adjuvants increased Cmax (21 ± 16 ng/ml vs 75 ± 33 ng/ml; 3.6-fold) and AUC(0-22 h) (10.6 ± 8.11 μg min/ml vs 22.9 ± 11.7 μg min/ml; 2.2-fold) values of buprenorphine (control vs adjuvant-treated, respectively).",Improving the oral bioavailability of buprenorphine: an in-vivo proof of concept. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781278/),[min·μg] / [ml],10.6,60074,DB01183,Naloxone
,27781278,AUC(0-22 h),"The adjuvants increased Cmax (21 ± 16 ng/ml vs 75 ± 33 ng/ml; 3.6-fold) and AUC(0-22 h) (10.6 ± 8.11 μg min/ml vs 22.9 ± 11.7 μg min/ml; 2.2-fold) values of buprenorphine (control vs adjuvant-treated, respectively).",Improving the oral bioavailability of buprenorphine: an in-vivo proof of concept. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781278/),[min·μg] / [ml],22.9,60075,DB01183,Naloxone
,27781278,absolute oral bioavailability,The absolute oral bioavailability of buprenorphine doubled (from 1.24% to 2.68%) in the presence of the adjuvants.,Improving the oral bioavailability of buprenorphine: an in-vivo proof of concept. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781278/),%,1.24,60076,DB01183,Naloxone
,27781278,absolute oral bioavailability,The absolute oral bioavailability of buprenorphine doubled (from 1.24% to 2.68%) in the presence of the adjuvants.,Improving the oral bioavailability of buprenorphine: an in-vivo proof of concept. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781278/),%,2.68,60077,DB01183,Naloxone
,29143400,peak concentration (Cmax ),"Mean peak concentration (Cmax ) values for 1 mg (1.51 ng/ml), 2 mg (2.87 ng/ml) and 4 mg (6.02 ng/ml) i.n. exceeded 0.4 mg i.m. (1.27 ng/ml) naloxone.",Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29143400/),[ng] / [ml],1.51,63476,DB01183,Naloxone
,29143400,peak concentration (Cmax ),"Mean peak concentration (Cmax ) values for 1 mg (1.51 ng/ml), 2 mg (2.87 ng/ml) and 4 mg (6.02 ng/ml) i.n. exceeded 0.4 mg i.m. (1.27 ng/ml) naloxone.",Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29143400/),[ng] / [ml],2.87,63477,DB01183,Naloxone
,29143400,peak concentration (Cmax ),"Mean peak concentration (Cmax ) values for 1 mg (1.51 ng/ml), 2 mg (2.87 ng/ml) and 4 mg (6.02 ng/ml) i.n. exceeded 0.4 mg i.m. (1.27 ng/ml) naloxone.",Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29143400/),[ng] / [ml],6.02,63478,DB01183,Naloxone
,29143400,peak concentration (Cmax ),"Mean peak concentration (Cmax ) values for 1 mg (1.51 ng/ml), 2 mg (2.87 ng/ml) and 4 mg (6.02 ng/ml) i.n. exceeded 0.4 mg i.m. (1.27 ng/ml) naloxone.",Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29143400/),[ng] / [ml],1.27,63479,DB01183,Naloxone
,29143400,Tmax,"All three i.n. doses rapidly achieved plasma levels > 50% of peak concentrations (T50%) by 10 minutes, peaking at 15-30 minutes (Tmax ).",Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29143400/),min,15-30,63480,DB01183,Naloxone
,29143400,Tmax,"For comparison, the i.m. reference reached Tmax at 10 minutes.",Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29143400/),min,10,63481,DB01183,Naloxone
,29143400,bioavailability,Mean bioavailability was 47-51% for i.n. relative to i.m. naloxone.,Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29143400/),%,47-51,63482,DB01183,Naloxone
,17224045,concentration,"Initial plasma R,S-methadone concentration was 1,204 ng/ml.",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),ng,"1,204",65499,DB01183,Naloxone
,17224045,maximal observed concentrations,"Decrease in plasma R- and S-methadone concentrations was linear and demonstrated a first-order pharmacokinetics (maximal observed concentrations 566 and 637 ng/ml, half-lives 16.1 and 13.2 hours, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),[ng] / [ml],566,65500,DB01183,Naloxone
,17224045,maximal observed concentrations,"Decrease in plasma R- and S-methadone concentrations was linear and demonstrated a first-order pharmacokinetics (maximal observed concentrations 566 and 637 ng/ml, half-lives 16.1 and 13.2 hours, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),[ng] / [ml],637,65501,DB01183,Naloxone
,17224045,half-lives,"Decrease in plasma R- and S-methadone concentrations was linear and demonstrated a first-order pharmacokinetics (maximal observed concentrations 566 and 637 ng/ml, half-lives 16.1 and 13.2 hours, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),h,16.1,65502,DB01183,Naloxone
,17224045,half-lives,"Decrease in plasma R- and S-methadone concentrations was linear and demonstrated a first-order pharmacokinetics (maximal observed concentrations 566 and 637 ng/ml, half-lives 16.1 and 13.2 hours, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),h,13.2,65503,DB01183,Naloxone
,17224045,half-maximum effect [EC50],"TK/TD correlation between naloxone infusion rate and R,S- and R-methadone concentrations fitted well a sigmoidal Emax model (concentration associated with a half-maximum effect [EC50] 334 and 173 ng/ml, Hill coefficient 10.0 and 7.8, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),[ng] / [ml],334,65504,DB01183,Naloxone
,17224045,half-maximum effect [EC50],"TK/TD correlation between naloxone infusion rate and R,S- and R-methadone concentrations fitted well a sigmoidal Emax model (concentration associated with a half-maximum effect [EC50] 334 and 173 ng/ml, Hill coefficient 10.0 and 7.8, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),[ng] / [ml],173,65505,DB01183,Naloxone
,17224045,Hill coefficient,"TK/TD correlation between naloxone infusion rate and R,S- and R-methadone concentrations fitted well a sigmoidal Emax model (concentration associated with a half-maximum effect [EC50] 334 and 173 ng/ml, Hill coefficient 10.0 and 7.8, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),,10.0,65506,DB01183,Naloxone
,17224045,Hill coefficient,"TK/TD correlation between naloxone infusion rate and R,S- and R-methadone concentrations fitted well a sigmoidal Emax model (concentration associated with a half-maximum effect [EC50] 334 and 173 ng/ml, Hill coefficient 10.0 and 7.8, respectively).",Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17224045/),,7.8,65507,DB01183,Naloxone
,15831777,oral-cecal transit time,"Steady state was achieved rapidly, and after repeated dosing for 3 days, methylnaltrexone decreased oral-cecal transit time from a pretreatment baseline value of 101.3 +/- 29.4 min (mean +/- SD) to 82.5 +/- 20.7 min.","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831777/),min,101.3,71142,DB01183,Naloxone
,15831777,oral-cecal transit time,"Steady state was achieved rapidly, and after repeated dosing for 3 days, methylnaltrexone decreased oral-cecal transit time from a pretreatment baseline value of 101.3 +/- 29.4 min (mean +/- SD) to 82.5 +/- 20.7 min.","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831777/),min,82.5,71143,DB01183,Naloxone
,15831777,Maximum observed plasma concentrations,"Maximum observed plasma concentrations, measured 5 minutes postdose, were 538 +/- 237 and 675 +/- 180 ng/mL after doses 1 and 2, respectively.","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831777/),[ng] / [ml],538,71144,DB01183,Naloxone
,15831777,Maximum observed plasma concentrations,"Maximum observed plasma concentrations, measured 5 minutes postdose, were 538 +/- 237 and 675 +/- 180 ng/mL after doses 1 and 2, respectively.","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831777/),[ng] / [ml],675,71145,DB01183,Naloxone
,15831777,plasma half-life,"Based on 6-hour sampling periods, the plasma half-life, 2.5 +/- 0.5 and 2.9 +/- 0.9 hours following the 1st and 12th doses, respectively, was unchanged at steady state.","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831777/),h,2.5,71146,DB01183,Naloxone
,15831777,plasma half-life,"Based on 6-hour sampling periods, the plasma half-life, 2.5 +/- 0.5 and 2.9 +/- 0.9 hours following the 1st and 12th doses, respectively, was unchanged at steady state.","Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831777/),h,2.9,71147,DB01183,Naloxone
,28776489,Cmax,"After single s.c. administrations of 0.075, 0.15, and 0.3 mg/kg of MNTX bromide, Cmax values of MNTX were 93.5 ± 28.6, 191 ± 37, and 364 ± 54 ng/mL, respectively, and AUC0-∞ were 88.8 ± 8.8, 181 ± 16, and 357 ± 34 ng⋅h/mL, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[ng] / [ml],93.5,71726,DB01183,Naloxone
,28776489,Cmax,"After single s.c. administrations of 0.075, 0.15, and 0.3 mg/kg of MNTX bromide, Cmax values of MNTX were 93.5 ± 28.6, 191 ± 37, and 364 ± 54 ng/mL, respectively, and AUC0-∞ were 88.8 ± 8.8, 181 ± 16, and 357 ± 34 ng⋅h/mL, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[ng] / [ml],191,71727,DB01183,Naloxone
,28776489,Cmax,"After single s.c. administrations of 0.075, 0.15, and 0.3 mg/kg of MNTX bromide, Cmax values of MNTX were 93.5 ± 28.6, 191 ± 37, and 364 ± 54 ng/mL, respectively, and AUC0-∞ were 88.8 ± 8.8, 181 ± 16, and 357 ± 34 ng⋅h/mL, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[ng] / [ml],364,71728,DB01183,Naloxone
,28776489,AUC0-∞,"After single s.c. administrations of 0.075, 0.15, and 0.3 mg/kg of MNTX bromide, Cmax values of MNTX were 93.5 ± 28.6, 191 ± 37, and 364 ± 54 ng/mL, respectively, and AUC0-∞ were 88.8 ± 8.8, 181 ± 16, and 357 ± 34 ng⋅h/mL, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[h·ng] / [ml],88.8,71729,DB01183,Naloxone
,28776489,AUC0-∞,"After single s.c. administrations of 0.075, 0.15, and 0.3 mg/kg of MNTX bromide, Cmax values of MNTX were 93.5 ± 28.6, 191 ± 37, and 364 ± 54 ng/mL, respectively, and AUC0-∞ were 88.8 ± 8.8, 181 ± 16, and 357 ± 34 ng⋅h/mL, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[h·ng] / [ml],181,71730,DB01183,Naloxone
,28776489,AUC0-∞,"After single s.c. administrations of 0.075, 0.15, and 0.3 mg/kg of MNTX bromide, Cmax values of MNTX were 93.5 ± 28.6, 191 ± 37, and 364 ± 54 ng/mL, respectively, and AUC0-∞ were 88.8 ± 8.8, 181 ± 16, and 357 ± 34 ng⋅h/mL, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[h·ng] / [ml],357,71731,DB01183,Naloxone
,28776489,t1/2,The t1/2 of MNTX was about 7.7 h.,Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),h,7.7,71732,DB01183,Naloxone
,28776489,Cmax,"After multiple doses administration, the Cmax, Cav, AUCss, and MRT0-∞ values were 191 ± 50, 3.79 ± 0.40 ng/mL, 182 ± 19 ng⋅h/mL, and 3.56 ± 1.17 h, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[ng] / [ml],191,71733,DB01183,Naloxone
,28776489,Cav,"After multiple doses administration, the Cmax, Cav, AUCss, and MRT0-∞ values were 191 ± 50, 3.79 ± 0.40 ng/mL, 182 ± 19 ng⋅h/mL, and 3.56 ± 1.17 h, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[ng] / [ml],3.79,71734,DB01183,Naloxone
,28776489,Cav,"After multiple doses administration, the Cmax, Cav, AUCss, and MRT0-∞ values were 191 ± 50, 3.79 ± 0.40 ng/mL, 182 ± 19 ng⋅h/mL, and 3.56 ± 1.17 h, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[h·ng] / [ml],182,71735,DB01183,Naloxone
,28776489,AUCss,"After multiple doses administration, the Cmax, Cav, AUCss, and MRT0-∞ values were 191 ± 50, 3.79 ± 0.40 ng/mL, 182 ± 19 ng⋅h/mL, and 3.56 ± 1.17 h, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[ng] / [ml],3.79,71736,DB01183,Naloxone
,28776489,AUCss,"After multiple doses administration, the Cmax, Cav, AUCss, and MRT0-∞ values were 191 ± 50, 3.79 ± 0.40 ng/mL, 182 ± 19 ng⋅h/mL, and 3.56 ± 1.17 h, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),[h·ng] / [ml],182,71737,DB01183,Naloxone
,28776489,MRT0-∞,"After multiple doses administration, the Cmax, Cav, AUCss, and MRT0-∞ values were 191 ± 50, 3.79 ± 0.40 ng/mL, 182 ± 19 ng⋅h/mL, and 3.56 ± 1.17 h, respectively.",Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776489/),h,3.56,71738,DB01183,Naloxone
,10485779,clearance,Ritonavir reduced the clearance of fentanyl by 67% from 15.6+/-8.2 to 5.2+/-2.0 ml x min(-1) x kg(-1) (P<0.01).,Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10485779/),[ml] / [kg·min],15.6,72309,DB01183,Naloxone
,10485779,clearance,Ritonavir reduced the clearance of fentanyl by 67% from 15.6+/-8.2 to 5.2+/-2.0 ml x min(-1) x kg(-1) (P<0.01).,Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10485779/),[ml] / [kg·min],5.2,72310,DB01183,Naloxone
,10485779,area under the fentanyl plasma concentration-time curve from 0 to 18 h,The area under the fentanyl plasma concentration-time curve from 0 to 18 h was increased from 4.8+/-2.7 to 8.8+/-2.3 ng x ml(-1) x h(-1) by ritonavir (P<0.01).,Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10485779/),[ng] / [h·ml],4.8,72311,DB01183,Naloxone
,10485779,area under the fentanyl plasma concentration-time curve from 0 to 18 h,The area under the fentanyl plasma concentration-time curve from 0 to 18 h was increased from 4.8+/-2.7 to 8.8+/-2.3 ng x ml(-1) x h(-1) by ritonavir (P<0.01).,Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10485779/),[ng] / [h·ml],8.8,72312,DB01183,Naloxone
,25724154,time to maximum concentration,Median time to maximum concentration was 12 h postdose when ALO-02 was administered with water or 20 % ethanol and decreased to 8 h postdose with 40 % ethanol.,Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724154/),h,12,72602,DB01183,Naloxone
,25724154,time to maximum concentration,Median time to maximum concentration was 12 h postdose when ALO-02 was administered with water or 20 % ethanol and decreased to 8 h postdose with 40 % ethanol.,Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724154/),h,8,72603,DB01183,Naloxone
,14563545,Cmax,Mean Cmax values ranged from 1.6 to 6.4 ng/ml and tmax from 0.5 to 3 h.,Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14563545/),[ng] / [ml],1.6 to 6.4,74743,DB01183,Naloxone
,14563545,tmax,Mean Cmax values ranged from 1.6 to 6.4 ng/ml and tmax from 0.5 to 3 h.,Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14563545/),h,0.5 to 3,74744,DB01183,Naloxone
,14563545,terminal half-life,The terminal half-life was approximately 26 h (range 9-69).,Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14563545/),h,26,74745,DB01183,Naloxone
,14563545,times of disintegration,Median times of disintegration were similar for all doses and formulations (range 6-12 min).,Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14563545/),min,6-12,74746,DB01183,Naloxone
,28504483,absolute bioavailability,"Relative to i.m. naloxone, geometric mean (90% confidence interval [CI]) absolute bioavailability of i.n. naloxone was modestly lower (55%; 90% CI, 43-70% vs. 41%; 90% CI, 27-62%), whereas average (±SE) mean absorption time was substantially shorter (74 ± 8.8 vs. 6.7 ± 4.9 min).",Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),%,55,78197,DB01183,Naloxone
,28504483,absolute bioavailability,"Relative to i.m. naloxone, geometric mean (90% confidence interval [CI]) absolute bioavailability of i.n. naloxone was modestly lower (55%; 90% CI, 43-70% vs. 41%; 90% CI, 27-62%), whereas average (±SE) mean absorption time was substantially shorter (74 ± 8.8 vs. 6.7 ± 4.9 min).",Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),%,41,78198,DB01183,Naloxone
,28504483,mean absorption time,"Relative to i.m. naloxone, geometric mean (90% confidence interval [CI]) absolute bioavailability of i.n. naloxone was modestly lower (55%; 90% CI, 43-70% vs. 41%; 90% CI, 27-62%), whereas average (±SE) mean absorption time was substantially shorter (74 ± 8.8 vs. 6.7 ± 4.9 min).",Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),min,74,78199,DB01183,Naloxone
,28504483,mean absorption time,"Relative to i.m. naloxone, geometric mean (90% confidence interval [CI]) absolute bioavailability of i.n. naloxone was modestly lower (55%; 90% CI, 43-70% vs. 41%; 90% CI, 27-62%), whereas average (±SE) mean absorption time was substantially shorter (74 ± 8.8 vs. 6.7 ± 4.9 min).",Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),min,6.7,78200,DB01183,Naloxone
,28504483,miosis,The i.m. and i.n. naloxone attenuated miosis by similar extents after water (40 ± 15 vs. 41 ± 21 h*%) and grapefruit juice (49 ± 18 vs. 50 ± 22 h*%) pretreatment.,Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),%·h,40,78201,DB01183,Naloxone
,28504483,miosis,The i.m. and i.n. naloxone attenuated miosis by similar extents after water (40 ± 15 vs. 41 ± 21 h*%) and grapefruit juice (49 ± 18 vs. 50 ± 22 h*%) pretreatment.,Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),%·h,41,78202,DB01183,Naloxone
,28504483,miosis,The i.m. and i.n. naloxone attenuated miosis by similar extents after water (40 ± 15 vs. 41 ± 21 h*%) and grapefruit juice (49 ± 18 vs. 50 ± 22 h*%) pretreatment.,Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),%·h,49,78203,DB01183,Naloxone
,28504483,miosis,The i.m. and i.n. naloxone attenuated miosis by similar extents after water (40 ± 15 vs. 41 ± 21 h*%) and grapefruit juice (49 ± 18 vs. 50 ± 22 h*%) pretreatment.,Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),%·h,50,78204,DB01183,Naloxone
,15948042,steady-state plasma concentration,A mean steady-state plasma concentration of 7.1 ng/ml was obtained after the application of transdermal patches of ME-carbonate.,In vitro/in vivo correlation of transdermal naltrexone prodrugs in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948042/),[ng] / [ml],7.1,79207,DB01183,Naloxone
,18971181,Cmax,"The main pharmacokinetic parameters of nalmefene (Cmax, Tmax, T1/2, AUC0-48, and AUC0-infinity) after the single intravenous dose were 7.34-/+1.56 microg/L, 0.08 h, 12.01-/+2.20 h, 30.29-/+9.84 microg.",[Pharmacokinetics of nalmefene after a single or multiple intravenous doses in Chinese healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18971181/),[μg] / [l],7.34,83041,DB01183,Naloxone
,18971181,AUC0-48,"The main pharmacokinetic parameters of nalmefene (Cmax, Tmax, T1/2, AUC0-48, and AUC0-infinity) after the single intravenous dose were 7.34-/+1.56 microg/L, 0.08 h, 12.01-/+2.20 h, 30.29-/+9.84 microg.",[Pharmacokinetics of nalmefene after a single or multiple intravenous doses in Chinese healthy volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18971181/),h,12.01,83042,DB01183,Naloxone
,18971181,AUC0-infinity,"The main pharmacokinetic parameters of nalmefene (Cmax, Tmax, T1/2, AUC0-48, and AUC0-infinity) after the single intravenous dose were 7.34-/+1.56 microg/L, 0.08 h, 12.01-/+2.20 h, 30.29-/+9.84 microg.",[Pharmacokinetics of nalmefene after a single or multiple intravenous doses in Chinese healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18971181/),μg,30.29,83043,DB01183,Naloxone
,18971181,Cav,"The steady-state pharmacokinetic parameters including the degree of fluctuation (DF), AUCss and Cav were 4.69-/+1.29, 19.64-/+6.20 microg.",[Pharmacokinetics of nalmefene after a single or multiple intravenous doses in Chinese healthy volunteers]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18971181/),μg,19.64,83044,DB01183,Naloxone
,688732,half-time for transfer,The mean half-time for transfer was 6.8 +/- 0.9 min.,Kinetics of acetaminophen absorption and gastric emptying in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688732/),min,6.8,83058,DB01183,Naloxone
,17402725,affinities,"Indium(III) complexes, linked to the indole nitrogen of NTI by six- to nine-atom spacers, display high affinities (0.1-0.2 nM) and excellent selectivities for binding to delta sites in vitro.",Indium-labeled macrocyclic conjugates of naltrindole: high-affinity radioligands for in vivo studies of peripheral delta opioid receptors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17402725/),nM,0.1-0.2,86961,DB01183,Naloxone
>,17402725,specific radioactivities,The [111In]-labeled complexes can be prepared in good isolated yields ( approximately 65%) with high specific radioactivities (>3300 mCi/mumol).,Indium-labeled macrocyclic conjugates of naltrindole: high-affinity radioligands for in vivo studies of peripheral delta opioid receptors. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17402725/),[mci] / [μM],3300,86962,DB01183,Naloxone
,17402725,log D7.4,"The spacers serve as pharmacokinetic modifiers, and log D7.4 values range from -2.74 to -1.79.",Indium-labeled macrocyclic conjugates of naltrindole: high-affinity radioligands for in vivo studies of peripheral delta opioid receptors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17402725/),,2.74,86963,DB01183,Naloxone
,17402725,log D7.4,"The spacers serve as pharmacokinetic modifiers, and log D7.4 values range from -2.74 to -1.79.",Indium-labeled macrocyclic conjugates of naltrindole: high-affinity radioligands for in vivo studies of peripheral delta opioid receptors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17402725/),,1.79,86964,DB01183,Naloxone
,8819305,terminal half-lives,5. Pharmacokinetic analysis of the rat plasma metabolite data indicated that terminal half-lives for nalmefene and nornalmefene were comparable (approximately 1 h).,"Disposition of the opioid antagonist, nalmefene, in rat and dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8819305/),h,1,89907,DB01183,Naloxone
,28597483,bioavailability,Sublingual bioavailability was very low (1%; relative to intravenous).,International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597483/),%,1,93327,DB01183,Naloxone
,28597483,bioavailability,Non-concentrated intranasal spray (1 mg mL-1 ; 1 mL per nostril) had low bioavailability (11%).,International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597483/),%,11,93328,DB01183,Naloxone
,28597483,bioavailability,"Concentrated intranasal formulations (≥10 mg mL-1 ) had bioavailability of 21-42% (relative to intravenous) and 26-57% (relative to intramuscular), with peak concentrations (dose-adjusted Cmax = 0.8-1.7 ng mL-1 ) reached in 19-30 min (tmax ).",International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597483/),%,21-42,93329,DB01183,Naloxone
,28597483,bioavailability,"Concentrated intranasal formulations (≥10 mg mL-1 ) had bioavailability of 21-42% (relative to intravenous) and 26-57% (relative to intramuscular), with peak concentrations (dose-adjusted Cmax = 0.8-1.7 ng mL-1 ) reached in 19-30 min (tmax ).",International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597483/),%,26-57,93330,DB01183,Naloxone
,28597483,peak concentrations (,"Concentrated intranasal formulations (≥10 mg mL-1 ) had bioavailability of 21-42% (relative to intravenous) and 26-57% (relative to intramuscular), with peak concentrations (dose-adjusted Cmax = 0.8-1.7 ng mL-1 ) reached in 19-30 min (tmax ).",International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597483/),[ng] / [ml],0.8-1.7,93331,DB01183,Naloxone
,28597483,tmax,"Concentrated intranasal formulations (≥10 mg mL-1 ) had bioavailability of 21-42% (relative to intravenous) and 26-57% (relative to intramuscular), with peak concentrations (dose-adjusted Cmax = 0.8-1.7 ng mL-1 ) reached in 19-30 min (tmax ).",International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597483/),min,19-30,93332,DB01183,Naloxone
,28597483,bioavailability,"We find consistent direction of development of intranasal sprays to high-concentration, low-volume formulations with bioavailability in the 20-60% range.",International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597483/),%,20-60,93333,DB01183,Naloxone
,28144724,Bioavailability,Bioavailability was 0.54 (0.45-0.63) for the 0.8 mg and 0.52 (0.37-0.67) for the 1.6 mg nasal naloxone formulation.,"Pharmacokinetics of a new, nasal formulation of naloxone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28144724/),,0.54,93917,DB01183,Naloxone
,28144724,Bioavailability,Bioavailability was 0.54 (0.45-0.63) for the 0.8 mg and 0.52 (0.37-0.67) for the 1.6 mg nasal naloxone formulation.,"Pharmacokinetics of a new, nasal formulation of naloxone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28144724/),,0.52,93918,DB01183,Naloxone
,28144724,Maximum concentration levels (C max),Maximum concentration levels (C max) were 1.45 ng/ml (1.07-1.84) for 0.8 mg and 2.57 ng/ml (1.49-3.66) for the 1.6 mg.,"Pharmacokinetics of a new, nasal formulation of naloxone. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28144724/),[ng] / [ml],1.45,93919,DB01183,Naloxone
,28144724,Maximum concentration levels (C max),Maximum concentration levels (C max) were 1.45 ng/ml (1.07-1.84) for 0.8 mg and 2.57 ng/ml (1.49-3.66) for the 1.6 mg.,"Pharmacokinetics of a new, nasal formulation of naloxone. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28144724/),[ng] / [ml],2.57,93920,DB01183,Naloxone
,28144724,Time to maximum concentrations (T max),"Time to maximum concentrations (T max) were reached at 17.9 min (11.4-24.5) and 18.6 min (14.4-22.9) for the 0.8 mg and the 1.6 mg doses, respectively.","Pharmacokinetics of a new, nasal formulation of naloxone. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28144724/),min,17.9,93921,DB01183,Naloxone
,28144724,Time to maximum concentrations (T max),"Time to maximum concentrations (T max) were reached at 17.9 min (11.4-24.5) and 18.6 min (14.4-22.9) for the 0.8 mg and the 1.6 mg doses, respectively.","Pharmacokinetics of a new, nasal formulation of naloxone. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28144724/),min,18.6,93922,DB01183,Naloxone
,3379669,distribution half-life,Plasma concentrations of the drug exhibited a rapid biexponential pattern of decline with an average distribution half-life of 0.99 min and an elimination half-life of 12.8 min.,The correlation of the thermal and mechanical antinociceptive activity of pethidine hydrochloride with plasma concentrations of the drug in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379669/),min,0.99,94640,DB01183,Naloxone
,3379669,elimination half-life,Plasma concentrations of the drug exhibited a rapid biexponential pattern of decline with an average distribution half-life of 0.99 min and an elimination half-life of 12.8 min.,The correlation of the thermal and mechanical antinociceptive activity of pethidine hydrochloride with plasma concentrations of the drug in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379669/),min,12.8,94641,DB01183,Naloxone
,9605377,initial plasma concentrations,"The initial plasma concentrations of morphine, M3G and M6G were 2160, 13100 and 2330 nM, respectively, compatible with a lethal dose in an opioid-naive patient.",Near fatal intoxication with controlled-release morphine tablets in a depressed woman. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9605377/),nM,2160,94817,DB01183,Naloxone
,9605377,initial plasma concentrations,"The initial plasma concentrations of morphine, M3G and M6G were 2160, 13100 and 2330 nM, respectively, compatible with a lethal dose in an opioid-naive patient.",Near fatal intoxication with controlled-release morphine tablets in a depressed woman. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9605377/),nM,13100,94818,DB01183,Naloxone
,9605377,initial plasma concentrations,"The initial plasma concentrations of morphine, M3G and M6G were 2160, 13100 and 2330 nM, respectively, compatible with a lethal dose in an opioid-naive patient.",Near fatal intoxication with controlled-release morphine tablets in a depressed woman. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9605377/),nM,2330,94819,DB01183,Naloxone
,9605377,urinary recovery,"The urinary recovery of morphine, M3G and M6G corresponded to 6.8 mmol, equivalent to an oral intake of at least 2500 mg.",Near fatal intoxication with controlled-release morphine tablets in a depressed woman. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9605377/),mM,6.8,94820,DB01183,Naloxone
,30636504,time,Median (interquartile range) time from ticagrelor administration to randomization was 41 (31-50) versus 45.5 (37-60) minutes ( P=0.16).,The MOVEMENT Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30636504/),min,41,94855,DB01183,Naloxone
,30636504,time,Median (interquartile range) time from ticagrelor administration to randomization was 41 (31-50) versus 45.5 (37-60) minutes ( P=0.16).,The MOVEMENT Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30636504/),min,45.5,94856,DB01183,Naloxone
,6791002,total clearance,"Mean total clearance of unconjugated naltrexone was 3510 (300) ml/min, and its mean urinary clearance was 76.0 (6.8) ml/min.",Overview of human pharmacokinetics of naltrexone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),[ml] / [min],3510,95053,DB01183,Naloxone
,6791002,urinary clearance,"Mean total clearance of unconjugated naltrexone was 3510 (300) ml/min, and its mean urinary clearance was 76.0 (6.8) ml/min.",Overview of human pharmacokinetics of naltrexone. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),[ml] / [min],76.0,95054,DB01183,Naloxone
,6791002,Fraction of dose excreted through,Fraction of dose excreted through urine was between 55 and 60%.,Overview of human pharmacokinetics of naltrexone. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),%,55 and 60,95055,DB01183,Naloxone
,6791002,Plasma curve,"Plasma curve resulting from intravenous administration contained three exponentials: 1.9 (.5)/min, 0.18 (.07)/min and 0.00106 (.00008)/min.",Overview of human pharmacokinetics of naltrexone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),1/[min],1.9,95056,DB01183,Naloxone
,6791002,Plasma curve,"Plasma curve resulting from intravenous administration contained three exponentials: 1.9 (.5)/min, 0.18 (.07)/min and 0.00106 (.00008)/min.",Overview of human pharmacokinetics of naltrexone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),1/[min],0.18,95057,DB01183,Naloxone
,6791002,Plasma curve,"Plasma curve resulting from intravenous administration contained three exponentials: 1.9 (.5)/min, 0.18 (.07)/min and 0.00106 (.00008)/min.",Overview of human pharmacokinetics of naltrexone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),1/[min],0.00106,95058,DB01183,Naloxone
,6791002,Distribution volumes,"Distribution volumes were 7.6 (.7) liters, 60 (12) liters and 164 (16) liters.",Overview of human pharmacokinetics of naltrexone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),l,7.6,95059,DB01183,Naloxone
,6791002,Distribution volumes,"Distribution volumes were 7.6 (.7) liters, 60 (12) liters and 164 (16) liters.",Overview of human pharmacokinetics of naltrexone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),l,60,95060,DB01183,Naloxone
,6791002,Distribution volumes,"Distribution volumes were 7.6 (.7) liters, 60 (12) liters and 164 (16) liters.",Overview of human pharmacokinetics of naltrexone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),l,164,95061,DB01183,Naloxone
,6791002,half life,The faster exponential corresponds to gastrointestinal absorption with a half life of about 1 hour.,Overview of human pharmacokinetics of naltrexone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6791002/),h,1,95062,DB01183,Naloxone
,6469932,half-lives,"The mean half-lives for naltrexone and beta-naltrexol were approximately 4 and 12 hours, respectively.","Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469932/),h,4,95201,DB01183,Naloxone
,6469932,half-lives,"The mean half-lives for naltrexone and beta-naltrexol were approximately 4 and 12 hours, respectively.","Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469932/),h,12,95202,DB01183,Naloxone
,6469932,renal clearance,"The renal clearance of naltrexone and beta-naltrexol was approximately 127 ml/min and 283 ml/min, respectively.","Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469932/),[ml] / [min],127,95203,DB01183,Naloxone
,6469932,renal clearance,"The renal clearance of naltrexone and beta-naltrexol was approximately 127 ml/min and 283 ml/min, respectively.","Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469932/),[ml] / [min],283,95204,DB01183,Naloxone
,6469932,total systemic clearance,The total systemic clearance for naltrexone was approximately 94 L/hr.,"Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469932/),[l] / [h],94,95205,DB01183,Naloxone
,10620557,blood clearance,"During hemodialysis, normeperidine average blood clearance was 73 mL/min, average plasma clearance was 50 mL/min, and average percentage of plasma extraction was 24%.",Successful treatment of normeperidine neurotoxicity by hemodialysis. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10620557/),[ml] / [min],73,96273,DB01183,Naloxone
,10620557,plasma clearance,"During hemodialysis, normeperidine average blood clearance was 73 mL/min, average plasma clearance was 50 mL/min, and average percentage of plasma extraction was 24%.",Successful treatment of normeperidine neurotoxicity by hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10620557/),[ml] / [min],50,96274,DB01183,Naloxone
,10620557,percentage of plasma extraction,"During hemodialysis, normeperidine average blood clearance was 73 mL/min, average plasma clearance was 50 mL/min, and average percentage of plasma extraction was 24%.",Successful treatment of normeperidine neurotoxicity by hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10620557/),%,24,96275,DB01183,Naloxone
,2618077,elimination phase,with a longer elimination phase between 238 and 1320 min.,"Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618077/),min,238 and 1320,96631,DB01183,Naloxone
,32000269,Precision,Precision ranged from 15-20%.,Therapeutic Drug Monitoring in Buprenorphine/Naloxone Treatment for Opioid Use Disorder: Clinical Feasibility and Optimizing Assay Precision. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32000269/),%,15-20,98138,DB01183,Naloxone
,32000269,limit of detection (LoD),"The estimated limit of detection (LoD) and limit of quantitation (LoQ) were 0.02 and 0.069 ng/mL, respectively.",Therapeutic Drug Monitoring in Buprenorphine/Naloxone Treatment for Opioid Use Disorder: Clinical Feasibility and Optimizing Assay Precision. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32000269/),[ng] / [ml],0.02,98139,DB01183,Naloxone
,32000269,limit of quantitation (LoQ),"The estimated limit of detection (LoD) and limit of quantitation (LoQ) were 0.02 and 0.069 ng/mL, respectively.",Therapeutic Drug Monitoring in Buprenorphine/Naloxone Treatment for Opioid Use Disorder: Clinical Feasibility and Optimizing Assay Precision. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32000269/),[ng] / [ml],0.069,98140,DB01183,Naloxone
,3958962,terminal elimination half-life,Pharmacokinetic analysis indicated that naltrexone has a terminal elimination half-life of 4.6 hr.,Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958962/),h,4.6,98302,DB01183,Naloxone
,3958962,plasma ED50,Probit analysis revealed a linear plasma level-response relationship for naltrexone antagonism of morphine analgesia with a plasma ED50 of 2.1 ng/ml when plasma morphine levels average 1126 ng/ml.,Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958962/),[ng] / [ml],2.1,98303,DB01183,Naloxone
,3559921,sensitivities,"Reversed-phase HPLC assays with electrochemical detection, developed to quantify naloxone, 6 beta-naloxol, and their hydrolyzed conjugates in biological fluids provided assay sensitivities of 10 to 20 ng/mL in plasma, urine, and bile.",Pharmacokinetics of morphine and its surrogates. VIII: Naloxone and naloxone conjugate pharmacokinetics in dogs as a function of dose and as affected by simultaneously administered morphine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3559921/),[ng] / [ml],10 to 20,98374,DB01183,Naloxone
,3559921,sequential half-lives,Plasma concentration-time data were well fitted by the sums of two exponentials with two sequential half-lives of 11 +/- 1 (SEM) and 56 +/- 3 min.,Pharmacokinetics of morphine and its surrogates. VIII: Naloxone and naloxone conjugate pharmacokinetics in dogs as a function of dose and as affected by simultaneously administered morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3559921/),min,11,98375,DB01183,Naloxone
,3559921,sequential half-lives,Plasma concentration-time data were well fitted by the sums of two exponentials with two sequential half-lives of 11 +/- 1 (SEM) and 56 +/- 3 min.,Pharmacokinetics of morphine and its surrogates. VIII: Naloxone and naloxone conjugate pharmacokinetics in dogs as a function of dose and as affected by simultaneously administered morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3559921/),min,56,98376,DB01183,Naloxone
,3559921,total,"Pharmacokinetics were dose-independent; total and renal clearances were 1334 +/- 133 mL/min and 42 +/- 9 mL/min, respectively, with a renal clearance of 65 +/- 5 mL/min for the conjugate.",Pharmacokinetics of morphine and its surrogates. VIII: Naloxone and naloxone conjugate pharmacokinetics in dogs as a function of dose and as affected by simultaneously administered morphine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3559921/),[ml] / [min],1334,98377,DB01183,Naloxone
,3559921,renal clearances,"Pharmacokinetics were dose-independent; total and renal clearances were 1334 +/- 133 mL/min and 42 +/- 9 mL/min, respectively, with a renal clearance of 65 +/- 5 mL/min for the conjugate.",Pharmacokinetics of morphine and its surrogates. VIII: Naloxone and naloxone conjugate pharmacokinetics in dogs as a function of dose and as affected by simultaneously administered morphine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3559921/),[ml] / [min],42,98378,DB01183,Naloxone
,3559921,renal clearance,"Pharmacokinetics were dose-independent; total and renal clearances were 1334 +/- 133 mL/min and 42 +/- 9 mL/min, respectively, with a renal clearance of 65 +/- 5 mL/min for the conjugate.",Pharmacokinetics of morphine and its surrogates. VIII: Naloxone and naloxone conjugate pharmacokinetics in dogs as a function of dose and as affected by simultaneously administered morphine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3559921/),[ml] / [min],65,98379,DB01183,Naloxone
,7657850,bioavailable,"Compared with two 100-mg MSC tablets, the 200-mg tablet was 96% bioavailable (90% confidence interval, 88.14-105.74%).",A bioequivalence study of oral controlled-release morphine using naltrexone blockade. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7657850/),%,96,99193,DB01183,Naloxone
,15653167,steady-state plasma concentrations,"The results of the in vivo studies showed mean steady-state plasma concentrations of NTX from NTX, ACE-NTX, PROP-NTX and HEX-NTX at 4.2, 25.2, 16.0, and 8.3 ng/mL, respectively.",In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15653167/),[ng] / [ml],4.2,103138,DB01183,Naloxone
,15653167,steady-state plasma concentrations,"The results of the in vivo studies showed mean steady-state plasma concentrations of NTX from NTX, ACE-NTX, PROP-NTX and HEX-NTX at 4.2, 25.2, 16.0, and 8.3 ng/mL, respectively.",In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15653167/),[ng] / [ml],25.2,103139,DB01183,Naloxone
,15653167,steady-state plasma concentrations,"The results of the in vivo studies showed mean steady-state plasma concentrations of NTX from NTX, ACE-NTX, PROP-NTX and HEX-NTX at 4.2, 25.2, 16.0, and 8.3 ng/mL, respectively.",In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15653167/),[ng] / [ml],16.0,103140,DB01183,Naloxone
,15653167,steady-state plasma concentrations,"The results of the in vivo studies showed mean steady-state plasma concentrations of NTX from NTX, ACE-NTX, PROP-NTX and HEX-NTX at 4.2, 25.2, 16.0, and 8.3 ng/mL, respectively.",In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15653167/),[ng] / [ml],8.3,103141,DB01183,Naloxone
,9495871,"EC50,u","For the EEG effect the in vivo potencies based on free drug concentrations (EC50,u) were 4.62 +/- 0.66 ng/ml (A), 0.69 +/- 0.05 ng/ml (F) and 0.29 +/- 0.06 ng/ml (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),[ng] / [ml],4.62,103388,DB01183,Naloxone
,9495871,"EC50,u","For the EEG effect the in vivo potencies based on free drug concentrations (EC50,u) were 4.62 +/- 0.66 ng/ml (A), 0.69 +/- 0.05 ng/ml (F) and 0.29 +/- 0.06 ng/ml (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),[ng] / [ml],0.69,103389,DB01183,Naloxone
,9495871,"EC50,u","For the EEG effect the in vivo potencies based on free drug concentrations (EC50,u) were 4.62 +/- 0.66 ng/ml (A), 0.69 +/- 0.05 ng/ml (F) and 0.29 +/- 0.06 ng/ml (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),[ng] / [ml],0.29,103390,DB01183,Naloxone
,9495871,affinities,"In the receptor binding studies the affinities at the mu-opioid receptor (Kl) were 47.4 +/- 6.6 nM (A), 8.6 +/- 4.1 nM (F) and 2.8 +/- 0.2 nM (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),nM,47.4,103391,DB01183,Naloxone
,9495871,affinities,"In the receptor binding studies the affinities at the mu-opioid receptor (Kl) were 47.4 +/- 6.6 nM (A), 8.6 +/- 4.1 nM (F) and 2.8 +/- 0.2 nM (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),nM,8.6,103392,DB01183,Naloxone
,9495871,affinities,"In the receptor binding studies the affinities at the mu-opioid receptor (Kl) were 47.4 +/- 6.6 nM (A), 8.6 +/- 4.1 nM (F) and 2.8 +/- 0.2 nM (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),nM,2.8,103393,DB01183,Naloxone
,9495871,intrinsic activity (Emax),"The intrinsic activity (Emax) of the three opioids in vivo was similar with values of 111 +/- 10 microV (A), 89 +/- 11 microV (F) and 104 +/- 4 microV (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),μv,111,103394,DB01183,Naloxone
,9495871,intrinsic activity (Emax),"The intrinsic activity (Emax) of the three opioids in vivo was similar with values of 111 +/- 10 microV (A), 89 +/- 11 microV (F) and 104 +/- 4 microV (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),μv,89,103395,DB01183,Naloxone
,9495871,intrinsic activity (Emax),"The intrinsic activity (Emax) of the three opioids in vivo was similar with values of 111 +/- 10 microV (A), 89 +/- 11 microV (F) and 104 +/- 4 microV (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),μv,104,103396,DB01183,Naloxone
,9495871,sodium shift,"However, the values of the sodium shift varied between 2.8 (S) and 19.1 (A).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),,2.8,103397,DB01183,Naloxone
,9495871,sodium shift,"However, the values of the sodium shift varied between 2.8 (S) and 19.1 (A).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),,19.1,103398,DB01183,Naloxone
,7073399,Plasma half-life,Plasma half-life of the radiolabel was determined to be 137 min.,Tissue uptake of 3H-naloxone in control and in hemorrhagic shock cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7073399/),min,137,103729,DB01183,Naloxone
,31556537,Bioavailability,Bioavailability for intranasal naloxone was 47 % (minimum-maximum values 24-66 %).,Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556537/),%,47,107037,DB01183,Naloxone
,31556537,minimum-maximum,Bioavailability for intranasal naloxone was 47 % (minimum-maximum values 24-66 %).,Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556537/),%,24-66,107038,DB01183,Naloxone
,31556537,Maximum concentration (Cmax),"Maximum concentration (Cmax) was 4.2 (1.5-7.1) ng/ml, and this was achieved (Tmax ) after 16 (5-25) minutes.",Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556537/),[ng] / [ml],4.2,107039,DB01183,Naloxone
,31556537,Tmax,"Maximum concentration (Cmax) was 4.2 (1.5-7.1) ng/ml, and this was achieved (Tmax ) after 16 (5-25) minutes.",Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556537/),min,16,107040,DB01183,Naloxone
,33662465,Cmax,"Additionally, the key findings of the pharmacokinetic study revealed Cmax, Tmax, AUC0-t, AUC0-∞, T1/2 and Ke was found to be 163.95 ± 2.64 ng/ml, 240 ± 2.1 min, 17.75 ± 1.08 ng.hr/ml, 18.82 ± 2.51 ng.hr/ml, 70.71 ± 0.115 min, 0.098 ± 0.01 h-1 respectively.",Intranasal delivery of Naloxone-loaded solid lipid nanoparticles as a promising simple and non-invasive approach for the management of opioid overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33662465/),[ng] / [ml],163.95,110590,DB01183,Naloxone
,33662465,Ke,"Additionally, the key findings of the pharmacokinetic study revealed Cmax, Tmax, AUC0-t, AUC0-∞, T1/2 and Ke was found to be 163.95 ± 2.64 ng/ml, 240 ± 2.1 min, 17.75 ± 1.08 ng.hr/ml, 18.82 ± 2.51 ng.hr/ml, 70.71 ± 0.115 min, 0.098 ± 0.01 h-1 respectively.",Intranasal delivery of Naloxone-loaded solid lipid nanoparticles as a promising simple and non-invasive approach for the management of opioid overdose. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33662465/),1/[h],0.098,110591,DB01183,Naloxone
,15842759,recovery,The mean recovery for nalmefene was 80% in human plasma.,Determination of nalmefene by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842759/),%,80,111209,DB01183,Naloxone
,15842759,area under curve for 0 to 24 h,"Following intravenous injection of 5 mg/kg nalmefene to rabbits, the mean area under curve for 0 to 24 h was 1116 (ng)(mL)(-1)(h), and the mean plasma clearance was 67.9 (mL)(min)(-1)(kg)(-1).",Determination of nalmefene by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842759/),1/[ng)(ml],1116,111210,DB01183,Naloxone
,15842759,plasma clearance,"Following intravenous injection of 5 mg/kg nalmefene to rabbits, the mean area under curve for 0 to 24 h was 1116 (ng)(mL)(-1)(h), and the mean plasma clearance was 67.9 (mL)(min)(-1)(kg)(-1).",Determination of nalmefene by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842759/),1/[ml)(min],67.9,111211,DB01183,Naloxone
,22381043,area under the concentration-time curve,"During ritonavir treatment, nortilidine area under the concentration-time curve was on average doubled, with no differences between CYP2C19 poor metabolizers [2242 h ng ml(-1) (95% confidence interval 1811-2674) vs. 996 h ng ml(-1) (95% confidence interval 872-1119)] and ultrarapid metabolizers [2074 h ng ml(-1) (95% confidence interval 1353-2795) vs. 1059 h ng ml(-1) (95% confidence interval 789-1330)].",Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22381043/),[h·ng] / [ml],2242,111449,DB01183,Naloxone
,22381043,area under the concentration-time curve,"During ritonavir treatment, nortilidine area under the concentration-time curve was on average doubled, with no differences between CYP2C19 poor metabolizers [2242 h ng ml(-1) (95% confidence interval 1811-2674) vs. 996 h ng ml(-1) (95% confidence interval 872-1119)] and ultrarapid metabolizers [2074 h ng ml(-1) (95% confidence interval 1353-2795) vs. 1059 h ng ml(-1) (95% confidence interval 789-1330)].",Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22381043/),[h·ng] / [ml],996,111450,DB01183,Naloxone
,22381043,area under the concentration-time curve,"During ritonavir treatment, nortilidine area under the concentration-time curve was on average doubled, with no differences between CYP2C19 poor metabolizers [2242 h ng ml(-1) (95% confidence interval 1811-2674) vs. 996 h ng ml(-1) (95% confidence interval 872-1119)] and ultrarapid metabolizers [2074 h ng ml(-1) (95% confidence interval 1353-2795) vs. 1059 h ng ml(-1) (95% confidence interval 789-1330)].",Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22381043/),[h·ng] / [ml],2074,111451,DB01183,Naloxone
,22381043,area under the concentration-time curve,"During ritonavir treatment, nortilidine area under the concentration-time curve was on average doubled, with no differences between CYP2C19 poor metabolizers [2242 h ng ml(-1) (95% confidence interval 1811-2674) vs. 996 h ng ml(-1) (95% confidence interval 872-1119)] and ultrarapid metabolizers [2074 h ng ml(-1) (95% confidence interval 1353-2795) vs. 1059 h ng ml(-1) (95% confidence interval 789-1330)].",Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22381043/),[h·ng] / [ml],1059,111452,DB01183,Naloxone
,21438849,C(max),The C(max) of BUP-3G was 8.78???5.23?ng/mL without TPV/r and increased to 12.7???11.7 after steady state of TPV/r was achieved.,Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21438849/),??,8.78,114146,DB01183,Naloxone
,21438849,C(max),The C(max) of BUP-3G was 8.78???5.23?ng/mL without TPV/r and increased to 12.7???11.7 after steady state of TPV/r was achieved.,Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21438849/),[?ng] / [ml],5.23,114147,DB01183,Naloxone
,21438849,C(max),The C(max) of BUP-3G was 8.78???5.23?ng/mL without TPV/r and increased to 12.7???11.7 after steady state of TPV/r was achieved.,Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21438849/),??,12.7,114148,DB01183,Naloxone
,21438849,C(max),The C(max) of BUP-3G was 8.78???5.23?ng/mL without TPV/r and increased to 12.7???11.7 after steady state of TPV/r was achieved.,Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21438849/),??,11.7,114149,DB01183,Naloxone
,21438849,AUC,The AUC of BUP-3G was 31.1???19.4?(ng/mL)?,Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21438849/),??,31.1,114150,DB01183,Naloxone
,21438849,AUC,The AUC of BUP-3G was 31.1???19.4?(ng/mL)?,Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21438849/),?(,19.4,114151,DB01183,Naloxone
,1965042,ED50,The potency of NPC 168 to antagonize morphine-induced analgesia was slightly less than that of naltrexone and nalmefene following either intraperitoneal (ED50 = 0.07 mg/kg) or oral (ED50 = 0.82 mg/kg) administration.,"Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1965042/),[mg] / [kg],0.07,114342,DB01183,Naloxone
,1965042,ED50,The potency of NPC 168 to antagonize morphine-induced analgesia was slightly less than that of naltrexone and nalmefene following either intraperitoneal (ED50 = 0.07 mg/kg) or oral (ED50 = 0.82 mg/kg) administration.,"Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1965042/),[mg] / [kg],0.82,114343,DB01183,Naloxone
,1965042,duration of action,"The duration of action of NPC 168 was approximately 8 hr following subcutaneous administration, compared to 4 hr for nalmefene, to antagonize oxymorphonazine-induced analgesia.","Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1965042/),h,8,114344,DB01183,Naloxone
,1965042,duration of action,"The duration of action of NPC 168 was approximately 8 hr following subcutaneous administration, compared to 4 hr for nalmefene, to antagonize oxymorphonazine-induced analgesia.","Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1965042/),h,4,114345,DB01183,Naloxone
,7954074,elimination half-lives,Mean (+/- SE) elimination half-lives for naloxone in lean (42.7 +/- 4.6 min) and obese (44.3 +/- 10.2 min) sheep were similar (p > 0.05).,Effect of dietary obesity on naloxone disposition in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954074/),min,42.7,116225,DB01183,Naloxone
,7954074,elimination half-lives,Mean (+/- SE) elimination half-lives for naloxone in lean (42.7 +/- 4.6 min) and obese (44.3 +/- 10.2 min) sheep were similar (p > 0.05).,Effect of dietary obesity on naloxone disposition in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954074/),min,44.3,116226,DB01183,Naloxone
,7954074,Volume of distribution of naloxone (Vd),Volume of distribution of naloxone (Vd) was extensive but also similar (p > 0.05) in lean (5.6 +/- 0.9 L/kg) and obese (4.1 +/- 0.6 L/kg) sheep.,Effect of dietary obesity on naloxone disposition in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954074/),[l] / [kg],5.6,116227,DB01183,Naloxone
,7954074,Volume of distribution of naloxone (Vd),Volume of distribution of naloxone (Vd) was extensive but also similar (p > 0.05) in lean (5.6 +/- 0.9 L/kg) and obese (4.1 +/- 0.6 L/kg) sheep.,Effect of dietary obesity on naloxone disposition in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954074/),[l] / [kg],4.1,116228,DB01183,Naloxone
,7954074,Vd,Naloxone was distributed extensively throughout the body fluids and trapped or stored in significant amount in extravascular tissues because the naloxone Vd greatly exceeded 100% of body weight in both lean (557 +/- 86 mL/100 g) and obese (413 +/- 58 mL/100 g) sheep.,Effect of dietary obesity on naloxone disposition in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954074/),[ml] / [100],557,116229,DB01183,Naloxone
,7954074,Vd,Naloxone was distributed extensively throughout the body fluids and trapped or stored in significant amount in extravascular tissues because the naloxone Vd greatly exceeded 100% of body weight in both lean (557 +/- 86 mL/100 g) and obese (413 +/- 58 mL/100 g) sheep.,Effect of dietary obesity on naloxone disposition in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954074/),[ml] / [100],413,116230,DB01183,Naloxone
,10442208,Maximum concentrations (Cmax),Maximum concentrations (Cmax) achieved were 22.28 ng/ml (tilidine) and 92.78 ng/ml (nortilidine) for the test preparation.,Bioavailability investigation of a new tilidine/naloxone liquid formulation compared to a reference formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10442208/),[ng] / [ml],22.28,117845,DB01183,Naloxone
,10442208,Maximum concentrations (Cmax),Maximum concentrations (Cmax) achieved were 22.28 ng/ml (tilidine) and 92.78 ng/ml (nortilidine) for the test preparation.,Bioavailability investigation of a new tilidine/naloxone liquid formulation compared to a reference formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10442208/),[ng] / [ml],92.78,117846,DB01183,Naloxone
,3963538,beta half life,Naloxone elimination was found to be biexponential with the mean beta half life equal to 0.023 +/- 0.002 reciprocal minutes in two patients and 0.015 +/- 0.02 reciprocal minutes in five patients.,A dosing nomogram for continuous infusion intravenous naloxone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3963538/),,0.023,119336,DB01183,Naloxone
,3963538,beta half life,Naloxone elimination was found to be biexponential with the mean beta half life equal to 0.023 +/- 0.002 reciprocal minutes in two patients and 0.015 +/- 0.02 reciprocal minutes in five patients.,A dosing nomogram for continuous infusion intravenous naloxone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3963538/),,0.015,119337,DB01183,Naloxone
,3963538,volume of distribution of the central compartment,The mean volume of distribution of the central compartment was found to be 0.806 +/- 0.408 L/kg.,A dosing nomogram for continuous infusion intravenous naloxone. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3963538/),[l] / [kg],0.806,119338,DB01183,Naloxone
,3963538,beta rate constant of elimination,The mean beta rate constant of elimination was found to be 0.036 +/- 0.027 reciprocal minutes.,A dosing nomogram for continuous infusion intravenous naloxone. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3963538/),min,0.036,119339,DB01183,Naloxone
,18641540,Relative bioavailability,"Relative bioavailability of intramuscular and intranasal naloxone was 36% and 4%, respectively.","Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641540/),%,36,119696,DB01183,Naloxone
,18641540,Relative bioavailability,"Relative bioavailability of intramuscular and intranasal naloxone was 36% and 4%, respectively.","Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641540/),%,4,119697,DB01183,Naloxone
,18641540,clearance,"The final parameter estimates were clearance, 91 L/hr; central volume, 2.87 L; first peripheral compartment volume, 1.49 L, second peripheral compartment volume, 33.6 L; first intercompartmental clearance, 5.66 L/hr; second intercompartmental clearance, 29.8 L/hr; Ka (intramuscular), 0.65; and Ka (intranasal), 1.52.","Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641540/),[l] / [h],91,119698,DB01183,Naloxone
,18641540,central volume,"The final parameter estimates were clearance, 91 L/hr; central volume, 2.87 L; first peripheral compartment volume, 1.49 L, second peripheral compartment volume, 33.6 L; first intercompartmental clearance, 5.66 L/hr; second intercompartmental clearance, 29.8 L/hr; Ka (intramuscular), 0.65; and Ka (intranasal), 1.52.","Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641540/),l,2.87,119699,DB01183,Naloxone
,18641540,first peripheral compartment volume,"The final parameter estimates were clearance, 91 L/hr; central volume, 2.87 L; first peripheral compartment volume, 1.49 L, second peripheral compartment volume, 33.6 L; first intercompartmental clearance, 5.66 L/hr; second intercompartmental clearance, 29.8 L/hr; Ka (intramuscular), 0.65; and Ka (intranasal), 1.52.","Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641540/),l,1.49,119700,DB01183,Naloxone
,18641540,second peripheral compartment volume,"The final parameter estimates were clearance, 91 L/hr; central volume, 2.87 L; first peripheral compartment volume, 1.49 L, second peripheral compartment volume, 33.6 L; first intercompartmental clearance, 5.66 L/hr; second intercompartmental clearance, 29.8 L/hr; Ka (intramuscular), 0.65; and Ka (intranasal), 1.52.","Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641540/),l,33.6,119701,DB01183,Naloxone
,18641540,first intercompartmental clearance,"The final parameter estimates were clearance, 91 L/hr; central volume, 2.87 L; first peripheral compartment volume, 1.49 L, second peripheral compartment volume, 33.6 L; first intercompartmental clearance, 5.66 L/hr; second intercompartmental clearance, 29.8 L/hr; Ka (intramuscular), 0.65; and Ka (intranasal), 1.52.","Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641540/),[l] / [h],5.66,119702,DB01183,Naloxone
,18641540,second intercompartmental clearance,"The final parameter estimates were clearance, 91 L/hr; central volume, 2.87 L; first peripheral compartment volume, 1.49 L, second peripheral compartment volume, 33.6 L; first intercompartmental clearance, 5.66 L/hr; second intercompartmental clearance, 29.8 L/hr; Ka (intramuscular), 0.65; and Ka (intranasal), 1.52.","Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641540/),[l] / [h],29.8,119703,DB01183,Naloxone
,18641540,Ka,"The final parameter estimates were clearance, 91 L/hr; central volume, 2.87 L; first peripheral compartment volume, 1.49 L, second peripheral compartment volume, 33.6 L; first intercompartmental clearance, 5.66 L/hr; second intercompartmental clearance, 29.8 L/hr; Ka (intramuscular), 0.65; and Ka (intranasal), 1.52.","Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641540/),,0.65,119704,DB01183,Naloxone
,18641540,Ka,"The final parameter estimates were clearance, 91 L/hr; central volume, 2.87 L; first peripheral compartment volume, 1.49 L, second peripheral compartment volume, 33.6 L; first intercompartmental clearance, 5.66 L/hr; second intercompartmental clearance, 29.8 L/hr; Ka (intramuscular), 0.65; and Ka (intranasal), 1.52.","Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641540/),,1.52,119705,DB01183,Naloxone
,18641540,time to peak concentration,"Median time to peak concentration for intramuscular naloxone was 12 minutes and for intranasal, 6 to 9 minutes.","Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641540/),min,12,119706,DB01183,Naloxone
,18641540,time to peak concentration,"Median time to peak concentration for intramuscular naloxone was 12 minutes and for intranasal, 6 to 9 minutes.","Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641540/),min,6 to 9,119707,DB01183,Naloxone
,28444856,time to maximum naloxone concentration (Tmax),"Median time to maximum naloxone concentration (Tmax) was 14.5 (95% CI: 9.0-16.5) min, mean maximum naloxone concentration (Cmax) was 1.09 ± 0.56 ng/ml and mean AUC0-90 min was 37.1 ± 15.0 ng*min/ml.",Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444856/),min,14.5,120716,DB01183,Naloxone
,28444856,maximum naloxone concentration (Cmax),"Median time to maximum naloxone concentration (Tmax) was 14.5 (95% CI: 9.0-16.5) min, mean maximum naloxone concentration (Cmax) was 1.09 ± 0.56 ng/ml and mean AUC0-90 min was 37.1 ± 15.0 ng*min/ml.",Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444856/),[ng] / [ml],1.09,120717,DB01183,Naloxone
,28444856,AUC0-90 min,"Median time to maximum naloxone concentration (Tmax) was 14.5 (95% CI: 9.0-16.5) min, mean maximum naloxone concentration (Cmax) was 1.09 ± 0.56 ng/ml and mean AUC0-90 min was 37.1 ± 15.0 ng*min/ml.",Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444856/),[min·ng] / [ml],37.1,120718,DB01183,Naloxone
,28444856,Elimination half-life,Elimination half-life estimated from the median concentration data was 28.2 min.,Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444856/),min,28.2,120719,DB01183,Naloxone
above,1623695,area under the plasma concentration-time curves,Withdrawal symptoms occurred with plasma naloxone area under the plasma concentration-time curves above 550 ng.,Treatment of opioid-induced constipation with oral naloxone: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623695/),ng,550,121859,DB01183,Naloxone
,32939317,tmax,"On POD1 oxycodone absorption was markedly delayed in five of six patients after CECC and in all six patients after OPCAB surgery; median of tmax after CECC 630 [range 270-1420] minutes and after OPCAB 1020 [720-1410] minutes, compared to median of 120-315 min preoperatively and on POD2-POD4.",Bioavailability of oxycodone by mouth in coronary artery bypass surgery patients - a randomized trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32939317/),min,630,122873,DB01183,Naloxone
,32939317,tmax,"On POD1 oxycodone absorption was markedly delayed in five of six patients after CECC and in all six patients after OPCAB surgery; median of tmax after CECC 630 [range 270-1420] minutes and after OPCAB 1020 [720-1410] minutes, compared to median of 120-315 min preoperatively and on POD2-POD4.",Bioavailability of oxycodone by mouth in coronary artery bypass surgery patients - a randomized trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32939317/),min,1020,122874,DB01183,Naloxone
,32939317,tmax,"On POD1 oxycodone absorption was markedly delayed in five of six patients after CECC and in all six patients after OPCAB surgery; median of tmax after CECC 630 [range 270-1420] minutes and after OPCAB 1020 [720-1410] minutes, compared to median of 120-315 min preoperatively and on POD2-POD4.",Bioavailability of oxycodone by mouth in coronary artery bypass surgery patients - a randomized trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32939317/),min,120-315,122875,DB01183,Naloxone
,7387817,peak levels,2 After intravenous administration of 35 and 70 microgram of naloxone peak levels of 4--15 ng/ml and 9--20 ng/ml respectively were reached in 5--40 min and the mean plasma half-life after both doses was 3.1 +/- 0.5 h.,Naloxone pharmacokinetics in the newborn. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7387817/),[ng] / [ml],4,122976,DB01183,Naloxone
,7387817,peak levels,2 After intravenous administration of 35 and 70 microgram of naloxone peak levels of 4--15 ng/ml and 9--20 ng/ml respectively were reached in 5--40 min and the mean plasma half-life after both doses was 3.1 +/- 0.5 h.,Naloxone pharmacokinetics in the newborn. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7387817/),[ng] / [ml],15,122977,DB01183,Naloxone
,7387817,peak levels,2 After intravenous administration of 35 and 70 microgram of naloxone peak levels of 4--15 ng/ml and 9--20 ng/ml respectively were reached in 5--40 min and the mean plasma half-life after both doses was 3.1 +/- 0.5 h.,Naloxone pharmacokinetics in the newborn. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7387817/),[ng] / [ml],9,122978,DB01183,Naloxone
,7387817,peak levels,2 After intravenous administration of 35 and 70 microgram of naloxone peak levels of 4--15 ng/ml and 9--20 ng/ml respectively were reached in 5--40 min and the mean plasma half-life after both doses was 3.1 +/- 0.5 h.,Naloxone pharmacokinetics in the newborn. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7387817/),[ng] / [ml],20,122979,DB01183,Naloxone
,7387817,plasma half-life,2 After intravenous administration of 35 and 70 microgram of naloxone peak levels of 4--15 ng/ml and 9--20 ng/ml respectively were reached in 5--40 min and the mean plasma half-life after both doses was 3.1 +/- 0.5 h.,Naloxone pharmacokinetics in the newborn. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7387817/),h,3.1,122980,DB01183,Naloxone
,7387817,Peak levels,3 Peak levels of 7--35 ng/ml were reached 0.5 to 2 h after intramuscular administration of 200 microgram.,Naloxone pharmacokinetics in the newborn. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7387817/),[ng] / [ml],7--35,122981,DB01183,Naloxone
≥,33629900,trough methadone concentrations,"Compared with baseline, temperatures significantly decreased for treatment 1 group dogs at 2 to ≥ 4 hours and from 16 to ≥ 50 hours (12 hours after last dose) and for treatment 2 group dogs at 2 to ≥ 36 hours (12 hours after last dose), when trough methadone concentrations were ≥ 21.3 ng/mL.",Multiple-dose pharmacokinetics and opioid effects of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33629900/),[ng] / [ml],21.3,123862,DB01183,Naloxone
,3677973,elimination rate constant,"Calculations from the serum concentration versus time relationship resulted in an elimination rate constant of 0.75 +/- 0.39/h, a half-life of 70.5 +/- 35.2 min, a systemic clearance of 39.13 +/- 14.53 ml/min/kg, and an apparent volume of distribution of 3.52 +/- 1.20 liters/kg.",The pharmacokinetics of naloxone in the premature newborn. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677973/),1/[h],0.75,125563,DB01183,Naloxone
,3677973,half-life,"Calculations from the serum concentration versus time relationship resulted in an elimination rate constant of 0.75 +/- 0.39/h, a half-life of 70.5 +/- 35.2 min, a systemic clearance of 39.13 +/- 14.53 ml/min/kg, and an apparent volume of distribution of 3.52 +/- 1.20 liters/kg.",The pharmacokinetics of naloxone in the premature newborn. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677973/),min,70.5,125564,DB01183,Naloxone
,3677973,systemic clearance,"Calculations from the serum concentration versus time relationship resulted in an elimination rate constant of 0.75 +/- 0.39/h, a half-life of 70.5 +/- 35.2 min, a systemic clearance of 39.13 +/- 14.53 ml/min/kg, and an apparent volume of distribution of 3.52 +/- 1.20 liters/kg.",The pharmacokinetics of naloxone in the premature newborn. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677973/),[ml] / [kg·min],39.13,125565,DB01183,Naloxone
,3677973,apparent volume of distribution,"Calculations from the serum concentration versus time relationship resulted in an elimination rate constant of 0.75 +/- 0.39/h, a half-life of 70.5 +/- 35.2 min, a systemic clearance of 39.13 +/- 14.53 ml/min/kg, and an apparent volume of distribution of 3.52 +/- 1.20 liters/kg.",The pharmacokinetics of naloxone in the premature newborn. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677973/),[l] / [kg],3.52,125566,DB01183,Naloxone
,30940694,time to reach Cmax (Tmax),"Nalmefene was absorbed slowly following IN administration, with a median time to reach Cmax (Tmax) of 2 hours.",Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30940694/),h,2,126814,DB01183,Naloxone
,30940694,Tmax,"Addition of the absorption enhancer dodecyl maltoside (Intravail, Neurelis, Inc., Encinitas, CA) reduced Tmax to 0.25 hour and increased Cmax by ∼2.2-fold.",Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30940694/),h,0.25,126815,DB01183,Naloxone
>,30940694,half-life,"The high affinity, very rapid onset, and long half-life (>7 hours) of IN nalmefene present distinct advantages as a rescue medication, particularly against longer-lived synthetic opioids.",Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30940694/),h,7,126816,DB01183,Naloxone
,6150815,absorption rate constant,The mean absorption rate constant was 0.091 +/- 0.008 min-1 (half-life of 7.6 min).,Naltrexone disposition in man after subcutaneous administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6150815/),1/[min],0.091,127021,DB01183,Naloxone
,6150815,half-life,The mean absorption rate constant was 0.091 +/- 0.008 min-1 (half-life of 7.6 min).,Naltrexone disposition in man after subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6150815/),min,7.6,127022,DB01183,Naloxone
,6150815,terminal phase plasma rate constant,"The terminal phase plasma rate constant was 0.413 +/- 0.035 hr-1 (half-life of 1.68 hr) for parent drug and 0.0786 +/- 0.0090 hr-1 (half-life of 8.8 hr) for the major metabolite, 6 beta-naltrexone.",Naltrexone disposition in man after subcutaneous administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6150815/),1/[h],0.413,127023,DB01183,Naloxone
,6150815,terminal phase plasma rate constant,"The terminal phase plasma rate constant was 0.413 +/- 0.035 hr-1 (half-life of 1.68 hr) for parent drug and 0.0786 +/- 0.0090 hr-1 (half-life of 8.8 hr) for the major metabolite, 6 beta-naltrexone.",Naltrexone disposition in man after subcutaneous administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6150815/),1/[h],0.0786,127024,DB01183,Naloxone
,6150815,half-life,"The terminal phase plasma rate constant was 0.413 +/- 0.035 hr-1 (half-life of 1.68 hr) for parent drug and 0.0786 +/- 0.0090 hr-1 (half-life of 8.8 hr) for the major metabolite, 6 beta-naltrexone.",Naltrexone disposition in man after subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6150815/),h,1.68,127025,DB01183,Naloxone
,6150815,half-life,"The terminal phase plasma rate constant was 0.413 +/- 0.035 hr-1 (half-life of 1.68 hr) for parent drug and 0.0786 +/- 0.0090 hr-1 (half-life of 8.8 hr) for the major metabolite, 6 beta-naltrexone.",Naltrexone disposition in man after subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6150815/),1/[h],0.0786,127026,DB01183,Naloxone
,6150815,half-life,"The terminal phase plasma rate constant was 0.413 +/- 0.035 hr-1 (half-life of 1.68 hr) for parent drug and 0.0786 +/- 0.0090 hr-1 (half-life of 8.8 hr) for the major metabolite, 6 beta-naltrexone.",Naltrexone disposition in man after subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6150815/),h,8.8,127027,DB01183,Naloxone
,18832863,Volume of distribution,Volume of distribution (approximately 2.5-3 l/kg) and the half-life (approximately 1 h) were similar.,"Disposition of naltrexone after intravenous bolus administration in Wistar rats, low-alcohol-drinking rats and high-alcohol-drinking rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18832863/),[l] / [kg],2.5-3,128114,DB01183,Naloxone
,18832863,half-life,Volume of distribution (approximately 2.5-3 l/kg) and the half-life (approximately 1 h) were similar.,"Disposition of naltrexone after intravenous bolus administration in Wistar rats, low-alcohol-drinking rats and high-alcohol-drinking rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18832863/),h,1,128115,DB01183,Naloxone
,16144748,bioavailability,"To assist the clinician in interpreting the relevant literature in establishing dosing parameters for prescription of tablet buprenorphine, this study was designed to compare the steady state: (1) pharmacokinetics and bioavailability, and (2) physiological, subjective and objective opiate effects of two 8 mg buprenorphine tablets (16 mg) to those of 1 ml (8 mg/ml) buprenorphine solution based upon early reports suggesting that the bioavailability of the tablet was approximately 50% of that of the liquid.","Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144748/),%,50,129202,DB01183,Naloxone
,16144748,relative bioavailability,"The relative bioavailability of tablet versus solution is estimated to be 0.71; thus, with respect to dosing parameters for the tablet, clinicians should consider using less than 16 mg to achieve bioequivalence to the 8 mg solution.","Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144748/),,0.71,129203,DB01183,Naloxone
,31666152,time to maximal concentration (Tmax),"Intranasal administration can provide a time to maximal concentration (Tmax) of drugs (e.g., naloxone and midazolam) of 30 min or less.",Intranasal Scopolamine for Motion Sickness. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31666152/),min,30,131501,DB01183,Naloxone
,31666152,Tmax,"Tmax was long for both dosages (High dose 75.0 ± 49.4 min, Low dose 61.9 ± 37.1 min), compared to other intranasally administered drugs and some previous studies with IN SCOP.",Intranasal Scopolamine for Motion Sickness. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31666152/),min,75.0,131502,DB01183,Naloxone
,31666152,Tmax,"Tmax was long for both dosages (High dose 75.0 ± 49.4 min, Low dose 61.9 ± 37.1 min), compared to other intranasally administered drugs and some previous studies with IN SCOP.",Intranasal Scopolamine for Motion Sickness. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31666152/),min,61.9,131503,DB01183,Naloxone
,2575491,Total urinary excretion,"Total urinary excretion of NTX and metabolites after po administration was 89% of that after iv administration, suggestive of good absorption of NTX from solution.",Disposition and pharmacokinetics of naltrexone after intravenous and oral administration in rhesus monkeys. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575491/),%,89,136712,DB01183,Naloxone
,2575491,extraction ratio,The calculated extraction ratio was 0.96-0.99.,Disposition and pharmacokinetics of naltrexone after intravenous and oral administration in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575491/),,0.96-0.,136713,DB01183,Naloxone
,26483076,systemic clearance,The typical subject in the population was estimated to have a systemic clearance of 60.4 l h(-1) and a central volume of distribution of 266 l.,Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26483076/),[l] / [h],60.4,137012,DB01183,Naloxone
,26483076,central volume of distribution,The typical subject in the population was estimated to have a systemic clearance of 60.4 l h(-1) and a central volume of distribution of 266 l.,Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26483076/),l,266,137013,DB01183,Naloxone
,26483076,Absolute oral bioavailability,Absolute oral bioavailability was estimated to 41% without food intake and with food about 53%.,Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26483076/),%,41,137014,DB01183,Naloxone
,26483076,Absolute oral bioavailability,Absolute oral bioavailability was estimated to 41% without food intake and with food about 53%.,Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26483076/),%,53,137015,DB01183,Naloxone
,17960304,CL,"Naltrexone CL (140 L/h) and V (38,300 L) were dependent on weight (changes of 0.548 L/h/kg and 0.655 L/kg, respectively) and were 23% and 35% higher, respectively, in subjects with alcohol and/or opioid dependence than in healthy subjects.",Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17960304/),[l] / [h],140,137702,DB01183,Naloxone
,17960304,V,"Naltrexone CL (140 L/h) and V (38,300 L) were dependent on weight (changes of 0.548 L/h/kg and 0.655 L/kg, respectively) and were 23% and 35% higher, respectively, in subjects with alcohol and/or opioid dependence than in healthy subjects.",Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17960304/),l,"38,300",137703,DB01183,Naloxone
,17960304,CL,"Naltrexone CL also was dependent on age (-0.108 L/h/year); 6beta-naltrexol CL (65.1 L/h) was dependent on creatinine CL (0.229 L/h/ml/minute) and alkaline phosphatase (-0.130 L/h/IU/L), and was increased by 18% in smokers and in alcohol- and/or opioid-dependent subjects.",Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17960304/),[l] / [h],65.1,137704,DB01183,Naloxone
,9374341,Clearance half-times,Clearance half-times from opioid receptors were 28.7 +/- 5.9 hr for 1 mg of nalmefene and 2.0 +/- 1.6 hr for 2 mg of naloxone.,Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9374341/),h,28.7,138023,DB01183,Naloxone
,9374341,Clearance half-times,Clearance half-times from opioid receptors were 28.7 +/- 5.9 hr for 1 mg of nalmefene and 2.0 +/- 1.6 hr for 2 mg of naloxone.,Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9374341/),h,2.0,138024,DB01183,Naloxone
,32375158,half-life,"MCAM plasma concentrations peaked 15-45 min after injection, with a half-life ranging from 13.7 to 199.8 min, and decreased markedly 1 day after injection.","Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32375158/),min,13.7 to 199.8,138215,DB01183,Naloxone
,19726139,AUC(0-24h),"Prior to starting TPV/r, the geometric mean BUP AUC(0-24h) and C(max) were 43.9 ng h/mL and 5.61 ng/mL, respectively.",Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726139/),[h·ng] / [ml],43.9,139075,DB01183,Naloxone
,19726139,C(max),"Prior to starting TPV/r, the geometric mean BUP AUC(0-24h) and C(max) were 43.9 ng h/mL and 5.61 ng/mL, respectively.",Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726139/),[ng] / [ml],5.61,139076,DB01183,Naloxone
,19726139,steady-state,"After achieving steady-state with TPV/r (> or = 7 days), these values were similar at 43.7 ng h/mL and 4.84 ng/mL, respectively.",Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726139/),[h·ng] / [ml],43.7,139077,DB01183,Naloxone
,19726139,steady-state,"After achieving steady-state with TPV/r (> or = 7 days), these values were similar at 43.7 ng h/mL and 4.84 ng/mL, respectively.",Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726139/),[ng] / [ml],4.84,139078,DB01183,Naloxone
,19726139,AUC(0-24h),"Similar analyses for norBUP, the primary metabolite of BUP, demonstrated a reduction in geometric mean for AUC(0-24h) [68.7-14.7 ng h/mL; ratio=0.21 (90% CI 0.19-0.25)] and C(max) [4.75-0.94 ng/mL; ratio=0.20 (90% CI 0.17-0.23)].",Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726139/),[h·ng] / [ml],68.7-14.7,139079,DB01183,Naloxone
,20407249,elimination half-life,"Remifentanil, due to its pharmacokinetic profile (elimination half-life: 9 min), is advantageous for ambulatory patients, though it is not known whether the high cost compensates the benefits.",Pharmacology of sedation agents and reversal agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20407249/),min,9,139670,DB01183,Naloxone
,29880278,Maximum plasma fentanyl concentrations,Maximum plasma fentanyl concentrations were variable among calves (0.726-6.923 ng mL-1).,Adverse reactions to fentanyl transdermal patches in calves: a preliminary clinical and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29880278/),[ng] / [ml],0.726-6.923,140378,DB01183,Naloxone
,32622946,half the maximal effect (EC50),"The PK/PD analysis revealed that the antiemetic effect was related to the plasma naldemedine concentration, with a half maximal effective concentration that produces half the maximal effect (EC50) of 3.51 ng/mL.","Preventive effects of naldemedine, peripherally acting μ-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32622946/),[ng] / [ml],3.51,144318,DB01183,Naloxone
,6488691,plasma clearance,Kinetics of naltrexone estimated from the intravenous dose indicated a plasma clearance range of 3.1 to 3.4 l/min and a t 1/2 range of 1.7 to 3.7 hr.,Kinetics of a naltrexone sustained-release preparation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6488691/),[l] / [min],3.1 to 3.4,147699,DB01183,Naloxone
,6488691,t 1/2,Kinetics of naltrexone estimated from the intravenous dose indicated a plasma clearance range of 3.1 to 3.4 l/min and a t 1/2 range of 1.7 to 3.7 hr.,Kinetics of a naltrexone sustained-release preparation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6488691/),h,1.7 to 3.7,147700,DB01183,Naloxone
,21209242,t(first),"After single doses, median t(first) was 0.08 to 0.25 hours and t(max) 0.50 to 1.00 hours.","Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209242/),h,0.08 to 0.25,147740,DB01183,Naloxone
,21209242,t(max),"After single doses, median t(first) was 0.08 to 0.25 hours and t(max) 0.50 to 1.00 hours.","Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209242/),h,0.50 to 1.00,147741,DB01183,Naloxone
,21209242,"t(max) (t(max,ss))","After repeat dosing, median t(max) (t(max,ss)) was 0.50 to 2.00 hours.","Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209242/),h,0.50 to 2.00,147742,DB01183,Naloxone
,3740151,terminal elimination half-life,"The maternal disposition of nalbuphine followed a two-compartment pharmacokinetic model, with an initial distribution phase of 4 to 20 minutes and a terminal elimination half-life of 2.4 +/- 0.4 hours.",Pharmacokinetics of nalbuphine during parturition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740151/),h,2.4,148372,DB01183,Naloxone
,19944650,score at pain flare,Mean score at pain flare was 7.1.,"ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19944650/),,7.1,151241,DB01183,Naloxone
less,12393357,ventilatory frequency,"Respiratory depression was defined as a ventilatory frequency less than10 breaths min(-1) on two occasions or a peripheral oxygen saturation < or =92%, or administration of naloxone.","Remifentanil compared with sufentanil during extra-corporeal shock wave lithotripsy with spontaneous ventilation: a double-blind, randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12393357/),[breaths] / [min],10,152612,DB01183,Naloxone
,20150521,C(max),"Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons).",Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150521/),[ng] / [ml],1.08,152668,DB01183,Naloxone
,20150521,C(max),"Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons).",Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150521/),[ng] / [ml],1.01,152669,DB01183,Naloxone
,20150521,AUC(0-12),"Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons).",Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150521/),[h·ng] / [ml],6.3,152670,DB01183,Naloxone
,20150521,AUC(0-12),"Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons).",Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150521/),[h·ng] / [ml],6.2,152671,DB01183,Naloxone
,20150521,AUC(inf),"Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons).",Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150521/),[h·ng] / [ml],9.14,152672,DB01183,Naloxone
,20150521,AUC(inf),"Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons).",Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150521/),[h·ng] / [ml],9.60,152673,DB01183,Naloxone
,15363499,plasma concentrations,"The 25 wt.% coated rods provided in vitro release of 0.36 mg/day/rod, and in vivo release of 0.29 mg/day/rod over 6 months, and showed dose-dependent nalmefene plasma concentrations (one rod: 3.33 +/- 0.56 ng/ml, three rods: 10.19 +/- 2.31 ng/ml).",Implantable technology for long-term delivery of nalmefene for treatment of alcoholism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15363499/),[ng] / [ml],3.33,153499,DB01183,Naloxone
,15363499,plasma concentrations,"The 25 wt.% coated rods provided in vitro release of 0.36 mg/day/rod, and in vivo release of 0.29 mg/day/rod over 6 months, and showed dose-dependent nalmefene plasma concentrations (one rod: 3.33 +/- 0.56 ng/ml, three rods: 10.19 +/- 2.31 ng/ml).",Implantable technology for long-term delivery of nalmefene for treatment of alcoholism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15363499/),ng,10.,153500,DB01183,Naloxone
,22123184,terminal plasma elimination half-life,The mean terminal plasma elimination half-life of 6β-naltrexol was 11.1±2.4 hours.,"6β-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22123184/),h,11.1,155698,DB01183,Naloxone
,22123184,effective dose (ED(50) ),"6β-Naltrexol potently blocked morphine-induced slowing of gastrointestinal transit, with a median effective dose (ED(50) ) of ~3 mg.","6β-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22123184/),mg,3,155699,DB01183,Naloxone
,7365688,plasma half-life,"After an i.v. bolus, the plasma half-life of naltrexone between 30 min and 3 hr was 55 +/- 5 min and 53 +/- 3 min for 1 and 5 mg/kg doses of naltrexone .","The seminal excretion, plasma elimination, tissue distribution and metabolism of naltrexone in the rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7365688/),min,30,157028,DB01183,Naloxone
,7365688,plasma half-life,"After an i.v. bolus, the plasma half-life of naltrexone between 30 min and 3 hr was 55 +/- 5 min and 53 +/- 3 min for 1 and 5 mg/kg doses of naltrexone .","The seminal excretion, plasma elimination, tissue distribution and metabolism of naltrexone in the rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7365688/),h,3,157029,DB01183,Naloxone
,7365688,plasma half-life,"After an i.v. bolus, the plasma half-life of naltrexone between 30 min and 3 hr was 55 +/- 5 min and 53 +/- 3 min for 1 and 5 mg/kg doses of naltrexone .","The seminal excretion, plasma elimination, tissue distribution and metabolism of naltrexone in the rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7365688/),min,55,157030,DB01183,Naloxone
,7365688,plasma half-life,"After an i.v. bolus, the plasma half-life of naltrexone between 30 min and 3 hr was 55 +/- 5 min and 53 +/- 3 min for 1 and 5 mg/kg doses of naltrexone .","The seminal excretion, plasma elimination, tissue distribution and metabolism of naltrexone in the rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7365688/),min,53,157031,DB01183,Naloxone
,7365688,semen/plasma drug concentration ratio,"At 120 min, the semen/plasma drug concentration ratio was 14 and 11 for the 1 and 5 mg/kg doses, respectively.","The seminal excretion, plasma elimination, tissue distribution and metabolism of naltrexone in the rabbit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7365688/),,14,157032,DB01183,Naloxone
,7365688,semen/plasma drug concentration ratio,"At 120 min, the semen/plasma drug concentration ratio was 14 and 11 for the 1 and 5 mg/kg doses, respectively.","The seminal excretion, plasma elimination, tissue distribution and metabolism of naltrexone in the rabbit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7365688/),,11,157033,DB01183,Naloxone
,6422028,release rate,"Application of the methodology to a biodegradable copolymer naltrexone delivery system in three monkeys showed an initial release rate of 3-8% of the dose per day over the first 3-5 days followed by a slow, rather constant release rate of 1-3% per day from day 5 to the time of the last measurable plasma sample (36-43 days).",Pharmacokinetic quantitation of naltrexone controlled release from a copolymer delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6422028/),[%] / [d],1-3,162346,DB01183,Naloxone
,21685245,Unbound fractions,"Unbound fractions in human plasma for NAQ and NAP were 0.026 ± 0.019 and 0.85 ± 0.12, respectively.",Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21685245/),,0.026,166958,DB01183,Naloxone
,21685245,Unbound fractions,"Unbound fractions in human plasma for NAQ and NAP were 0.026 ± 0.019 and 0.85 ± 0.12, respectively.",Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21685245/),,0.85,166959,DB01183,Naloxone
,21685245,K(m),"The metabolic oxidative reaction rates, fitted to a Michaelis-Menten model, yielded K(m) and V(max) values of 15.8 ± 5.5 μM and 192 ± 24 pmol/min for NAQ and 1.8 ± 1.5 μM and 8.1 ± 1.4 pmol/min for NAP.",Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21685245/),μM,15.8,166960,DB01183,Naloxone
,21685245,K(m),"The metabolic oxidative reaction rates, fitted to a Michaelis-Menten model, yielded K(m) and V(max) values of 15.8 ± 5.5 μM and 192 ± 24 pmol/min for NAQ and 1.8 ± 1.5 μM and 8.1 ± 1.4 pmol/min for NAP.",Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21685245/),μM,1.8,166961,DB01183,Naloxone
,21685245,V(max),"The metabolic oxidative reaction rates, fitted to a Michaelis-Menten model, yielded K(m) and V(max) values of 15.8 ± 5.5 μM and 192 ± 24 pmol/min for NAQ and 1.8 ± 1.5 μM and 8.1 ± 1.4 pmol/min for NAP.",Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21685245/),[pM] / [min],192,166962,DB01183,Naloxone
,21685245,V(max),"The metabolic oxidative reaction rates, fitted to a Michaelis-Menten model, yielded K(m) and V(max) values of 15.8 ± 5.5 μM and 192 ± 24 pmol/min for NAQ and 1.8 ± 1.5 μM and 8.1 ± 1.4 pmol/min for NAP.",Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21685245/),[pM] / [min],8.1,166963,DB01183,Naloxone
,21685245,Intrinsic hepatic clearance,"Intrinsic hepatic clearance was estimated to be 13 and 5 ml · min(-1) · kg(-1) for NAQ and NAP, respectively.",Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21685245/),[ml] / [kg·min],13,166964,DB01183,Naloxone
,21685245,Intrinsic hepatic clearance,"Intrinsic hepatic clearance was estimated to be 13 and 5 ml · min(-1) · kg(-1) for NAQ and NAP, respectively.",Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21685245/),[ml] / [kg·min],5,166965,DB01183,Naloxone
,11752106,transit time,"We observed that in the first group (n = 6) morphine (0.05 mg/kg intravenously) increased the transit time from a baseline level of 85 +/- 20.5 min to 155 +/- 27.9 min (mean +/- S.D., P < 0.01).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,85,167046,DB01183,Naloxone
,11752106,transit time,"We observed that in the first group (n = 6) morphine (0.05 mg/kg intravenously) increased the transit time from a baseline level of 85 +/- 20.5 min to 155 +/- 27.9 min (mean +/- S.D., P < 0.01).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,155,167047,DB01183,Naloxone
,11752106,transit time,"After 0.1 mg/kg subcutaneous methylnaltrexone plus morphine, the transit time reduced to 110 +/- 41.0 min.",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,110,167048,DB01183,Naloxone
,11752106,transit time,"In the second group (n = 6), morphine increased the transit time from a baseline level of 98 +/- 49.1 min to 140 +/- 58.2 min (P < 0.01).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,98,167049,DB01183,Naloxone
,11752106,transit time,"In the second group (n = 6), morphine increased the transit time from a baseline level of 98 +/- 49.1 min to 140 +/- 58.2 min (P < 0.01).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,140,167050,DB01183,Naloxone
,11752106,transit time,"After 0.3 mg/kg subcutaneous methylnaltrexone plus morphine, the transit time reduced to 108 +/- 59.6 min (P < 0.05 compared with placebo plus morphine).",Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752106/),min,108,167051,DB01183,Naloxone
>,32486995,bioavailability,For drugs with a high bioavailability (> 70 %) only the impaired hepatic clearance has to be considered.,[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167613,DB01183,Naloxone
>,32486995,bioavailability,"Buprenorphine, fentanyl, hydromorphone, morphine, naloxone und tapentadol are drugs with a high first-pass effect, while the bioavailability of methadone, oxycodone and tramadol is > 70 %.",[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167614,DB01183,Naloxone
,3067620,concentrations,Mean (+/- SEM) plasma acetaldehyde concentrations of flushers (28.2 +/- 11.8 microM) were significantly greater than nonflushers (1.4 +/- 0.5 microM) following ethanol ingestion (p less than 0.001).,Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),μM,28.,171538,DB01183,Naloxone
,3067620,concentrations,Mean (+/- SEM) plasma acetaldehyde concentrations of flushers (28.2 +/- 11.8 microM) were significantly greater than nonflushers (1.4 +/- 0.5 microM) following ethanol ingestion (p less than 0.001).,Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),μ,1,171539,DB01183,Naloxone
,3067620,area under the curve (AUC),"Ethanol alone always induced a significant rise in facial skin temperature [mean area under the curve (AUC) = 5142 +/- 648 % delta T x min, p less than 0.01] and of pulse (mean AUC = 1622 +/- 120 bpm x min, p less than 0.001) in flushers compared to water ingestion.",Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),%·delta·min·t,5142,171540,DB01183,Naloxone
,3067620,AUC,"Ethanol alone always induced a significant rise in facial skin temperature [mean area under the curve (AUC) = 5142 +/- 648 % delta T x min, p less than 0.01] and of pulse (mean AUC = 1622 +/- 120 bpm x min, p less than 0.001) in flushers compared to water ingestion.",Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),bpm·min,1622,171541,DB01183,Naloxone
,16239359,apparent half-lives,"The long apparent half-lives of naltrexone and 6beta-naltrexol (5-8 days) were attributed to the slow release of naltrexone (long-acting naltrexone exhibits absorption rate-limited elimination or ""flip-flop"" kinetics); elimination was not altered in subjects with hepatic impairment.",Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239359/),d,5-8,172816,DB01183,Naloxone
,19108793,AUC(t),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],473.49,175280,DB01183,Naloxone
,19108793,AUC(t),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],491.22,175281,DB01183,Naloxone
,19108793,AUC(t),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],488.89,175282,DB01183,Naloxone
,19108793,AUC(t),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],502.28,175283,DB01183,Naloxone
,19108793,C(max),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],34.91,175284,DB01183,Naloxone
,19108793,C(max),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],35.73,175285,DB01183,Naloxone
,19108793,C(max),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],34.46,175286,DB01183,Naloxone
,19108793,C(max),"With oxycodone, the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 473.49 (72.16), 491.22 (82.18), 488.89 (91.04), and 502.28 (84.13) ng . h/mL, respectively; mean C(max) values were 34.91 (4.36), 35.73 (4.93), 34.46 (5.03), and 40.45 (4.71) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],40.45,175287,DB01183,Naloxone
,19108793,AUC(t),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],539.93,175288,DB01183,Naloxone
,19108793,AUC(t),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],522.45,175289,DB01183,Naloxone
,19108793,AUC(t),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],520.10,175290,DB01183,Naloxone
,19108793,AUC(t),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[h·ng] / [ml],523.37,175291,DB01183,Naloxone
,19108793,C(max),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],62.01,175292,DB01183,Naloxone
,19108793,C(max),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],63.62,175293,DB01183,Naloxone
,19108793,C(max),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],61.95,175294,DB01183,Naloxone
,19108793,C(max),"For naloxone-3-glucuronide (the primary analyte of naloxone), the mean (SD) AUC(t) values with OXN 10/5, 20/10, and 40/20 mg and oxycodone PR + naloxone PR were 539.93 (142.24), 522.45 (128.57), 520.10 (133.18), and 523.37 (119.75) ng . h/mL, respectively; mean C(max) values were 62.01 (15.96), 63.62 (19.51), 61.95 (18.37), and 63.55 (16.75) ng/mL.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],63.55,175295,DB01183,Naloxone
,19108793,"C(min,ss)","Mean C(min,ss) values of 22.6 and 24.0 ng/mL were obtained for the OXN combination and naloxone PR tablet, respectively.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],22.6,175296,DB01183,Naloxone
,19108793,"C(min,ss)","Mean C(min,ss) values of 22.6 and 24.0 ng/mL were obtained for the OXN combination and naloxone PR tablet, respectively.",Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19108793/),[ng] / [ml],24.0,175297,DB01183,Naloxone
,8346837,systemic clearance,"Except for systemic clearance of morphine during halothane and isoflurane (40.1 +/- 6.1 and 53.7 +/- 5.6 mL.min-1.kg-1, respectively), there were no differences in disposition kinetics of free morphine associated with the two inhaled anesthetics.",Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),[ml] / [kg·min],40.1,177182,DB01183,Naloxone
,8346837,systemic clearance,"Except for systemic clearance of morphine during halothane and isoflurane (40.1 +/- 6.1 and 53.7 +/- 5.6 mL.min-1.kg-1, respectively), there were no differences in disposition kinetics of free morphine associated with the two inhaled anesthetics.",Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),[ml] / [kg·min],53.7,177183,DB01183,Naloxone
,8346837,PaCO2,Morphine increased PaCO2 to a similar degree with both halothane (from 42.2 +/- 2.1 mm Hg to 55.6 +/- 2.3 mm Hg) and isoflurane (46.2 +/- 2.4 mm Hg to 55.3 +/- 2.1 mm Hg).,Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),hg·mm,42.2,177184,DB01183,Naloxone
,8346837,PaCO2,Morphine increased PaCO2 to a similar degree with both halothane (from 42.2 +/- 2.1 mm Hg to 55.6 +/- 2.3 mm Hg) and isoflurane (46.2 +/- 2.4 mm Hg to 55.3 +/- 2.1 mm Hg).,Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),mm,55.6,177185,DB01183,Naloxone
,8346837,PaCO2,Morphine increased PaCO2 to a similar degree with both halothane (from 42.2 +/- 2.1 mm Hg to 55.6 +/- 2.3 mm Hg) and isoflurane (46.2 +/- 2.4 mm Hg to 55.3 +/- 2.1 mm Hg).,Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),h·mm,46.2,177186,DB01183,Naloxone
,8346837,PaCO2,Morphine increased PaCO2 to a similar degree with both halothane (from 42.2 +/- 2.1 mm Hg to 55.6 +/- 2.3 mm Hg) and isoflurane (46.2 +/- 2.4 mm Hg to 55.3 +/- 2.1 mm Hg).,Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),mm,55.3,177187,DB01183,Naloxone
,20376593,Peak serum topiramate level,"Peak serum topiramate level was 356.6 microg/ml (reference range, 5-20 microg/ml).",Clinical effects and toxicokinetic evaluation following massive topiramate ingestion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20376593/),[μg] / [ml],356.6,179957,DB01183,Naloxone
,20376593,Serum half-life,"Serum half-life, which has not been studied after overdose, was 16 h.",Clinical effects and toxicokinetic evaluation following massive topiramate ingestion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20376593/),h,16,179958,DB01183,Naloxone
exceeded,9726277,plasma concentrations,"After injection, NTX plasma concentrations exceeded a mean of 1 ng/ml for 21 days.",Sustained-release naltrexone for alcoholism treatment: a preliminary study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9726277/),[ng] / [ml],1,181059,DB01183,Naloxone
,8852390,clearance,"Although the hemodialysis clearance of nalmefene glucuronide was 179.3 +/- 24.1 mL/min and its t1/2 was significantly reduced during dialysis to 5.2 +/- 2.3 hours, a dramatic rebound of nalmefene glucuronide concentrations of 75.7% was observed 7.7 +/- 5.4 hours after the end of hemodialysis.",The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852390/),[ml] / [min],179.3,181955,DB01183,Naloxone
,8852390,t1/2,"Although the hemodialysis clearance of nalmefene glucuronide was 179.3 +/- 24.1 mL/min and its t1/2 was significantly reduced during dialysis to 5.2 +/- 2.3 hours, a dramatic rebound of nalmefene glucuronide concentrations of 75.7% was observed 7.7 +/- 5.4 hours after the end of hemodialysis.",The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852390/),h,5.2,181956,DB01183,Naloxone
,33330726,plasma concentration,"Ingestion of an FTP was not observed but the fentanyl plasma concentration on the day of intoxication was 20.7 ng/ml, while at its peak after FTP administration it was only 0.492 ng/ml.",Case Report: Intoxication in a Pig (Sus Scrofa Domesticus) After Transdermal Fentanyl Patch Ingestion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33330726/),,20.,182127,DB01183,Naloxone
,26317320,ka1,"The final model was a two compartment disposition model with dual absorptions, comprising one first order absorption (ka1 4.56 h(-1) ) and one more complex absorption with a transit compartment (ktr 2.78 h(-1) ).",Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26317320/),1/[h],4.56,184819,DB01183,Naloxone
,26317320,ktr,"The final model was a two compartment disposition model with dual absorptions, comprising one first order absorption (ka1 4.56 h(-1) ) and one more complex absorption with a transit compartment (ktr 2.78 h(-1) ).",Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26317320/),1/[h],2.78,184820,DB01183,Naloxone
,26317320,CL/F,"Mean (SE) parameter estimates for CL/F and Vc /F, the parameters assessed for covariate effects, were 115 (3.41) l h(-1) and 160 (27.4) l, respectively.",Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26317320/),[l] / [h],115,184821,DB01183,Naloxone
,26317320,Vc /F,"Mean (SE) parameter estimates for CL/F and Vc /F, the parameters assessed for covariate effects, were 115 (3.41) l h(-1) and 160 (27.4) l, respectively.",Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26317320/),l,160,184822,DB01183,Naloxone
,30867551,peak occupancies,"Estimated peak occupancies were 67 and 85% following 2 and 4 mg IN doses, respectively.",Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30867551/),%,67,186162,DB01183,Naloxone
,30867551,peak occupancies,"Estimated peak occupancies were 67 and 85% following 2 and 4 mg IN doses, respectively.",Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30867551/),%,85,186163,DB01183,Naloxone
,30867551,half-life of occupancy disappearance,The estimated half-life of occupancy disappearance was ~100 min.,Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30867551/),min,100,186164,DB01183,Naloxone
,10053209,lipid-water partition coefficient,"Naloxone possesses characteristics favorable to percutaneous absorption: i.e. a low molecular weight (327.37), water solubility and a good lipid-water partition coefficient of 12.94+/-1.29 at pH 7.4.",Transdermal delivery of naloxone: ex vivo permeation studies. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10053209/),,12.94,187361,DB01183,Naloxone
,10053209,flux,The flux (microg/cm2/h) values varied from 6.59+/-0.72 in control to 27. 18+/-4.26 in dimethyl formamide.,Transdermal delivery of naloxone: ex vivo permeation studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10053209/),[μg] / [cm2·h],6.59,187362,DB01183,Naloxone
,10053209,flux,The flux (microg/cm2/h) values varied from 6.59+/-0.72 in control to 27. 18+/-4.26 in dimethyl formamide.,Transdermal delivery of naloxone: ex vivo permeation studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10053209/),[μg] / [cm2·h],27. 18,187363,DB01183,Naloxone
,6520774,limit of sensitivity,The procedure has a limit of sensitivity of 0.2 ng/mL of nalmefene using a 0.5-mL sample of plasma for analysis.,Nalmefene: radioimmunoassay for a new opioid antagonist. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6520774/),[ng] / [ml],0.2,188355,DB01183,Naloxone
,15268689,MAC,The baseline isoflurane MAC was 1.51 +/- 0.21% (mean +/- SD).,Effect of transdermally administered fentanyl on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15268689/),%,1.51,189985,DB01183,Naloxone
,15268689,MAC,Isoflurane MAC determined during administration of fentanyl 25 micro g hour(-1) and naloxone (1.44 +/- 0.16%) and fentanyl 50 micro g hour(-1) and naloxone (1.51 +/- 0.19%) was not significantly different from baseline MAC (1.51 +/- 0.21%).,Effect of transdermally administered fentanyl on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15268689/),%,1,189986,DB01183,Naloxone
,24107112,plasma concentrations,"After a single injection of naltrexone 200 and 400 mg, means (SD) of naltrexone plasma concentrations were .57 (.28) ng/ml and 1.5 (.8) ng/ml 30 days post-injection.","Phase I study of injectable, depot naltrexone for the relapse prevention treatment of opioid dependence. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24107112/),[ng] / [ml],.57,190095,DB01183,Naloxone
,24107112,plasma concentrations,"After a single injection of naltrexone 200 and 400 mg, means (SD) of naltrexone plasma concentrations were .57 (.28) ng/ml and 1.5 (.8) ng/ml 30 days post-injection.","Phase I study of injectable, depot naltrexone for the relapse prevention treatment of opioid dependence. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24107112/),[ng] / [ml],1.5,190096,DB01183,Naloxone
,27390058,extraction recoveries,The extraction recoveries for all the analytes ranged from 55 to 86.9%.,"Quantitative determination of buprenorphine, naloxone and their metabolites in rat plasma using hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390058/),%,55 to 86.9,190897,DB01183,Naloxone
,15956985,t(1/2),The mean t(1/2) of nalmefene was 13.4 h after single and repeated dosing.,Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15956985/),h,13.4,193356,DB01183,Naloxone
,15956985,occupancy,High nalmefene occupancy (83-100%) persisted at 26 h after the dosings.,Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15956985/),%,83-100,193357,DB01183,Naloxone
,16740093,steady-state volume of distribution,"The time-concentration data for MNTX disposition best fit a 2-compartment model with a steady-state volume of distribution of 244.6 +/- 21.8 mL/kg, t1/2 of 47.04 +/- 11.65 minutes, and clearance of 11.43 +/- 1.06 mL/min/kg.",Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740093/),[ml] / [kg],244.6,195175,DB01183,Naloxone
,16740093,t1/2,"The time-concentration data for MNTX disposition best fit a 2-compartment model with a steady-state volume of distribution of 244.6 +/- 21.8 mL/kg, t1/2 of 47.04 +/- 11.65 minutes, and clearance of 11.43 +/- 1.06 mL/min/kg.",Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740093/),min,47.04,195176,DB01183,Naloxone
,16740093,clearance,"The time-concentration data for MNTX disposition best fit a 2-compartment model with a steady-state volume of distribution of 244.6 +/- 21.8 mL/kg, t1/2 of 47.04 +/- 11.65 minutes, and clearance of 11.43 +/- 1.06 mL/min/kg.",Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740093/),[ml] / [kg·min],11.43,195177,DB01183,Naloxone
,15778059,surface area (SA),"Based on ex vivo data, the surface area (SA) of the patch was predicted to be 39.6 cm(2) in order to achieve therapeutic blood levels.","Transdermal delivery of naloxone: skin permeation, pharmacokinetic, irritancy and stability studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778059/),cm(2),39.6,199946,DB01183,Naloxone
,1623908,t1/2s,The t1/2s for effect compartment equilibration were 29 and 42 min for clonidine + naloxone and clonidine.,"Pharmacokinetic-pharmacodynamic modeling of the effects of clonidine on pain threshold, blood pressure, and salivary flow. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623908/),min,29,199972,DB01183,Naloxone
,1623908,t1/2s,The t1/2s for effect compartment equilibration were 29 and 42 min for clonidine + naloxone and clonidine.,"Pharmacokinetic-pharmacodynamic modeling of the effects of clonidine on pain threshold, blood pressure, and salivary flow. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623908/),min,42,199973,DB01183,Naloxone
,21502953,effective concentration 50,GSK1521498 had high affinity for human brain ORs (GSK1521498 effective concentration 50 = 7.10 ng ml(-1)) and there was a direct relationship between receptor occupancy (RO) and plasma concentrations of GSK1521498.,Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502953/),[ng] / [ml],7.10,200324,DB01183,Naloxone
,3680580,elimination half-life,"Model-independent pharmacokinetic analysis of the plasma concentration-time data showed that nalmefene was rapidly absorbed and had an elimination half-life that ranged from seven to 15 hours (mean, 10.7 hr).",Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680580/),h,seven to 15,201292,DB01183,Naloxone
,3680580,elimination half-life,"Model-independent pharmacokinetic analysis of the plasma concentration-time data showed that nalmefene was rapidly absorbed and had an elimination half-life that ranged from seven to 15 hours (mean, 10.7 hr).",Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680580/),h,10.7,201293,DB01183,Naloxone
,30644628,Area under the curve from administration to last measured concentration (AUC0-last ),"Area under the curve from administration to last measured concentration (AUC0-last ) for i.n. 1.4 mg and i.m. 0.8 mg were 2.62 ± 0.94 and 3.09 ± 0.64 h × ng/ml, respectively (P = 0.33).","Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30644628/),[h·ng] / [ml],2.62,203403,DB01183,Naloxone
,30644628,Area under the curve from administration to last measured concentration (AUC0-last ),"Area under the curve from administration to last measured concentration (AUC0-last ) for i.n. 1.4 mg and i.m. 0.8 mg were 2.62 ± 0.94 and 3.09 ± 0.64 h × ng/ml, respectively (P = 0.33).","Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30644628/),[h·ng] / [ml],3.09,203404,DB01183,Naloxone
,30644628,Maximum concentration (Cmax ),Maximum concentration (Cmax ) was 2.36 ± 0.68 ng/ml for i.n. 1.4 mg and 3.73 ± 3.34 for i.m. 0.8 mg (P = 0.72).,"Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30644628/),[ng] / [ml],2.36,203405,DB01183,Naloxone
,30644628,Maximum concentration (Cmax ),Maximum concentration (Cmax ) was 2.36 ± 0.68 ng/ml for i.n. 1.4 mg and 3.73 ± 3.34 for i.m. 0.8 mg (P = 0.72).,"Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30644628/),,3.73,203406,DB01183,Naloxone
,30644628,Cmax,Two i.n. doses showed dose linearity and achieved a Cmax of 4.18 ± 1.53 ng/ml.,"Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30644628/),[ng] / [ml],4.18,203407,DB01183,Naloxone
,30644628,Tmax,Tmax was reached after 20.2 ± 9.4 minutes for i.n. 1.4 mg and 13.6 ± 15.4 minutes for i.m. 0.8 mg (P = 0.098).,"Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30644628/),min,20.2,203408,DB01183,Naloxone
,30644628,Tmax,Tmax was reached after 20.2 ± 9.4 minutes for i.n. 1.4 mg and 13.6 ± 15.4 minutes for i.m. 0.8 mg (P = 0.098).,"Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30644628/),min,13.6,203409,DB01183,Naloxone
,30644628,absolute bioavailability,"The absolute bioavailability for i.n. 1.4 mg was 0.49 (±0.24), while the relative i.n./i.m. bioavailability was 0.52 (±0.25).","Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30644628/),,0.49,203410,DB01183,Naloxone
,21593282,t(max),Administration with 40% alcohol did not affect overall morphine exposure but was associated with a 2-fold increase in C(max) and reduction of t(max) from 9 to 4 hours versus MS-sNT taken with water.,Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21593282/),h,9,203445,DB01183,Naloxone
,21593282,t(max),Administration with 40% alcohol did not affect overall morphine exposure but was associated with a 2-fold increase in C(max) and reduction of t(max) from 9 to 4 hours versus MS-sNT taken with water.,Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21593282/),h,4,203446,DB01183,Naloxone
,6090829,half-lives,"The half-lives of alpha-phase and beta-phase were 2.6 +/- 0.5 min and 6.2 +/- 1.6 hr (mean +/- SE; n = 6), respectively.",Pharmacokinetic study of exogenously administered beta-endorphin using a rapid radioreceptor assay in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6090829/),min,2.6,203574,DB01183,Naloxone
,6090829,half-lives,"The half-lives of alpha-phase and beta-phase were 2.6 +/- 0.5 min and 6.2 +/- 1.6 hr (mean +/- SE; n = 6), respectively.",Pharmacokinetic study of exogenously administered beta-endorphin using a rapid radioreceptor assay in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6090829/),h,6.2,203575,DB01183,Naloxone
,6090829,volume of the central compartment (V1),"The volume of the central compartment (V1) and that of steady-state (Vdss) were 67 +/- 16 and 480 +/- 75 ml/kg (mean +/- SE; n = 6), respectively.",Pharmacokinetic study of exogenously administered beta-endorphin using a rapid radioreceptor assay in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6090829/),[ml] / [kg],67,203576,DB01183,Naloxone
,6090829,steady-state (Vdss),"The volume of the central compartment (V1) and that of steady-state (Vdss) were 67 +/- 16 and 480 +/- 75 ml/kg (mean +/- SE; n = 6), respectively.",Pharmacokinetic study of exogenously administered beta-endorphin using a rapid radioreceptor assay in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6090829/),[ml] / [kg],480,203577,DB01183,Naloxone
,6090829,total body serum clearance (CLtot),The total body serum clearance (CLtot) was 2.1 +/- 0.9 ml/min/kg (mean +/- SE; n = 6).,Pharmacokinetic study of exogenously administered beta-endorphin using a rapid radioreceptor assay in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6090829/),[ml] / [kg·min],2.1,203578,DB01183,Naloxone
,3385649,plasma half-life,"The plasma half-life (127 min) in the Swiss CD1 mouse was used as a basis for chronic administration, which was strictly every half-life as in clinical use.",Pharmacokinetic patterns of repeated administration of antidepressants in animals. I. Implications for antinociceptive action of clomipramine in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3385649/),min,127,205520,DB01183,Naloxone
,8996532,plasma clearance rate,The plasma clearance rate of a bolus dose of 100 mg/kg 5-FU was significantly reduced from 54 to 28 ml/min per kg and the elimination half-life was increased from 6.9 to 12.2 min by prior administration of morphine.,Opiate effects on 5-fluorouracil disposition in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996532/),[ml] / [kg·min],54 to 28,206813,DB01183,Naloxone
,8996532,elimination half-life,The plasma clearance rate of a bolus dose of 100 mg/kg 5-FU was significantly reduced from 54 to 28 ml/min per kg and the elimination half-life was increased from 6.9 to 12.2 min by prior administration of morphine.,Opiate effects on 5-fluorouracil disposition in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996532/),min,6.9 to 12.2,206814,DB01183,Naloxone
,8996532,plasma clearance rate,"When 5-FU was infused at 0.5 mg/kg per min, morphine reduced its plasma clearance rate from 145 to 94 ml/min per kg.",Opiate effects on 5-fluorouracil disposition in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996532/),[ml] / [kg·min],145,206815,DB01183,Naloxone
,8996532,plasma clearance rate,"When 5-FU was infused at 0.5 mg/kg per min, morphine reduced its plasma clearance rate from 145 to 94 ml/min per kg.",Opiate effects on 5-fluorouracil disposition in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996532/),[ml] / [kg·min],94,206816,DB01183,Naloxone
,1448475,half-life,Morphine sulfate administered IV and SC had a half-life of approximately 1 h whereas delayed-release morphine alkaloid delivered SC had a half-life of 28 h.,Acute and chronic morphine administration in swine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1448475/),h,1,208049,DB01183,Naloxone
,1448475,half-life,Morphine sulfate administered IV and SC had a half-life of approximately 1 h whereas delayed-release morphine alkaloid delivered SC had a half-life of 28 h.,Acute and chronic morphine administration in swine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1448475/),h,28,208050,DB01183,Naloxone
,23327357,Tmax,"Tmax was 180 min, C(max) was 1083.7 ± 293.9 ng/mL, and T(½) was 496 min for the MNTX-PC group.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),min,180,209595,DB01183,Naloxone
,23327357,C(max),"Tmax was 180 min, C(max) was 1083.7 ± 293.9 ng/mL, and T(½) was 496 min for the MNTX-PC group.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),[ng] / [ml],1083.7,209596,DB01183,Naloxone
,23327357,T(½),"Tmax was 180 min, C(max) was 1083.7 ± 293.9 ng/mL, and T(½) was 496 min for the MNTX-PC group.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),min,496,209597,DB01183,Naloxone
,23327357,T(max),"For control, T(max) was 180 min, C(max) was 448.4 ± 126.0 ng/mL, and T(½) was 259 min.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),min,180,209598,DB01183,Naloxone
,23327357,C(max),"For control, T(max) was 180 min, C(max) was 448.4 ± 126.0 ng/mL, and T(½) was 259 min.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),[ng] / [ml],448.4,209599,DB01183,Naloxone
,23327357,T(½),"For control, T(max) was 180 min, C(max) was 448.4 ± 126.0 ng/mL, and T(½) was 259 min.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),min,259,209600,DB01183,Naloxone
,23327357,AUC₀₋₅₄₀ min,"The AUC₀₋₅₄₀ min for the MNTX-PC group was 5758.2 ± 1474.2 ngh/mL; for control, 1405.9 ± 447.8 ngh/mL.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),[ngh] / [ml],5758.2,209601,DB01183,Naloxone
,23327357,AUC₀₋₅₄₀ min,"The AUC₀₋₅₄₀ min for the MNTX-PC group was 5758.2 ± 1474.2 ngh/mL; for control, 1405.9 ± 447.8 ngh/mL.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),[ngh] / [ml],1405.9,209602,DB01183,Naloxone
,23327357,relative bioavailability,"Thus, the relative bioavailability after the oral administration of MNTX-PC was 410% compared to that of control.",Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23327357/),%,410,209603,DB01183,Naloxone
,17922561,rate constants of receptor association (k(on)),"For buprenorphine, the values of the rate constants of receptor association (k(on)) and dissociation (k(off)) were 0.203 mL/ng/min and 0.0172 min(-)(1), respectively.",Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922561/),[ml] / [min·ng],0.203,210557,DB01183,Naloxone
,17922561,dissociation (k(off)),"For buprenorphine, the values of the rate constants of receptor association (k(on)) and dissociation (k(off)) were 0.203 mL/ng/min and 0.0172 min(-)(1), respectively.",Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922561/),min(-)(1),0.0172,210558,DB01183,Naloxone
,17922561,equilibrium dissociation constant (K(D)),The value of the equilibrium dissociation constant (K(D)) was 0.18 nmol/L.,Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922561/),[nM] / [l],0.18,210559,DB01183,Naloxone
,17922561,half-life (t((1/2))),The half-life (t((1/2))) of biophase equilibration was 173 minutes.,Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922561/),min,173,210560,DB01183,Naloxone
,17922561,half-life of biophase distribution,"For naloxone, the half-life of biophase distribution was 6.5 minutes.",Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922561/),min,6.5,210561,DB01183,Naloxone
,22717418,C(max),"The bioavailability of oxycodone from IRO-A tablets in the fed state was comparable with IRO tablets based on AUC parameters, although C(max) was ~16.5% lower.","Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22717418/),%,16.5,210871,DB01183,Naloxone
,2839637,half-time of blockade,"The half-time of blockade by naltrexone in the brain ranged from 72 to 108 hr which is greater than the fast plasma clearance components (4-12 hr) of naltrexone or its metabolite, beta-naltrexol, but corresponds well to the half-time of the terminal phase of plasma naltrexone clearance (96 hr).",Duration of occupancy of opiate receptors by naltrexone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2839637/),h,72 to 108,214228,DB01183,Naloxone
,2839637,half-time of blockade,"The half-time of blockade by naltrexone in the brain ranged from 72 to 108 hr which is greater than the fast plasma clearance components (4-12 hr) of naltrexone or its metabolite, beta-naltrexol, but corresponds well to the half-time of the terminal phase of plasma naltrexone clearance (96 hr).",Duration of occupancy of opiate receptors by naltrexone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2839637/),h,4-12,214229,DB01183,Naloxone
,2839637,half-time of the terminal phase,"The half-time of blockade by naltrexone in the brain ranged from 72 to 108 hr which is greater than the fast plasma clearance components (4-12 hr) of naltrexone or its metabolite, beta-naltrexol, but corresponds well to the half-time of the terminal phase of plasma naltrexone clearance (96 hr).",Duration of occupancy of opiate receptors by naltrexone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2839637/),h,96,214230,DB01183,Naloxone
,2875678,clearance rate,"The alfentanil clearance rate was significantly lower in patients with liver dysfunction (2.3 +/- 1.3 vs 4.2 +/- 2.0 ml X kg-1 X min-1, mean +/- SD).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ml] / [kg·min],2.3,215709,DB01183,Naloxone
,2875678,clearance rate,"The alfentanil clearance rate was significantly lower in patients with liver dysfunction (2.3 +/- 1.3 vs 4.2 +/- 2.0 ml X kg-1 X min-1, mean +/- SD).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ml] / [kg·min],4.2,215710,DB01183,Naloxone
,2875678,clearance rates,"In addition, the patients who required opioid antagonists to reverse postoperative respiratory depression had lower clearance rates (1.5 +/- 0.7 vs 4.1 +/- 1.9 ml X kg-1 X min-1) and longer elimination half-life values (406 +/- 304 vs 87 +/- 53 min).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ml] / [kg·min],1.5,215711,DB01183,Naloxone
,2875678,clearance rates,"In addition, the patients who required opioid antagonists to reverse postoperative respiratory depression had lower clearance rates (1.5 +/- 0.7 vs 4.1 +/- 1.9 ml X kg-1 X min-1) and longer elimination half-life values (406 +/- 304 vs 87 +/- 53 min).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ml] / [kg·min],4.1,215712,DB01183,Naloxone
,2875678,elimination half-life,"In addition, the patients who required opioid antagonists to reverse postoperative respiratory depression had lower clearance rates (1.5 +/- 0.7 vs 4.1 +/- 1.9 ml X kg-1 X min-1) and longer elimination half-life values (406 +/- 304 vs 87 +/- 53 min).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),min,406,215713,DB01183,Naloxone
,2875678,elimination half-life,"In addition, the patients who required opioid antagonists to reverse postoperative respiratory depression had lower clearance rates (1.5 +/- 0.7 vs 4.1 +/- 1.9 ml X kg-1 X min-1) and longer elimination half-life values (406 +/- 304 vs 87 +/- 53 min).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),min,87,215714,DB01183,Naloxone
exceeding,2875678,ED95,"For maintenance of hemodynamic stability during superficial and intraabdominal operations, alfentanil serum concentration-response curves revealed ED95 values exceeding 300 ng/ml and 400 ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ng] / [ml],300,215715,DB01183,Naloxone
,2875678,ED95,"For maintenance of hemodynamic stability during superficial and intraabdominal operations, alfentanil serum concentration-response curves revealed ED95 values exceeding 300 ng/ml and 400 ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ng] / [ml],400,215716,DB01183,Naloxone
,2979128,maximum inspired concentration,"After intubation, anesthesia was maintained with nitrous oxide-oxygen and halothane to a maximum inspired concentration of 0.6%.",Alfentanil in infants and children with congenital heart defects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979128/),%,0.6,216495,DB01183,Naloxone
,2979128,total plasma clearance,"In the infants and children, total plasma clearance was 8.2 +/- 2.2 mL/kg/min and 6.3 +/- 0.8 mL/kg/min, respectively.",Alfentanil in infants and children with congenital heart defects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979128/),[ml] / [kg·min],8.2,216496,DB01183,Naloxone
,2979128,total plasma clearance,"In the infants and children, total plasma clearance was 8.2 +/- 2.2 mL/kg/min and 6.3 +/- 0.8 mL/kg/min, respectively.",Alfentanil in infants and children with congenital heart defects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979128/),[ml] / [kg·min],6.3,216497,DB01183,Naloxone
,33352843,tmax,"PK non-compartmental characteristics showed considerable variability in parameters between the subjects over the 8-h sampling time (tmax = 1.5 ± 0.7 h, Co = 1.6 ± 1.4 ng/mL, Cmax= 7.1 ± 6 ng/mL, and AUC0-8h = 26.8 ± 17.8 h·ng/mL).",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),h,1.5,217404,DB01183,Naloxone
,33352843,Co,"PK non-compartmental characteristics showed considerable variability in parameters between the subjects over the 8-h sampling time (tmax = 1.5 ± 0.7 h, Co = 1.6 ± 1.4 ng/mL, Cmax= 7.1 ± 6 ng/mL, and AUC0-8h = 26.8 ± 17.8 h·ng/mL).",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),[ng] / [ml],1.6,217405,DB01183,Naloxone
,33352843,Cmax,"PK non-compartmental characteristics showed considerable variability in parameters between the subjects over the 8-h sampling time (tmax = 1.5 ± 0.7 h, Co = 1.6 ± 1.4 ng/mL, Cmax= 7.1 ± 6 ng/mL, and AUC0-8h = 26.8 ± 17.8 h·ng/mL).",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),[ng] / [ml],7.1,217406,DB01183,Naloxone
,33352843,AUC0-8h,"PK non-compartmental characteristics showed considerable variability in parameters between the subjects over the 8-h sampling time (tmax = 1.5 ± 0.7 h, Co = 1.6 ± 1.4 ng/mL, Cmax= 7.1 ± 6 ng/mL, and AUC0-8h = 26.8 ± 17.8 h·ng/mL).",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),[h·ng] / [ml],26.8,217407,DB01183,Naloxone
,33352843,AUC0-8h ratios,"Subjects had a significantly higher tendency towards CYP-mediated N-demethylation, with the AUC0-8h ratios of the molar concentrations of [Nor-BUP + Nor-BUP-g] to BUP being (3.4 ± 1.9) significantly higher compared with BUP-g to BUP (0.19 ± 0.2).",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),,3.4,217408,DB01183,Naloxone
,33352843,AUC0-8h ratios,"Subjects had a significantly higher tendency towards CYP-mediated N-demethylation, with the AUC0-8h ratios of the molar concentrations of [Nor-BUP + Nor-BUP-g] to BUP being (3.4 ± 1.9) significantly higher compared with BUP-g to BUP (0.19 ± 0.2).",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),,0.19,217409,DB01183,Naloxone
,33352843,ka,"A two-compartment population-PK model with linear absorption (ka = 2.54 h-1), distribution (k12= 2.34 h-1, k14 = 1.29 h-1), metabolism (k24 = 1.28 × 10-1 h-1, k23 = 6.43 × 10-2 h-1, k35 = 1.23 × 10-1 h-1, k45 = 8.73 × 10-1 h-1), and elimination (k30 = 3.81 × 10-3 h-1, k50 = 1.27 × 10-1 h-1) adequately described the time-course of BUP and its metabolites, which has been externally validated using published data.",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),1/[h],2.54,217410,DB01183,Naloxone
,33352843,k12,"A two-compartment population-PK model with linear absorption (ka = 2.54 h-1), distribution (k12= 2.34 h-1, k14 = 1.29 h-1), metabolism (k24 = 1.28 × 10-1 h-1, k23 = 6.43 × 10-2 h-1, k35 = 1.23 × 10-1 h-1, k45 = 8.73 × 10-1 h-1), and elimination (k30 = 3.81 × 10-3 h-1, k50 = 1.27 × 10-1 h-1) adequately described the time-course of BUP and its metabolites, which has been externally validated using published data.",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),1/[h],2.34,217411,DB01183,Naloxone
,33352843,k14,"A two-compartment population-PK model with linear absorption (ka = 2.54 h-1), distribution (k12= 2.34 h-1, k14 = 1.29 h-1), metabolism (k24 = 1.28 × 10-1 h-1, k23 = 6.43 × 10-2 h-1, k35 = 1.23 × 10-1 h-1, k45 = 8.73 × 10-1 h-1), and elimination (k30 = 3.81 × 10-3 h-1, k50 = 1.27 × 10-1 h-1) adequately described the time-course of BUP and its metabolites, which has been externally validated using published data.",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),1/[h],1.29,217412,DB01183,Naloxone
,33352843,k24,"A two-compartment population-PK model with linear absorption (ka = 2.54 h-1), distribution (k12= 2.34 h-1, k14 = 1.29 h-1), metabolism (k24 = 1.28 × 10-1 h-1, k23 = 6.43 × 10-2 h-1, k35 = 1.23 × 10-1 h-1, k45 = 8.73 × 10-1 h-1), and elimination (k30 = 3.81 × 10-3 h-1, k50 = 1.27 × 10-1 h-1) adequately described the time-course of BUP and its metabolites, which has been externally validated using published data.",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),1/[h],1.28 × 10-1,217413,DB01183,Naloxone
,33352843,k23,"A two-compartment population-PK model with linear absorption (ka = 2.54 h-1), distribution (k12= 2.34 h-1, k14 = 1.29 h-1), metabolism (k24 = 1.28 × 10-1 h-1, k23 = 6.43 × 10-2 h-1, k35 = 1.23 × 10-1 h-1, k45 = 8.73 × 10-1 h-1), and elimination (k30 = 3.81 × 10-3 h-1, k50 = 1.27 × 10-1 h-1) adequately described the time-course of BUP and its metabolites, which has been externally validated using published data.",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),1/[h],6.43 × 10-2,217414,DB01183,Naloxone
,33352843,k35,"A two-compartment population-PK model with linear absorption (ka = 2.54 h-1), distribution (k12= 2.34 h-1, k14 = 1.29 h-1), metabolism (k24 = 1.28 × 10-1 h-1, k23 = 6.43 × 10-2 h-1, k35 = 1.23 × 10-1 h-1, k45 = 8.73 × 10-1 h-1), and elimination (k30 = 3.81 × 10-3 h-1, k50 = 1.27 × 10-1 h-1) adequately described the time-course of BUP and its metabolites, which has been externally validated using published data.",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),1/[h],1.23 × 10-1,217415,DB01183,Naloxone
,33352843,k45,"A two-compartment population-PK model with linear absorption (ka = 2.54 h-1), distribution (k12= 2.34 h-1, k14 = 1.29 h-1), metabolism (k24 = 1.28 × 10-1 h-1, k23 = 6.43 × 10-2 h-1, k35 = 1.23 × 10-1 h-1, k45 = 8.73 × 10-1 h-1), and elimination (k30 = 3.81 × 10-3 h-1, k50 = 1.27 × 10-1 h-1) adequately described the time-course of BUP and its metabolites, which has been externally validated using published data.",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),1/[h],8.73 × 10-1,217416,DB01183,Naloxone
,33352843,k30,"A two-compartment population-PK model with linear absorption (ka = 2.54 h-1), distribution (k12= 2.34 h-1, k14 = 1.29 h-1), metabolism (k24 = 1.28 × 10-1 h-1, k23 = 6.43 × 10-2 h-1, k35 = 1.23 × 10-1 h-1, k45 = 8.73 × 10-1 h-1), and elimination (k30 = 3.81 × 10-3 h-1, k50 = 1.27 × 10-1 h-1) adequately described the time-course of BUP and its metabolites, which has been externally validated using published data.",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),1/[h],3.81 × 10-3,217417,DB01183,Naloxone
,33352843,k50,"A two-compartment population-PK model with linear absorption (ka = 2.54 h-1), distribution (k12= 2.34 h-1, k14 = 1.29 h-1), metabolism (k24 = 1.28 × 10-1 h-1, k23 = 6.43 × 10-2 h-1, k35 = 1.23 × 10-1 h-1, k45 = 8.73 × 10-1 h-1), and elimination (k30 = 3.81 × 10-3 h-1, k50 = 1.27 × 10-1 h-1) adequately described the time-course of BUP and its metabolites, which has been externally validated using published data.",Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352843/),1/[h],1.27 × 10-1,217418,DB01183,Naloxone
,21337353,flow rate,The flow rate was 0.3 mL/min and the total run time was 2 min.,Validated LC-MS/MS assay for the quantitative determination of nalbuphine in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21337353/),[ml] / [min],0.3,217734,DB01183,Naloxone
,21337353,total run time,The flow rate was 0.3 mL/min and the total run time was 2 min.,Validated LC-MS/MS assay for the quantitative determination of nalbuphine in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21337353/),min,2,217735,DB01183,Naloxone
,21337353,m/,The mass transitions were m/z 358 → 340 for nalbuphine and m/z 328 → 310 for naloxone.,Validated LC-MS/MS assay for the quantitative determination of nalbuphine in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21337353/),,358,217736,DB01183,Naloxone
,21337353,m/,The mass transitions were m/z 358 → 340 for nalbuphine and m/z 328 → 310 for naloxone.,Validated LC-MS/MS assay for the quantitative determination of nalbuphine in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21337353/),,340,217737,DB01183,Naloxone
,21337353,signal-to-noise ratio,The lower limit of quantitation was set at 0.5 ng/mL plasma based on an average signal-to-noise ratio of 44.79.,Validated LC-MS/MS assay for the quantitative determination of nalbuphine in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21337353/),,44.79,217738,DB01183,Naloxone
>,33603137,Occupancy,Occupancy >90% was achieved in most brain regions with plasma concentrations >7 µg/L.,Pharmacokinetic neuroimaging to study the dose-related brain kinetics and target engagement of buprenorphine in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33603137/),%,90,219631,DB01183,Naloxone
,30698833,Tmax,The addition of the absorption enhancer dodecyl maltoside (Intravail) increased Cmax by ∼3-fold and reduced the Tmax from 0.5 to 0.17 hours.,Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30698833/),h,0.5,219742,DB01183,Naloxone
,30698833,Tmax,The addition of the absorption enhancer dodecyl maltoside (Intravail) increased Cmax by ∼3-fold and reduced the Tmax from 0.5 to 0.17 hours.,Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30698833/),h,0.17,219743,DB01183,Naloxone
,30698833,half-life,"Despite these very rapid increases in plasma concentrations of naltrexone, its short half-life following intranasal administration (∼2.2 hours) could limit its usefulness as a rescue medication, particularly against longer-lived synthetic opioids.",Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30698833/),h,∼2.2,219744,DB01183,Naloxone
,30977959,Renal,"Renal clearance decreased with reduced renal function (normal function 1.3 L/h; mild impairment 1.1 L/h; moderate impairment 1.0 L/h; severe impairment 0.5 L/h), and only 2.7% of naldemedine was removed by hemodialysis.","The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977959/),[l] / [h],1.3,220994,DB01183,Naloxone
,30977959,Renal,"Renal clearance decreased with reduced renal function (normal function 1.3 L/h; mild impairment 1.1 L/h; moderate impairment 1.0 L/h; severe impairment 0.5 L/h), and only 2.7% of naldemedine was removed by hemodialysis.","The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977959/),,1,220995,DB01183,Naloxone
,17470643,K(i),ELN441958 competitively inhibited the binding of the B(1) agonist ligand [(3)H]desArg(10)-kallidin ([(3)H]DAKD) to IMR-90 human fibroblast membranes with high affinity (K(i) = 0.26 +/- 0.02 nM).,"Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470643/),nM,0.26,223016,DB01183,Naloxone
,17470643,ED(50),"ELN441958 dose-dependently reduced carrageenan-induced thermal hyperalgesia in a rhesus monkey tail-withdrawal model, with an ED(50) approximately 3 mg/kg s.c.","Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470643/),[mg] / [kg],3,223017,DB01183,Naloxone
,1267205,Serum concentration,Serum concentration of naloxone at 5 minutes was 1.45 +/- 0.1 mug/ml (mean +/- SE) and that of morphine was 1.0 +/- 0.08 mug/ml.,Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1267205/),[μg] / [ml],1.45,224375,DB01183,Naloxone
,1267205,Serum concentration,Serum concentration of naloxone at 5 minutes was 1.45 +/- 0.1 mug/ml (mean +/- SE) and that of morphine was 1.0 +/- 0.08 mug/ml.,Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1267205/),[μg] / [ml],1.0,224376,DB01183,Naloxone
,1267205,serum half-lives,"Their serum half-lives from one to four hours were approximately the same, 30-40 minutes.",Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1267205/),h,one to four,224377,DB01183,Naloxone
,1267205,serum half-lives,"Their serum half-lives from one to four hours were approximately the same, 30-40 minutes.",Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1267205/),min,30-40,224378,DB01183,Naloxone
,1267205,brain-serum concentration ratios,"With naloxone, the brain-serum concentration ratios ranged from 2.7 to 4.6.",Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1267205/),,2.7 to 4.6,224379,DB01183,Naloxone
,1267205,initial brain concentration,"However, with morphine the initial brain concentration was approximately one tenth that in the serum (0.096 +/- 0.04 mug/ml).",Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1267205/),[μg] / [ml],0.096,224380,DB01183,Naloxone
,1267205,serum half-life,"From 20 minutes to two hours after injection, the calculated mean serum half-life of naloxone was 64 minutes.",Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1267205/),min,64,224381,DB01183,Naloxone
,905632,first pass effect,The values for the first pass effect were 79.6 +/- 4.6% and 78.0 +/- 3.0% for acute and chronic treatment respectively.,Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/905632/),%,79.6,225306,DB01183,Naloxone
,905632,first pass effect,The values for the first pass effect were 79.6 +/- 4.6% and 78.0 +/- 3.0% for acute and chronic treatment respectively.,Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/905632/),%,78.0,225307,DB01183,Naloxone
,905632,apparent chronic release rate (ACRR),From our pharmacokinetic data an apparent chronic release rate (ACRR) for a sustained release preparation of naltrexone was calculated as 11.8 microgram/kg/hr.,Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/905632/),[μg] / [h·kg],11.8,225308,DB01183,Naloxone
,6204757,ED50,"Acutely, oxymorphazone (ED50, 0.6 mg/kg, sc) was approximately half as potent as oxymorphone (ED50, 0.3 mg/kg, sc) in the tail-flick assay.",Oxymorphazone: a long-acting opiate analgesic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6204757/),[mg] / [kg],0.3,225561,DB01183,Naloxone
,8706774,plasma half-life,An estimated plasma half-life of 4.1 h was calculated from two determinations in the neonate based on the assumption of a monoexponential decay of nalbuphine concentrations.,Therapeutic monitoring of nalbuphine: transplacental transfer and estimated pharmacokinetics in the neonate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706774/),h,4.1,229355,DB01183,Naloxone
,19806909,t1/2alpha,"The main parameters of single dosing were as follows: t1/2alpha was (0.26 +/- 0.23) h, t1/2beta was (4.77 +/- 1.65) h, C(max) was (81.65 +/- 5.61) ng x mL(-1), t(peak) was (0.27 +/- 0.07) h, CL(s) was (1.20 +/- 0.06) L x kg(-1) x h(-1), V/F(c) was (1.94 +/- 0.15) L x kg(-1), and AUC(0-t) was (166.82 +/- 7.68) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),h,0.26,230137,DB01183,Naloxone
,19806909,t1/2beta,"The main parameters of single dosing were as follows: t1/2alpha was (0.26 +/- 0.23) h, t1/2beta was (4.77 +/- 1.65) h, C(max) was (81.65 +/- 5.61) ng x mL(-1), t(peak) was (0.27 +/- 0.07) h, CL(s) was (1.20 +/- 0.06) L x kg(-1) x h(-1), V/F(c) was (1.94 +/- 0.15) L x kg(-1), and AUC(0-t) was (166.82 +/- 7.68) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),h,4.77,230138,DB01183,Naloxone
,19806909,C(max),"The main parameters of single dosing were as follows: t1/2alpha was (0.26 +/- 0.23) h, t1/2beta was (4.77 +/- 1.65) h, C(max) was (81.65 +/- 5.61) ng x mL(-1), t(peak) was (0.27 +/- 0.07) h, CL(s) was (1.20 +/- 0.06) L x kg(-1) x h(-1), V/F(c) was (1.94 +/- 0.15) L x kg(-1), and AUC(0-t) was (166.82 +/- 7.68) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[ng] / [ml],81.65,230139,DB01183,Naloxone
,19806909,t(peak),"The main parameters of single dosing were as follows: t1/2alpha was (0.26 +/- 0.23) h, t1/2beta was (4.77 +/- 1.65) h, C(max) was (81.65 +/- 5.61) ng x mL(-1), t(peak) was (0.27 +/- 0.07) h, CL(s) was (1.20 +/- 0.06) L x kg(-1) x h(-1), V/F(c) was (1.94 +/- 0.15) L x kg(-1), and AUC(0-t) was (166.82 +/- 7.68) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),h,0.27,230140,DB01183,Naloxone
,19806909,CL(s),"The main parameters of single dosing were as follows: t1/2alpha was (0.26 +/- 0.23) h, t1/2beta was (4.77 +/- 1.65) h, C(max) was (81.65 +/- 5.61) ng x mL(-1), t(peak) was (0.27 +/- 0.07) h, CL(s) was (1.20 +/- 0.06) L x kg(-1) x h(-1), V/F(c) was (1.94 +/- 0.15) L x kg(-1), and AUC(0-t) was (166.82 +/- 7.68) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[l] / [h·kg],1.20,230141,DB01183,Naloxone
,19806909,V/F(c),"The main parameters of single dosing were as follows: t1/2alpha was (0.26 +/- 0.23) h, t1/2beta was (4.77 +/- 1.65) h, C(max) was (81.65 +/- 5.61) ng x mL(-1), t(peak) was (0.27 +/- 0.07) h, CL(s) was (1.20 +/- 0.06) L x kg(-1) x h(-1), V/F(c) was (1.94 +/- 0.15) L x kg(-1), and AUC(0-t) was (166.82 +/- 7.68) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[l] / [kg],1.94,230142,DB01183,Naloxone
,19806909,AUC(0-t),"The main parameters of single dosing were as follows: t1/2alpha was (0.26 +/- 0.23) h, t1/2beta was (4.77 +/- 1.65) h, C(max) was (81.65 +/- 5.61) ng x mL(-1), t(peak) was (0.27 +/- 0.07) h, CL(s) was (1.20 +/- 0.06) L x kg(-1) x h(-1), V/F(c) was (1.94 +/- 0.15) L x kg(-1), and AUC(0-t) was (166.82 +/- 7.68) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[h·ng] / [ml],166.82,230143,DB01183,Naloxone
,19806909,t1/2alpha,"The main parameters of the last dosing were as follows: t1/2alpha was (0.19 +/- 0.18) h, t1/2beta was (5.79 +/- 1.50) h, C(max) was (79.82 +/- 10.5) ng x mL(-1), t(peak) was (0.18 +/- 0.08) h, CL(s) was (1.12 +/- 0.07) L x kg(-1) x h(-1), V/F(c) was (2.10 +/- 0.27) L x kg(-1), and AUC(0-t) was (173.23 +/- 9.49) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),h,0.19,230144,DB01183,Naloxone
,19806909,t1/2beta,"The main parameters of the last dosing were as follows: t1/2alpha was (0.19 +/- 0.18) h, t1/2beta was (5.79 +/- 1.50) h, C(max) was (79.82 +/- 10.5) ng x mL(-1), t(peak) was (0.18 +/- 0.08) h, CL(s) was (1.12 +/- 0.07) L x kg(-1) x h(-1), V/F(c) was (2.10 +/- 0.27) L x kg(-1), and AUC(0-t) was (173.23 +/- 9.49) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),h,5.79,230145,DB01183,Naloxone
,19806909,C(max),"The main parameters of the last dosing were as follows: t1/2alpha was (0.19 +/- 0.18) h, t1/2beta was (5.79 +/- 1.50) h, C(max) was (79.82 +/- 10.5) ng x mL(-1), t(peak) was (0.18 +/- 0.08) h, CL(s) was (1.12 +/- 0.07) L x kg(-1) x h(-1), V/F(c) was (2.10 +/- 0.27) L x kg(-1), and AUC(0-t) was (173.23 +/- 9.49) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[ng] / [ml],79.82,230146,DB01183,Naloxone
,19806909,t(peak),"The main parameters of the last dosing were as follows: t1/2alpha was (0.19 +/- 0.18) h, t1/2beta was (5.79 +/- 1.50) h, C(max) was (79.82 +/- 10.5) ng x mL(-1), t(peak) was (0.18 +/- 0.08) h, CL(s) was (1.12 +/- 0.07) L x kg(-1) x h(-1), V/F(c) was (2.10 +/- 0.27) L x kg(-1), and AUC(0-t) was (173.23 +/- 9.49) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),h,0.18,230147,DB01183,Naloxone
,19806909,CL(s),"The main parameters of the last dosing were as follows: t1/2alpha was (0.19 +/- 0.18) h, t1/2beta was (5.79 +/- 1.50) h, C(max) was (79.82 +/- 10.5) ng x mL(-1), t(peak) was (0.18 +/- 0.08) h, CL(s) was (1.12 +/- 0.07) L x kg(-1) x h(-1), V/F(c) was (2.10 +/- 0.27) L x kg(-1), and AUC(0-t) was (173.23 +/- 9.49) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[l] / [h·kg],1.12,230148,DB01183,Naloxone
,19806909,V/F(c),"The main parameters of the last dosing were as follows: t1/2alpha was (0.19 +/- 0.18) h, t1/2beta was (5.79 +/- 1.50) h, C(max) was (79.82 +/- 10.5) ng x mL(-1), t(peak) was (0.18 +/- 0.08) h, CL(s) was (1.12 +/- 0.07) L x kg(-1) x h(-1), V/F(c) was (2.10 +/- 0.27) L x kg(-1), and AUC(0-t) was (173.23 +/- 9.49) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[l] / [kg],2.10,230149,DB01183,Naloxone
,19806909,AUC(0-t),"The main parameters of the last dosing were as follows: t1/2alpha was (0.19 +/- 0.18) h, t1/2beta was (5.79 +/- 1.50) h, C(max) was (79.82 +/- 10.5) ng x mL(-1), t(peak) was (0.18 +/- 0.08) h, CL(s) was (1.12 +/- 0.07) L x kg(-1) x h(-1), V/F(c) was (2.10 +/- 0.27) L x kg(-1), and AUC(0-t) was (173.23 +/- 9.49) ng x h x mL(-1), separately.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[h·ng] / [ml],173.23,230150,DB01183,Naloxone
,19806909,peak,"In the course of multiple administration, the peak and valley concentration of plasma 6beta-naltrexol were (79.03 +/- 10.3) and (1.50 +/- 0.93) ng x mL(-1), respectively.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[ng] / [ml],79.03,230151,DB01183,Naloxone
,19806909,valley concentration,"In the course of multiple administration, the peak and valley concentration of plasma 6beta-naltrexol were (79.03 +/- 10.3) and (1.50 +/- 0.93) ng x mL(-1), respectively.",[Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806909/),[ng] / [ml],1.50,230152,DB01183,Naloxone
,16628138,0- to 24-hour,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],32,230689,DB01183,Naloxone
,16628138,0- to 24-hour,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],88,230690,DB01183,Naloxone
,16628138,0- to 24-hour,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],26,230691,DB01183,Naloxone
,16628138,areas under the curve,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],32,230692,DB01183,Naloxone
,16628138,areas under the curve,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],88,230693,DB01183,Naloxone
,16628138,areas under the curve,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],26,230694,DB01183,Naloxone
,16628138,areas under the curve,"In plasma collected from 5 subjects on maintenance daily sublingual doses of 16 mg BUP and 4 mg naloxone, respective 0- to 24-hour areas under the curve were 32, 88, 26, and 316 ng/mL x h for BUP, NBUP, BUPG, and NBUPG.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),[ng] / [h·ml],316,230695,DB01183,Naloxone
,16628138,percent of daily dose excreted,"In urine samples respective percent of daily dose excreted in the 24-hour urine were 0.014%, 1.89%, 1.01%, and 7.76%.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),%,0.014,230696,DB01183,Naloxone
,16628138,percent of daily dose excreted,"In urine samples respective percent of daily dose excreted in the 24-hour urine were 0.014%, 1.89%, 1.01%, and 7.76%.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),%,1.89,230697,DB01183,Naloxone
,16628138,percent of daily dose excreted,"In urine samples respective percent of daily dose excreted in the 24-hour urine were 0.014%, 1.89%, 1.01%, and 7.76%.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),%,1.01,230698,DB01183,Naloxone
,16628138,percent of daily dose excreted,"In urine samples respective percent of daily dose excreted in the 24-hour urine were 0.014%, 1.89%, 1.01%, and 7.76%.",The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628138/),%,7.76,230699,DB01183,Naloxone
,17319131,peak plasma concentration (C(max)),"Carfentanil was rapidly absorbed following administration, with the peak plasma concentration (C(max)) at 13.8 min.",Pharmacokinetics and pharmacodynamics of carfentanil and naltrexone in female common eland (Taurotragus oryx). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17319131/),min,13,232829,DB01183,Naloxone
,17319131,C(max),Naltrexone was readily absorbed and reached C(max) at 23.4 +/- 16.8 min after administration.,Pharmacokinetics and pharmacodynamics of carfentanil and naltrexone in female common eland (Taurotragus oryx). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17319131/),min,23.4,232830,DB01183,Naloxone
,17319131,half-life,"Carfentanil has a half-life of 7.7 hr, whereas naltrexone has a much shorter half-life of 3.7 hr.",Pharmacokinetics and pharmacodynamics of carfentanil and naltrexone in female common eland (Taurotragus oryx). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17319131/),h,7.7,232831,DB01183,Naloxone
,17319131,half-life,"Carfentanil has a half-life of 7.7 hr, whereas naltrexone has a much shorter half-life of 3.7 hr.",Pharmacokinetics and pharmacodynamics of carfentanil and naltrexone in female common eland (Taurotragus oryx). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17319131/),h,3.7,232832,DB01183,Naloxone
,29940217,perceived dissolve times,Median perceived dissolve times were significantly shorter for BNX-RDT than BNX at high (8.5 versus 16.2 min) and low (7.6 versus 9.1 min) doses.,Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29940217/),min,8.5,233624,DB01183,Naloxone
,29940217,perceived dissolve times,Median perceived dissolve times were significantly shorter for BNX-RDT than BNX at high (8.5 versus 16.2 min) and low (7.6 versus 9.1 min) doses.,Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29940217/),min,16.2,233625,DB01183,Naloxone
,29940217,perceived dissolve times,Median perceived dissolve times were significantly shorter for BNX-RDT than BNX at high (8.5 versus 16.2 min) and low (7.6 versus 9.1 min) doses.,Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29940217/),min,7.6,233626,DB01183,Naloxone
,29940217,perceived dissolve times,Median perceived dissolve times were significantly shorter for BNX-RDT than BNX at high (8.5 versus 16.2 min) and low (7.6 versus 9.1 min) doses.,Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29940217/),min,9.1,233627,DB01183,Naloxone
,23599011,AUCtau,"Compared with baseline values, buprenorphine mean AUCtau (69.0 versus 95.6 hr*ng/mL) and mean Cmax (8.4 versus 9.3 ng/mL) increased significantly in the presence of EVG/COBI.",The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[h·ng] / [ml],69.0,234347,DB01183,Naloxone
,23599011,AUCtau,"Compared with baseline values, buprenorphine mean AUCtau (69.0 versus 95.6 hr*ng/mL) and mean Cmax (8.4 versus 9.3 ng/mL) increased significantly in the presence of EVG/COBI.",The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[h·ng] / [ml],95.6,234348,DB01183,Naloxone
,23599011,Cmax,"Compared with baseline values, buprenorphine mean AUCtau (69.0 versus 95.6 hr*ng/mL) and mean Cmax (8.4 versus 9.3 ng/mL) increased significantly in the presence of EVG/COBI.",The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[ng] / [ml],8.4,234349,DB01183,Naloxone
,23599011,Cmax,"Compared with baseline values, buprenorphine mean AUCtau (69.0 versus 95.6 hr*ng/mL) and mean Cmax (8.4 versus 9.3 ng/mL) increased significantly in the presence of EVG/COBI.",The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[ng] / [ml],9.3,234350,DB01183,Naloxone
,23599011,AUCtau,"Compared with baseline values, norbuprenorphine mean AUCtau (103.4 versus 163.4 hr*ng/mL) and mean Cmax (6.9 versus 9 ng/mL) also increased significantly after achieving steady state EVG/COBI.",The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[h·ng] / [ml],103.4,234351,DB01183,Naloxone
,23599011,AUCtau,"Compared with baseline values, norbuprenorphine mean AUCtau (103.4 versus 163.4 hr*ng/mL) and mean Cmax (6.9 versus 9 ng/mL) also increased significantly after achieving steady state EVG/COBI.",The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[h·ng] / [ml],163.4,234352,DB01183,Naloxone
,23599011,Cmax,"Compared with baseline values, norbuprenorphine mean AUCtau (103.4 versus 163.4 hr*ng/mL) and mean Cmax (6.9 versus 9 ng/mL) also increased significantly after achieving steady state EVG/COBI.",The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[ng] / [ml],6.9,234353,DB01183,Naloxone
,23599011,Cmax,"Compared with baseline values, norbuprenorphine mean AUCtau (103.4 versus 163.4 hr*ng/mL) and mean Cmax (6.9 versus 9 ng/mL) also increased significantly after achieving steady state EVG/COBI.",The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[ng] / [ml],9,234354,DB01183,Naloxone
,23599011,AUCtau,Naloxone mean AUCtau (0.57 versus 0.45 hr*ng/mL) and mean Cmax (0.25 versus 0.16 ng/mL) decreased after the addition of EVG/COBI.,The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[h·ng] / [ml],0.57,234355,DB01183,Naloxone
,23599011,AUCtau,Naloxone mean AUCtau (0.57 versus 0.45 hr*ng/mL) and mean Cmax (0.25 versus 0.16 ng/mL) decreased after the addition of EVG/COBI.,The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[h·ng] / [ml],0.45,234356,DB01183,Naloxone
,23599011,Cmax,Naloxone mean AUCtau (0.57 versus 0.45 hr*ng/mL) and mean Cmax (0.25 versus 0.16 ng/mL) decreased after the addition of EVG/COBI.,The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[ng] / [ml],0.25,234357,DB01183,Naloxone
,23599011,Cmax,Naloxone mean AUCtau (0.57 versus 0.45 hr*ng/mL) and mean Cmax (0.25 versus 0.16 ng/mL) decreased after the addition of EVG/COBI.,The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23599011/),[ng] / [ml],0.16,234358,DB01183,Naloxone
,17539894,t1/2,"Small bowel, ascending colon half-life (in pharmacokinetics) (t1/2), and colonic geometric centre (8, 24, 48 h) were assessed by scintigraphy.",Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17539894/),h,8,237806,DB01183,Naloxone
,17539894,t1/2,"Small bowel, ascending colon half-life (in pharmacokinetics) (t1/2), and colonic geometric centre (8, 24, 48 h) were assessed by scintigraphy.",Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17539894/),h,24,237807,DB01183,Naloxone
,17539894,t1/2,"Small bowel, ascending colon half-life (in pharmacokinetics) (t1/2), and colonic geometric centre (8, 24, 48 h) were assessed by scintigraphy.",Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17539894/),h,48,237808,DB01183,Naloxone
,8520812,area under the plasma morphine concentration-time curve from 0-24 h (AUC0-24),"Although naltrexone did not qualitatively alter the concentration-time curve for controlled-release morphine, the area under the plasma morphine concentration-time curve from 0-24 h (AUC0-24) was significantly greater (p < 0.01) for morphine given with naltrexone (265 ng x h/ml) than for morphine given alone (215 ng x h/ml).",Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8520812/),[h·ng] / [ml],265,243028,DB01183,Naloxone
,8520812,area under the plasma morphine concentration-time curve from 0-24 h (AUC0-24),"Although naltrexone did not qualitatively alter the concentration-time curve for controlled-release morphine, the area under the plasma morphine concentration-time curve from 0-24 h (AUC0-24) was significantly greater (p < 0.01) for morphine given with naltrexone (265 ng x h/ml) than for morphine given alone (215 ng x h/ml).",Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8520812/),[h·ng] / [ml],215,243029,DB01183,Naloxone
,8520812,apparent absorption half-life,"Compared to morphine given alone, the apparent absorption half-life of morphine was decreased from 0.94-0.58 h (p = 0.01) and Cmax was increased from 28.17 ng/ml to 32.26 ng/ml (p = 0.04) during naltrexone blockade, whereas the Tmax and apparent elimination half-life of morphine were not significantly affected.",Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8520812/),h,0.94-0.58,243030,DB01183,Naloxone
,8520812,Cmax,"Compared to morphine given alone, the apparent absorption half-life of morphine was decreased from 0.94-0.58 h (p = 0.01) and Cmax was increased from 28.17 ng/ml to 32.26 ng/ml (p = 0.04) during naltrexone blockade, whereas the Tmax and apparent elimination half-life of morphine were not significantly affected.",Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8520812/),[ng] / [ml],28.17,243031,DB01183,Naloxone
,8520812,Cmax,"Compared to morphine given alone, the apparent absorption half-life of morphine was decreased from 0.94-0.58 h (p = 0.01) and Cmax was increased from 28.17 ng/ml to 32.26 ng/ml (p = 0.04) during naltrexone blockade, whereas the Tmax and apparent elimination half-life of morphine were not significantly affected.",Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8520812/),[ng] / [ml],32.26,243032,DB01183,Naloxone
,15726882,Cmax,The Cmax at the inlet and at the outlet the dialyzer were higher (255+/-117 ng/mL and 206+/-137 ng/ml respectively) in comparison with healthy subjects (9 - 44 ng/mL).,Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726882/),[ng] / [ml],255,243889,DB01183,Naloxone
,15726882,Cmax,The Cmax at the inlet and at the outlet the dialyzer were higher (255+/-117 ng/mL and 206+/-137 ng/ml respectively) in comparison with healthy subjects (9 - 44 ng/mL).,Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726882/),[ng] / [ml],206,243890,DB01183,Naloxone
,15726882,Cmax,The Cmax at the inlet and at the outlet the dialyzer were higher (255+/-117 ng/mL and 206+/-137 ng/ml respectively) in comparison with healthy subjects (9 - 44 ng/mL).,Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726882/),[ng] / [ml],9 - 44,243891,DB01183,Naloxone
,15726882,Tmax,Tmax before and after dialysis plates remain unchanged as healthy subjects (approximately 1h).,Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726882/),h,1,243892,DB01183,Naloxone
,15726882,clearance,"With regard to dialysability, a high dialyzer extraction ratio averating 30 % was found with a low dialysis clearance of 58.70+/-17 mL/min.",Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726882/),[ml] / [min],58.70,243893,DB01183,Naloxone
,15726882,amount removed,The amount removed by dialysis is only 1.27 mg.,Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726882/),mg,1.27,243894,DB01183,Naloxone
,34327552,time to maximum concentration (Tmax),"Under remifentanil exposure, the time to maximum concentration (Tmax) for N3G was significantly higher for intranasal administration of 71 min compared to intramuscular administration of 40 min.",The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34327552/),min,71,244210,DB01183,Naloxone
,34327552,time to maximum concentration (Tmax),"Under remifentanil exposure, the time to maximum concentration (Tmax) for N3G was significantly higher for intranasal administration of 71 min compared to intramuscular administration of 40 min.",The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34327552/),min,40,244211,DB01183,Naloxone
,34327552,dose-corrected Cmax,The dose-corrected Cmax of N3G after intranasal administration of naloxone under remifentanil exposure was significantly lower (4.5 ng/mL) than in subjects not exposed to remifentanil (7.8-8.4 ng/mL).,The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34327552/),[ng] / [ml],4.5,244212,DB01183,Naloxone
,34327552,dose-corrected Cmax,The dose-corrected Cmax of N3G after intranasal administration of naloxone under remifentanil exposure was significantly lower (4.5 ng/mL) than in subjects not exposed to remifentanil (7.8-8.4 ng/mL).,The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34327552/),[ng] / [ml],7.8-8.4,244213,DB01183,Naloxone
,3943269,t1/2,"The plasma concentration-time data were best fit with a triexponential equation, and the terminal elimination phase had a harmonic mean t1/2 of 8 to 9 hours.",Nalmefene: intravenous safety and kinetics of a new opioid antagonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943269/),h,8 to 9,245062,DB01183,Naloxone
,13957,half-life,The half-life of morphine between 20 minutes and 6 hours is 2 to 3 hours and this value does not appear to be influenced by the age of the patient.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),min,20,245762,DB01183,Naloxone
,13957,half-life,The half-life of morphine between 20 minutes and 6 hours is 2 to 3 hours and this value does not appear to be influenced by the age of the patient.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),h,6,245763,DB01183,Naloxone
,13957,half-life,The half-life of morphine between 20 minutes and 6 hours is 2 to 3 hours and this value does not appear to be influenced by the age of the patient.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),h,2 to 3,245764,DB01183,Naloxone
,13957,half-life,The half-life of methadone averages 25 hours.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),h,25,245765,DB01183,Naloxone
,13957,half-life,Naloxone rapidly disappears from the serum in man and the initial distribution phase has a half-life of 4 minutes.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),min,4,245766,DB01183,Naloxone
,13957,half-life,The half-life of naloxone in serum following distribution is 64 minutes.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),min,64,245767,DB01183,Naloxone
,762657,serum half-life during the elimination phase,Serum levels of both naloxone and naltrexone fell rapidly; serum half-life during the elimination phase was 71.2 +/- 8.9 min (mean +/- S.E.) for naloxone and 85.1 +/- 9.0 min (mean +/- S.E.) for naltrexone.,Pharmacokinetics of naloxone and naltrexone in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/762657/),min,71.2,246187,DB01183,Naloxone
,762657,serum half-life during the elimination phase,Serum levels of both naloxone and naltrexone fell rapidly; serum half-life during the elimination phase was 71.2 +/- 8.9 min (mean +/- S.E.) for naloxone and 85.1 +/- 9.0 min (mean +/- S.E.) for naltrexone.,Pharmacokinetics of naloxone and naltrexone in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/762657/),min,85.1,246188,DB01183,Naloxone
>,22642416,water solubility,"None of the drugs were highly lipophilic, showing high water solubility (> 45 mM) and low distribution into octanol (log D7.4 < 2).","Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642416/),mM,45,250539,DB01183,Naloxone
<,22642416,log D7.4,"None of the drugs were highly lipophilic, showing high water solubility (> 45 mM) and low distribution into octanol (log D7.4 < 2).","Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642416/),,2,250540,DB01183,Naloxone
,2452249,tail-flick latencies,"In contrast, OxyPNPH at 25 mg/kg elevated tail-flick latencies from 2 to over 8 sec after 10 hr.",Irreversible opiate agonists and antagonists. Analgesic actions of 14-hydroxydihydromorphinone hydrazones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452249/),s,2,250726,DB01183,Naloxone
,2452249,tail-flick latencies,"In contrast, OxyPNPH at 25 mg/kg elevated tail-flick latencies from 2 to over 8 sec after 10 hr.",Irreversible opiate agonists and antagonists. Analgesic actions of 14-hydroxydihydromorphinone hydrazones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452249/),s,over,250727,DB01183,Naloxone
,2452249,tail-flick latencies,"In contrast, OxyPNPH at 25 mg/kg elevated tail-flick latencies from 2 to over 8 sec after 10 hr.",Irreversible opiate agonists and antagonists. Analgesic actions of 14-hydroxydihydromorphinone hydrazones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452249/),s,8,250728,DB01183,Naloxone
,2452249,latencies,The 50-mg/kg dose elevated latencies to approximately 5 sec after 24 hr.,Irreversible opiate agonists and antagonists. Analgesic actions of 14-hydroxydihydromorphinone hydrazones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452249/),s,5,250729,DB01183,Naloxone
,16766719,ED(50),"Surprisingly given this pharmacologic profile, RWJ-394674 exhibited potent oral antinociception (ED(50) = 10.5 micromol/kg or 5 mg/kg) in the mouse hot-plate (48 degrees C) test and produced a moderate Straub tail.","The novel, orally active, delta opioid RWJ-394674 is biotransformed to the potent mu opioid RWJ-413216. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16766719/),,10,251132,DB01183,Naloxone
,9915332,elimination half life,Drug activity in the tissue revealed an elimination half life of 2.3 h and negligible concentration in the blood.,Characterization of the antihyperalgesic action of a novel peripheral mu-opioid receptor agonist--loperamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9915332/),h,2.3,251568,DB01183,Naloxone
,660555,half-life,"Further, this analysis yielded 20 minutes as the half-life of naloxone.",The relationship between pharmacokinetics and pharmacodynamic action as applied to in vivo pA2: application to the analgesic effect of morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/660555/),min,20,252676,DB01183,Naloxone
,3368920,elimination constant,"Plasma clearance of gentamicin was nearly halved by morphine, due primarily to lowering of the elimination constant of gentamicin from 0.03 to 0.02 min-1 (p less than 0.01).",Morphine effects on gentamicin disposition and toxicity in mice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3368920/),1/[min],0.03,253553,DB01183,Naloxone
,3368920,elimination constant,"Plasma clearance of gentamicin was nearly halved by morphine, due primarily to lowering of the elimination constant of gentamicin from 0.03 to 0.02 min-1 (p less than 0.01).",Morphine effects on gentamicin disposition and toxicity in mice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3368920/),1/[min],0.02,253554,DB01183,Naloxone
,3368920,LD50,"LD50 of acutely administered iv gentamicin was 51.6 mg/kg after saline and 45.3 mg/kg after treatment with morphine, 20 mg/kg sc.",Morphine effects on gentamicin disposition and toxicity in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3368920/),[mg] / [kg],51.6,253555,DB01183,Naloxone
,3368920,LD50,"LD50 of acutely administered iv gentamicin was 51.6 mg/kg after saline and 45.3 mg/kg after treatment with morphine, 20 mg/kg sc.",Morphine effects on gentamicin disposition and toxicity in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3368920/),[mg] / [kg],45.3,253556,DB01183,Naloxone
,16499489,apparent elimination half-lives,Mean apparent elimination half-lives for naltrexone and 6beta-naltrexol ranged from 5 to 7 days.,Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16499489/),d,5 to 7,255998,DB01183,Naloxone
,32700999,maximum observed concentration,"Geometric mean maximum observed concentration of methadone in plasma was 35.1 and 33.5 ng/mL and geometric mean terminal half-life was 7.92 and 7.09 hours after methadone-fluconazole and methadone-fluconazole-naltrexone treatment, respectively.",Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700999/),[ng] / [ml],35.1,258336,DB01183,Naloxone
,32700999,maximum observed concentration,"Geometric mean maximum observed concentration of methadone in plasma was 35.1 and 33.5 ng/mL and geometric mean terminal half-life was 7.92 and 7.09 hours after methadone-fluconazole and methadone-fluconazole-naltrexone treatment, respectively.",Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700999/),[ng] / [ml],33.5,258337,DB01183,Naloxone
,32700999,terminal half-life,"Geometric mean maximum observed concentration of methadone in plasma was 35.1 and 33.5 ng/mL and geometric mean terminal half-life was 7.92 and 7.09 hours after methadone-fluconazole and methadone-fluconazole-naltrexone treatment, respectively.",Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700999/),h,7.92,258338,DB01183,Naloxone
,32700999,terminal half-life,"Geometric mean maximum observed concentration of methadone in plasma was 35.1 and 33.5 ng/mL and geometric mean terminal half-life was 7.92 and 7.09 hours after methadone-fluconazole and methadone-fluconazole-naltrexone treatment, respectively.",Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32700999/),h,7.09,258339,DB01183,Naloxone
,19530072,apparent influx clearance,The apparent influx clearance of [(3)H]naloxone across the BBB was 0.305 mL/min/g brain.,Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),[ml] / [brain·g·min],0.305,261249,DB01183,Naloxone
,19530072,apparent elimination half-life,[(3)H]naloxone was eliminated from the brain with an apparent elimination half-life of 15.1 min after microinjection into the parietal cortex area 2 regions of the rat brain.,Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),min,15.1,261250,DB01183,Naloxone
,19530072,apparent efflux clearance,"The apparent efflux clearance of [(3)H]naloxone across the BBB was 0.152 mL/min/g brain, which was calculated from the elimination rate constant (4.79 x 10(-2) min(-1)) and the distribution volume in the brain (3.18 mL/g brain).",Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),[ml] / [brain·g·min],0.152,261251,DB01183,Naloxone
,19530072,elimination rate constant,"The apparent efflux clearance of [(3)H]naloxone across the BBB was 0.152 mL/min/g brain, which was calculated from the elimination rate constant (4.79 x 10(-2) min(-1)) and the distribution volume in the brain (3.18 mL/g brain).",Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),1/[min],4.79 x 10(-2),261252,DB01183,Naloxone
,19530072,distribution volume,"The apparent efflux clearance of [(3)H]naloxone across the BBB was 0.152 mL/min/g brain, which was calculated from the elimination rate constant (4.79 x 10(-2) min(-1)) and the distribution volume in the brain (3.18 mL/g brain).",Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),[ml] / [brain·g],3.18,261253,DB01183,Naloxone
,23421567,AUC(0-24 h),"Compared with baseline values, buprenorphine AUC(0-24 h) (58.2 vs. 56.0 hr*ng/mL) and C(max) (7.37 vs. 6.60 ng/mL) did not differ significantly after achieving steady-state raltegravir.",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[h·ng] / [ml],58.2,261491,DB01183,Naloxone
,23421567,AUC(0-24 h),"Compared with baseline values, buprenorphine AUC(0-24 h) (58.2 vs. 56.0 hr*ng/mL) and C(max) (7.37 vs. 6.60 ng/mL) did not differ significantly after achieving steady-state raltegravir.",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[h·ng] / [ml],56.0,261492,DB01183,Naloxone
,23421567,C(max),"Compared with baseline values, buprenorphine AUC(0-24 h) (58.2 vs. 56.0 hr*ng/mL) and C(max) (7.37 vs. 6.60 ng/mL) did not differ significantly after achieving steady-state raltegravir.",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[ng] / [ml],7.37,261493,DB01183,Naloxone
,23421567,C(max),"Compared with baseline values, buprenorphine AUC(0-24 h) (58.2 vs. 56.0 hr*ng/mL) and C(max) (7.37 vs. 6.60 ng/mL) did not differ significantly after achieving steady-state raltegravir.",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[ng] / [ml],6.60,261494,DB01183,Naloxone
,23421567,AUC(0-24 h),"Naloxone concentrations were unchanged for AUC(0-24 h) (.595 vs. .581 hr*ng/mL), C(max) (.251 vs. .243 ng/mL) and T(max) (.75 vs.1.08 h).",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[h·ng] / [ml],.595,261495,DB01183,Naloxone
,23421567,AUC(0-24 h),"Naloxone concentrations were unchanged for AUC(0-24 h) (.595 vs. .581 hr*ng/mL), C(max) (.251 vs. .243 ng/mL) and T(max) (.75 vs.1.08 h).",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[h·ng] / [ml],.581,261496,DB01183,Naloxone
,23421567,C(max),"Naloxone concentrations were unchanged for AUC(0-24 h) (.595 vs. .581 hr*ng/mL), C(max) (.251 vs. .243 ng/mL) and T(max) (.75 vs.1.08 h).",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[ng] / [ml],.251,261497,DB01183,Naloxone
,23421567,C(max),"Naloxone concentrations were unchanged for AUC(0-24 h) (.595 vs. .581 hr*ng/mL), C(max) (.251 vs. .243 ng/mL) and T(max) (.75 vs.1.08 h).",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[ng] / [ml],.243,261498,DB01183,Naloxone
,23421567,T(max),"Naloxone concentrations were unchanged for AUC(0-24 h) (.595 vs. .581 hr*ng/mL), C(max) (.251 vs. .243 ng/mL) and T(max) (.75 vs.1.08 h).",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),h,.75,261499,DB01183,Naloxone
,23421567,T(max),"Naloxone concentrations were unchanged for AUC(0-24 h) (.595 vs. .581 hr*ng/mL), C(max) (.251 vs. .243 ng/mL) and T(max) (.75 vs.1.08 h).",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),h,1.08,261500,DB01183,Naloxone
,23421567,AUC(0-12 h),"The AUC(0-12 h) and C(max) of raltegravir did not significantly differ from historical controls (5543 vs. 4428 h*ng/mL and 1070 vs. 1266 ng/mL), respectively.",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[h·ng] / [ml],5543,261501,DB01183,Naloxone
,23421567,AUC(0-12 h),"The AUC(0-12 h) and C(max) of raltegravir did not significantly differ from historical controls (5543 vs. 4428 h*ng/mL and 1070 vs. 1266 ng/mL), respectively.",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[h·ng] / [ml],4428,261502,DB01183,Naloxone
,23421567,C(max),"The AUC(0-12 h) and C(max) of raltegravir did not significantly differ from historical controls (5543 vs. 4428 h*ng/mL and 1070 vs. 1266 ng/mL), respectively.",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[ng] / [ml],1070,261503,DB01183,Naloxone
,23421567,C(max),"The AUC(0-12 h) and C(max) of raltegravir did not significantly differ from historical controls (5543 vs. 4428 h*ng/mL and 1070 vs. 1266 ng/mL), respectively.",Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23421567/),[ng] / [ml],1266,261504,DB01183,Naloxone
,20637968,Plasma C(max),"Plasma C(max) and AUC(0-t) of naltrexone after the administration of crushed pellets of MS-sNT (579 pg/mL and 1811 h . pg/mL, respectively) and naltrexone solution (584 pg/mL and 1954 h . pg/mL) were not significantly different; 90% CIs were 83.8% to 116% and 83.3% to 102%, meeting the regulatory requirements for assuming bioequivalence in this study population.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[pg] / [ml],579,262116,DB01183,Naloxone
,20637968,Plasma C(max),"Plasma C(max) and AUC(0-t) of naltrexone after the administration of crushed pellets of MS-sNT (579 pg/mL and 1811 h . pg/mL, respectively) and naltrexone solution (584 pg/mL and 1954 h . pg/mL) were not significantly different; 90% CIs were 83.8% to 116% and 83.3% to 102%, meeting the regulatory requirements for assuming bioequivalence in this study population.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[pg] / [ml],584,262117,DB01183,Naloxone
,20637968,AUC(0-t),"Plasma C(max) and AUC(0-t) of naltrexone after the administration of crushed pellets of MS-sNT (579 pg/mL and 1811 h . pg/mL, respectively) and naltrexone solution (584 pg/mL and 1954 h . pg/mL) were not significantly different; 90% CIs were 83.8% to 116% and 83.3% to 102%, meeting the regulatory requirements for assuming bioequivalence in this study population.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[h·pg] / [ml],1811,262118,DB01183,Naloxone
,20637968,AUC(0-t),"Plasma C(max) and AUC(0-t) of naltrexone after the administration of crushed pellets of MS-sNT (579 pg/mL and 1811 h . pg/mL, respectively) and naltrexone solution (584 pg/mL and 1954 h . pg/mL) were not significantly different; 90% CIs were 83.8% to 116% and 83.3% to 102%, meeting the regulatory requirements for assuming bioequivalence in this study population.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[h·pg] / [ml],1954,262119,DB01183,Naloxone
,20637968,AUC(0-t),"Morphine AUC(0-t) was not significantly different whether MS-sNT was crushed (163 h . ng/mL) or administered whole (174 h . ng/mL), but C(max) was numerically higher (24.5 vs 7.7 ng/mL) and T(max) was numerically shorter (2.00 vs 7.03 hours) with MS-sNT crushed versus whole.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[h·ng] / [ml],163,262120,DB01183,Naloxone
,20637968,AUC(0-t),"Morphine AUC(0-t) was not significantly different whether MS-sNT was crushed (163 h . ng/mL) or administered whole (174 h . ng/mL), but C(max) was numerically higher (24.5 vs 7.7 ng/mL) and T(max) was numerically shorter (2.00 vs 7.03 hours) with MS-sNT crushed versus whole.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[h·ng] / [ml],174,262121,DB01183,Naloxone
,20637968,C(max),"Morphine AUC(0-t) was not significantly different whether MS-sNT was crushed (163 h . ng/mL) or administered whole (174 h . ng/mL), but C(max) was numerically higher (24.5 vs 7.7 ng/mL) and T(max) was numerically shorter (2.00 vs 7.03 hours) with MS-sNT crushed versus whole.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[ng] / [ml],24.5,262122,DB01183,Naloxone
,20637968,C(max),"Morphine AUC(0-t) was not significantly different whether MS-sNT was crushed (163 h . ng/mL) or administered whole (174 h . ng/mL), but C(max) was numerically higher (24.5 vs 7.7 ng/mL) and T(max) was numerically shorter (2.00 vs 7.03 hours) with MS-sNT crushed versus whole.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),[ng] / [ml],7.7,262123,DB01183,Naloxone
,20637968,T(max),"Morphine AUC(0-t) was not significantly different whether MS-sNT was crushed (163 h . ng/mL) or administered whole (174 h . ng/mL), but C(max) was numerically higher (24.5 vs 7.7 ng/mL) and T(max) was numerically shorter (2.00 vs 7.03 hours) with MS-sNT crushed versus whole.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),h,2.00,262124,DB01183,Naloxone
,20637968,T(max),"Morphine AUC(0-t) was not significantly different whether MS-sNT was crushed (163 h . ng/mL) or administered whole (174 h . ng/mL), but C(max) was numerically higher (24.5 vs 7.7 ng/mL) and T(max) was numerically shorter (2.00 vs 7.03 hours) with MS-sNT crushed versus whole.","Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637968/),h,7.03,262125,DB01183,Naloxone
,25542074,C(max),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),[ng] / [ml],125.4,262297,DB01183,Naloxone
,25542074,C(max),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),[ng] / [ml],57.2,262298,DB01183,Naloxone
,25542074,AUC(0-t),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),[h·ng] / [ml],2561,262299,DB01183,Naloxone
,25542074,AUC(0-t),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),[h·ng] / [ml],1095,262300,DB01183,Naloxone
,25542074,T(max),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),h,5.0,262301,DB01183,Naloxone
,25542074,T(max),"As expected, C(max) was higher (125.4 vs 57.2 ng/mL), AUC(0-t) was higher (2561 vs 1095 ng·h/mL), and T(max) occurred earlier (5.0 vs 8.0 hours) with multiple-dose administration.","Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),h,8.0,262302,DB01183,Naloxone
,25542074,R(obs),Mean R(obs) after multiple-dose administration of hydrocodone ER was also slightly higher than predicted from single-dose data (2.8 vs 2.4).,"Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),,2.8,262303,DB01183,Naloxone
,25542074,R(obs),Mean R(obs) after multiple-dose administration of hydrocodone ER was also slightly higher than predicted from single-dose data (2.8 vs 2.4).,"Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25542074/),,2.4,262304,DB01183,Naloxone
,7406276,half-life,Propoxyphene exhibited a dose dependent half-life of from 61 to 135 minutes and an apparent volume of distribution of from 2.54 to 4.26 L/kg.,"Cardiopulmonary, behavioral, and pharmacokinetic effects of propoxyphene in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7406276/),min,61 to 135,265260,DB01183,Naloxone
,7406276,apparent volume of distribution,Propoxyphene exhibited a dose dependent half-life of from 61 to 135 minutes and an apparent volume of distribution of from 2.54 to 4.26 L/kg.,"Cardiopulmonary, behavioral, and pharmacokinetic effects of propoxyphene in horses. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7406276/),[l] / [kg],2.54 to 4.26,265261,DB01183,Naloxone
,7406276,Total body clearance,Total body clearance was 21.9-28.4 ml/min/kg.,"Cardiopulmonary, behavioral, and pharmacokinetic effects of propoxyphene in horses. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7406276/),[ml] / [kg·min],21.9-28.4,265262,DB01183,Naloxone
,3981418,sensitivities,"Sensitive reversed-phase HPLC assays with electrochemical detection, developed to quantify naltrexone, 6 beta-naltrexol, and their conjugates in biological fluids, provided assay sensitivities of 2-14 ng/mL in plasma, urine, and bile.",Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),[ng] / [ml],2-14,265314,DB01183,Naloxone
,3981418,P,Plasma-time data showed two sequential half-lives of 5 +/- 1 (SEM) and 47 +/- 5 min.,Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),min,5,265315,DB01183,Naloxone
,3981418,half-lives,Plasma-time data showed two sequential half-lives of 5 +/- 1 (SEM) and 47 +/- 5 min.,Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),min,5,265316,DB01183,Naloxone
,3981418,half-lives,Plasma-time data showed two sequential half-lives of 5 +/- 1 (SEM) and 47 +/- 5 min.,Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),min,47,265317,DB01183,Naloxone
,3981418,total,"Pharmacokinetics were dose-independent; total and renal clearances were 1043 +/- 98 mL/min and 72 +/- 11 mL/min, respectively, with a similar renal clearance (85 +/- 12) for the conjugate.",Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),[ml] / [min],1043,265318,DB01183,Naloxone
,3981418,renal clearances,"Pharmacokinetics were dose-independent; total and renal clearances were 1043 +/- 98 mL/min and 72 +/- 11 mL/min, respectively, with a similar renal clearance (85 +/- 12) for the conjugate.",Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),[ml] / [min],72,265319,DB01183,Naloxone
,3981418,renal clearance,"Pharmacokinetics were dose-independent; total and renal clearances were 1043 +/- 98 mL/min and 72 +/- 11 mL/min, respectively, with a similar renal clearance (85 +/- 12) for the conjugate.",Pharmacokinetics of morphine and its surrogates V: Naltrexone and naltrexone conjugate pharmacokinetics in the dog as a function of dose. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981418/),,85,265320,DB01183,Naloxone
,30992306,half-life,"The addition of naltrexone [17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one], another μ-receptor antagonist, which has a reported half-life of 3 1/2 hours, may extend the available time to receive medical treatment.",Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30992306/),h,3 1/2,266989,DB01183,Naloxone
,12401350,flow-rate,"The procedure was performed using a Phenomenex Prodigy ODS-2, 5 microm, 150x3.2 mm analytical column and 50 mM potassium acetate buffer, with 11% methanol as organic modifier at pH* 4.5 at a flow-rate of 0.5 ml/min.",Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),[ml] / [min],0.5,268919,DB01183,Naloxone
,12401350,detection potential,The detection potential was 700 mV.,Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),m,700,268920,DB01183,Naloxone
,12401350,limit of quantification (LOQ),"The lower limit of detection (LOD) and limit of quantification (LOQ) were found to be 2.0 and 5.0 ng/ml, respectively.",Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),[ng] / [ml],5.0,268921,DB01183,Naloxone
,12401350,Recovery,Recovery of the drug from plasma was in the region of 94%.,Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),%,94,268922,DB01183,Naloxone
,12401350,C(max),"The pharmacokinetics parameters for a single dose of 0.1 or 0.3 mg/kg in plasma were C(max) = 110 (+/-55) and 287 (+/-101) ng/ml and t(max) = 16.7 (+/-10.8) and 20.0 (+/-9.5) min, respectively.",Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),[ng] / [ml],110,268923,DB01183,Naloxone
,12401350,C(max),"The pharmacokinetics parameters for a single dose of 0.1 or 0.3 mg/kg in plasma were C(max) = 110 (+/-55) and 287 (+/-101) ng/ml and t(max) = 16.7 (+/-10.8) and 20.0 (+/-9.5) min, respectively.",Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),[ng] / [ml],287,268924,DB01183,Naloxone
,12401350,t(max),"The pharmacokinetics parameters for a single dose of 0.1 or 0.3 mg/kg in plasma were C(max) = 110 (+/-55) and 287 (+/-101) ng/ml and t(max) = 16.7 (+/-10.8) and 20.0 (+/-9.5) min, respectively.",Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),min,16.7,268925,DB01183,Naloxone
,12401350,t(max),"The pharmacokinetics parameters for a single dose of 0.1 or 0.3 mg/kg in plasma were C(max) = 110 (+/-55) and 287 (+/-101) ng/ml and t(max) = 16.7 (+/-10.8) and 20.0 (+/-9.5) min, respectively.",Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401350/),min,20.0,268926,DB01183,Naloxone
,9024170,systemic clearance,The systemic clearance of nalmefene was reduced by 32% (0.61 +/- 0.21 versus 0.90 +/- 0.27 L/hr/kg [mean +/- SD]) and the terminal elimination half-life was increased by 31% (10.5 +/- 1.9 versus 8.0 +/- 2.2 hours) in the patients with liver disease.,Effects of liver disease on the disposition of the opioid antagonist nalmefene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024170/),[l] / [h·kg],0.61,269910,DB01183,Naloxone
,9024170,systemic clearance,The systemic clearance of nalmefene was reduced by 32% (0.61 +/- 0.21 versus 0.90 +/- 0.27 L/hr/kg [mean +/- SD]) and the terminal elimination half-life was increased by 31% (10.5 +/- 1.9 versus 8.0 +/- 2.2 hours) in the patients with liver disease.,Effects of liver disease on the disposition of the opioid antagonist nalmefene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024170/),[l] / [h·kg],0.90,269911,DB01183,Naloxone
,9024170,terminal elimination half-life,The systemic clearance of nalmefene was reduced by 32% (0.61 +/- 0.21 versus 0.90 +/- 0.27 L/hr/kg [mean +/- SD]) and the terminal elimination half-life was increased by 31% (10.5 +/- 1.9 versus 8.0 +/- 2.2 hours) in the patients with liver disease.,Effects of liver disease on the disposition of the opioid antagonist nalmefene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024170/),h,10.5,269912,DB01183,Naloxone
,9024170,terminal elimination half-life,The systemic clearance of nalmefene was reduced by 32% (0.61 +/- 0.21 versus 0.90 +/- 0.27 L/hr/kg [mean +/- SD]) and the terminal elimination half-life was increased by 31% (10.5 +/- 1.9 versus 8.0 +/- 2.2 hours) in the patients with liver disease.,Effects of liver disease on the disposition of the opioid antagonist nalmefene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024170/),h,8.0,269913,DB01183,Naloxone
,18434204,half-life,Positron emission tomography (PET) studies performed in 6 adult female baboons indicated extremely rapid brain uptake reaching a peak accounting for 3.3% of the total administered dose in 40 s and clearing with a half-life of 8 min.,"Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18434204/),min,8,270261,DB01183,Naloxone
>,26730511,recoveries,The recoveries were >63% and matrix effects were tracked by the deuterated internal standards (IS) with the IS-normalized matrix factor ranging from 0.96 to 1.33 for all three analytes.,"Simultaneous determination of buprenorphine, norbuprenorphine and naloxone in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26730511/),%,63,270954,DB01183,Naloxone
,28430384,Bioavailability,(1) Bioavailability was F% = 25-28% for intranasal naloxone.,Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),%,25-28,271021,DB01183,Naloxone
,28430384,bioavailability (F%,Sublingual had low bioavailability (F% = 2%) and was not considered further.,Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),%,2,271022,DB01183,Naloxone
,28430384,Cmax,Mean Cmax values for 8 mg (12.83 ng/ml) and 16 mg (18.25 ng/ml) intranasal exceeded 1 mg intravenous (9.64 ng/ml) naloxone.,Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),[ng] / [ml],12.83,271023,DB01183,Naloxone
,28430384,Cmax,Mean Cmax values for 8 mg (12.83 ng/ml) and 16 mg (18.25 ng/ml) intranasal exceeded 1 mg intravenous (9.64 ng/ml) naloxone.,Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),[ng] / [ml],18.25,271024,DB01183,Naloxone
,28430384,Cmax,Mean Cmax values for 8 mg (12.83 ng/ml) and 16 mg (18.25 ng/ml) intranasal exceeded 1 mg intravenous (9.64 ng/ml) naloxone.,Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),[ng] / [ml],9.64,271025,DB01183,Naloxone
,28430384,t50%,"(2) Following intranasal administration, t50% was reached within 8 minutes and tmax within 20 minutes.",Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),min,8,271026,DB01183,Naloxone
,28430384,tmax,"(2) Following intranasal administration, t50% was reached within 8 minutes and tmax within 20 minutes.",Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),min,20,271027,DB01183,Naloxone
,28430384,absorption from dosing to 30 minutes (AUC30 ),Mean naloxone absorption from dosing to 30 minutes (AUC30 ) was greater following 8 mg (4.17 h × ng/ml) and 16 mg (5.91 h × ng/ml) intranasal than following 1 mg intravenous (1.70 h × ng/ml) administration.,Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),[h·ng] / [ml],4.17,271028,DB01183,Naloxone
,28430384,absorption from dosing to 30 minutes (AUC30 ),Mean naloxone absorption from dosing to 30 minutes (AUC30 ) was greater following 8 mg (4.17 h × ng/ml) and 16 mg (5.91 h × ng/ml) intranasal than following 1 mg intravenous (1.70 h × ng/ml) administration.,Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),[h·ng] / [ml],5.91,271029,DB01183,Naloxone
,28430384,absorption from dosing to 30 minutes (AUC30 ),Mean naloxone absorption from dosing to 30 minutes (AUC30 ) was greater following 8 mg (4.17 h × ng/ml) and 16 mg (5.91 h × ng/ml) intranasal than following 1 mg intravenous (1.70 h × ng/ml) administration.,Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430384/),[h·ng] / [ml],1.70,271030,DB01183,Naloxone
,30189012,clearance,The haemodialysis clearance of oxycodone based on its recovery in dialysate was (mean ± SD) 8.4 ± 2.1 L/h.,Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30189012/),[l] / [h],8.4,271360,DB01183,Naloxone
,30189012,plasma elimination half-life,The geometric mean (coefficient of variation) plasma elimination half-life of oxycodone during the 4-h haemodialysis period was 3.9 h (39%) which was significantly shorter than the 5.7 h (22%) without haemodialysis.,Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30189012/),h,3.9,271361,DB01183,Naloxone
,30189012,plasma elimination half-life,The geometric mean (coefficient of variation) plasma elimination half-life of oxycodone during the 4-h haemodialysis period was 3.9 h (39%) which was significantly shorter than the 5.7 h (22%) without haemodialysis.,Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30189012/),h,5.7,271362,DB01183,Naloxone
,31278694,Cmax,"Under fed conditions, the Cmax for morphine was 33% higher (44.78 vs. 33.30 ng/ml for fed and fasted conditions, respectively) and the median Tmax was 30 min longer than under fasted conditions.","A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31278694/),[ng] / [ml],44.78,272649,DB01183,Naloxone
,31278694,Cmax,"Under fed conditions, the Cmax for morphine was 33% higher (44.78 vs. 33.30 ng/ml for fed and fasted conditions, respectively) and the median Tmax was 30 min longer than under fasted conditions.","A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31278694/),[ng] / [ml],33.30,272650,DB01183,Naloxone
,31278694,Tmax,"Under fed conditions, the Cmax for morphine was 33% higher (44.78 vs. 33.30 ng/ml for fed and fasted conditions, respectively) and the median Tmax was 30 min longer than under fasted conditions.","A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31278694/),min,30,272651,DB01183,Naloxone
,31278694,AUC0-∞,The overall morphine exposure (AUC0-∞) was similar for fed (440.6 ng · h/ml) vs. fasted conditions (395.1 ng · h/ml).,"A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31278694/),[h·ng] / [ml],440.6,272652,DB01183,Naloxone
,31278694,AUC0-∞,The overall morphine exposure (AUC0-∞) was similar for fed (440.6 ng · h/ml) vs. fasted conditions (395.1 ng · h/ml).,"A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31278694/),[h·ng] / [ml],395.1,272653,DB01183,Naloxone
,19874646,recoveries,The mean recoveries were 69.2% for naloxone and 32.0% for nornaloxone.,Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization- tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874646/),%,69.2,273880,DB01183,Naloxone
,19874646,recoveries,The mean recoveries were 69.2% for naloxone and 32.0% for nornaloxone.,Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization- tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874646/),%,32.0,273881,DB01183,Naloxone
,19874646,AUC(0-24),Mean AUC(0-24) was 0.303 +/- 0.145 ng/mL.h; mean C(max) was 0.139 +/- 0.062 ng/mL; and T(max) was 0.5 h.,Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization- tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874646/),[ng] / [h·ml],0.303,273882,DB01183,Naloxone
,19874646,C(max),Mean AUC(0-24) was 0.303 +/- 0.145 ng/mL.h; mean C(max) was 0.139 +/- 0.062 ng/mL; and T(max) was 0.5 h.,Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization- tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874646/),[ng] / [ml],0.139,273883,DB01183,Naloxone
,19874646,T(max),Mean AUC(0-24) was 0.303 +/- 0.145 ng/mL.h; mean C(max) was 0.139 +/- 0.062 ng/mL; and T(max) was 0.5 h.,Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization- tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874646/),h,0.5,273884,DB01183,Naloxone
